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Abstract 
One of the most devastating hallmarks of cancer is invasion, a prerequisite for 
tumour metastasis. Recently, the concept of migrastatics, a term used for drugs 
that interfere with cancer cell invasion/migration, has championed the 
development of drugs targeting the actin polymerisation pathway, as a main 
driver of cell migration. Targeting this cellular phenomenon offers an opportunity 
to improve the treatment of invasive and highly migratory tumours such as 
glioblastoma (GBM) and to better understand the mechanisms controlling glioma 
cell migration. 
 
In this study, a small molecule inhibitor, CCG-1423, was identified that 
distinctively failed to halt migration. These observations suggest that cells 
continue to migrate via mesenchymal-amoeboid transition (MAT). 
Immunofluorescence studies and western blotting supported this novel MAT 
switch by demonstrating the loss of nuclear MKL1, a regulator of CCN1; a key 
adhesion and secretory protein in mesenchymal cell migration.  
 
MAT induction was confirmed at high resolution by Instant Structured Illumination 
Microscopy (iSIM) and a newly developed ImageJ plugin allowing identification 
and quantification of MAT associated features such as lamellipodia or filopodia. 
This approach allowed for the first time, the detailed characterisation of CCG-
1423 effects on MAT in gliomas. 
 
Clinical relevance of CCN1 was established by an association with tumour grade 
including increases in CCN1 concentration detected in matched patient blood 
  
V 
samples. CCN1 levels were significantly increased in recurrent patient blood 
samples in comparison to their primary blood samples, suggesting that CCN1 is 
a key player in GBM invasion and progression.  
 
The presented findings support pharmacological intervention with migrastatics 
through the development of combination treatments to target both mesenchymal 
and amoeboid cell migration in GBM management to fully inhibit invasion. In 
addition, this work has generated compelling evidence that CCN1 is a potential 
blood biomarker to monitor and potentially predict GBM recurrence earlier, 
therefore increasing survival rates of this devastating disease. 
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Chapter 1: Background 
1.1 The hallmarks of cancer 
Cancer research has rapidly progressed over the past decades and with it our 
knowledge of this disease. For example, we now know that cancer is 
characterised by active changes to the genome. The foundations of these 
changes are established from mutations that produce the recessive loss of 
tumour suppressor gene function and the dominant gain of oncogenes (1). Both 
types of mutations have been extensively researched and confirmed in 
experimental human clinical trials and animal cancer models. As a result,  a 
selection of fundamental underlying principles (Figure 1) shared by all cancer 
types has been proposed as being the hallmarks of cancer, simplifying how we 
look at cancer as a whole (2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The first hallmarks of cancer to be identified. It is suggested that most, if not all, 
cancers share these traits during development through various mechanistic processes 
(Hanahan and Weinberg, 2000).   
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1.1.1 Tissue invasion and metastasis  
One of the hallmarks of cancer is tissue invasion and metastasis. Ninety percent 
of all cancer mortalities are caused by tissue invasion and metastasis highlighting 
the importance of cancer cell transition to invasiveness (3). During the 
development of most cancers it is inevitable that a primary tumour will produce 
cells that possess the ability to move away from their original tumour site and 
migrate to healthy tissue where they will invade and create new tumours. It is this 
process of invasion and seeding of new tumours (metastases) that are the 
biggest cause of deaths due to cancer (4). Cell migration and invasion enables 
new tumours to establish themselves avoiding competition for nutrients and 
space within the original tumour, leading to a tumour blend of cancer cells and 
normal cells, recruited to support tumour growth. Processes involved in 
metastasis and invasion remain poorly understood due to their exceptionally 
complex mechanisms. They are closely linked processes illustrated by their 
paired association in the hallmarks of cancer. They both share functional 
characteristics, allowing them to manipulate their environment and activate 
extracellular processes to their advantage (5).  
 
1.2 Cell migration 
The underlying basis for invasion and metastasis is the mobility of cancer cells. 
Common treatment regimens targeting the removal or destruction of primary 
tumours include surgery, radiotherapy and chemotherapy depending on cancer 
type. In some cancers, this approach has been shown to be successful in 
promoting cancer remission (6). However, when cancer cells start to spread via 
cell migration and invade surrounding tissues, treatment becomes more difficult. 
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The potential of a malignant tumour to induce a metastatic cascade highlights the 
importance of treating cancer as early as possible or targeting migratory activity 
at late diagnosis.  
 
Cell migration is a vital cellular process; the orchestrated movement of cells to a 
specific site, in a directed manner, allowing for a number of biological processes 
including the developmental formation of organs, wound healing and immune 
responses (7). Cell migration, regardless of cell type, occurs by similar molecular 
mechanisms that have been evolutionally protected. However, deviations in the 
migratory process can be detrimental to health and have devastating 
consequences resulting in disease, organ failure and in many cases death (8).  
 
In order for cells to migrate, a dynamic interaction between cell and substratum 
must occur. It also requires an orchestrated interaction between the cell actin 
cytoskeleton (cell motility), the microtubules (cell polarity) and focal adhesions 
(cell attachment). These interactions can create very distinct modes of migration 
leading to a diverse range of cell movement. For motility of a single cell, two main 
types of migration ‘mesenchymal’ or ‘amoeboid’, are recognised (9).  
 
1.2.1 Mesenchymal migration  
Mesenchymal cell migration is characterised by a leading-edge protrusion 
caused by actin extensions (lamellipodia) through cell polarisation. This 
protrusion leads to adhesion formation, cell body translocation, de-adhesion and 
retraction of cell rear (10). This process requires the interaction of multiple 
members of the Rho family, in particular the Rho GTPases Rac1, active Rho and 
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Cdc42, which work collectively to control the actin cytoskeleton (11). Rho 
GTPases, a sub-group of the Ras superfamily, are a small family of signalling G 
proteins that are expressed across all species. They are involved in a wide 
spectrum of cellular functions and like all members of the Ras superfamily, Rho 
GTPases are a collection of molecular switches within the signal transduction 
pathways in eukaryotic cells. This means they have an ability to switch between 
active and inactive states allowing fast cellular responses to extracellular stimuli, 
resulting in precise coordination of intracellular activities for cell migration.  
 
The regulation of membrane protrusions and actin polymerisation requires Rac1 
at the front of the cell, which is spatially restricted (12). Rac1 activation leads to 
cell polarisation, which subsequently coordinates actin polymerisation and 
protrusion of lamellipodia. Cdc42 also has a role in encouraging actin 
polymerisation by maintaining cell directionality through attachment and 
alignment of microtubules. These events form an actin-rich protrusion (13). Rho 
regulates the formation of actin stress fibres and drives translocation of the cell 
body (14). This activity is reduced during protrusion extension and promoted 
during retraction.  
 
The extracellular matrix (ECM) is a three-dimensional (3D) structure that is 
present in all tissues. The ECM is composed of water, proteins and 
polysaccharides; however, each tissue has a specific ECM composition and 
topology established during development. It provides an essential physical 
framework for the cellular components and initiates vital biomechanical and 
biochemical signals (15). It regulates cell adhesion, migration, proliferation and 
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differentiation by transmitting signals via cell-surface receptors (16). Cell 
differentiation is regulated by ECM remodelling. This important and controlled 
process involves quantitative and qualitative changes in the ECM and is mediated 
by specific enzymes that regulate ECM degradation (17). ECM remodelling plays 
a crucial role in governing structural integrity and regulating cell motility, growth 
and shape (18). 
 
1.2.2 Amoeboid migration 
In contrast, amoeboid cell migration is characterised by a rapid mode of motility 
with weak substratum adhesion (Table 1). It is driven by actin-rich pseudopods; 
elongated narrow structures that are as thick as the non-nuclear cytoplasm (in 
contrast to lamellipodia). More than one pseudopod extension is common in 
migrating cells along with secondary pseudopodia branching, resulting in a round 
or irregular morphology (19). Rho and Cdc42 signalling are the key players in 
amoeboid movement as they drive actomyosin contractility. However, the mode 
of cell movement is dependent on the activation of Rho/ROCK signalling (20). 
This signalling pathway is believed to induce blebbing through stimulation of 
actomyosin contraction. The enhancement of contractility enables amoeboid 
migrating cells to distort their shape in order to push themselves into gaps of free 
space in the ECM or to produce a significant amount of force to instead distort 
the surrounding ECM. Such intense invasiveness makes amoeboid migration, 
arguably, the most effective mode of cell movement (21). The differences 
between mesenchymal and amoeboid cell migration are summarised in Table 1.  
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1.2.3 Collective cell migration 
A third main mode of migration is called collective cell motility. In this form, cells 
sustain their cell-cell interactions and migrate in sheets, clusters or strands 
(Figure 2). This can occur as an independent migrating cluster or remaining in 
connection with the tissue of origin (13). Collective migrating cells respond in 
coordination with the environment and promote otherwise immobile or 
directionally contrasting cells to adhere to the overall movement. This profound 
feature increases migration efficiency compared to single cell movements (22). 
The number of cells in a collective migration movement can vary from as few as 
10 cells to thousands of cells, as can the distance they travel. Guidance signals 
take the form of chemical diffusion gradients (23). These guidance signals usually 
involve leader and follower cells, within the collective, to be in coordination. At 
Table 1. Phenotypic characteristics of mesenchymal and amoeboid modes of 
migration 
 Mesenchymal Amoeboid 
Morphology Elongated Rounded 
Attachment 
Integrin clusters creating 
focal adhesions 
Weak, integrins diffused in 
membrane 
Migration 
ECM degradation and 
remodelling 
Pushing through ECM 
Organisation 
Actin framework and stress 
fibres 
Contractile actin cortex 
Speed/ Velocity 
Low 
(0.1-0.4µm/min) 
High 
(0.4-5µm/min) 
Extensions Filopodia and lamellipodia Blebbing and pseudopodia 
Table 1. A comparison between the phenotypic characteristics of mesenchymal 
migration and amoeboid migration in ECM. 
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the front of the group are leader cells that receive the guidance signals and 
instruct the follower cells to conform to the collective movement, via cell-cell 
junctions (7).  
 
1.3 Cancer cell invasion 
As previously stated, cell migration is the directed translocation of cells from one 
site to another and occurs in the early stages of invasion, however it does not 
involve cell-cell interactions with neighbouring cells. Invasion is a separate, highly 
dynamic process that implicates cell-cell adhesion and proteolysis of the ECM 
(24). The process of invasion promotes the dissemination of tumour cells in the 
primary tumour to navigate through the ECM within a tissue or to infiltrate 
neighbouring tissues. Cancer cells that become invasive may infiltrate the 
circulatory and lymphatic systems, cross endothelial walls and basement 
membranes to colonise distant organs forming metastases. Amoeboid migrating 
cells undergo invasion by different means as their mechanisms do not involve 
ECM proteolysis but the process of expansion and retraction to squeeze through 
Figure 2. A diagram illustrating the different types of migration, collective, mesenchymal and 
amoeboid, and their properties. 
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gaps in the ECM (25).  
 
1.3.1 Cell adhesion molecules  
Changes to cell-cell adhesion occur via fluctuations in the levels of adhesion 
molecules that promote this linkage. When adhesion between cells is lost, tumour 
cells can dissociate themselves from the original tumour mass and initiate cellular 
events that lead to metastasis. Typically, cell adhesion molecules can be grouped 
into four families; the cadherins, the selectins, the integrins and the 
immunoglobulin superfamily (26).  
 
Cadherins are transmembrane cell-cell adhesion molecules that are present in 
both simple and complex organisms. In addition to adhesion between cells, 
cadherins are responsible for a number of different processes in tissue 
morphogenesis including boundary formation, cell sorting and the induction and 
maintenance of cell polarity (27). During cell-cell communication, cadherins from 
one cell form trans-bonds at the position of contact. Once the cells are connected 
in trans-bonds, the cadherins control the development of cell-cell contact via 
three different mechanisms: using adhesion tension to directly reduce the local 
interfacial tension, signalling to the actomyosin cytoskeleton to indirectly reduce 
interfacial tension and determining the mechanical coupling of communicating 
cells (28).  
 
One of the most well-characterised and important cadherins in cancer cell 
invasion is epithelial-cadherin (E-cadherin). As well as being involved in cell-cell 
adhesion, E-cadherin is responsible for the formation of epithelial cell sheets (29). 
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The E-cadherin gene has been extensively studied in the field of cancer 
progression and has been found to play a major role in malignant cell 
transformation. It is known as the ‘suppressor of invasion’ gene, due to the fact 
that E-cadherin gene suppression is recognised as one of the key events 
accountable for the dysregulation of cell-cell adhesion. Most tumours that have a 
loss of this gene present with abnormal cell morphology and reduced tissue 
stability leading to invasion. The loss of E-cadherin function directly correlates 
with metastasis and invasiveness (30). Interestingly, although this is true for most 
cancers, in gliomas E-cadherin has little value as a prognostic marker. A study 
into the prognostic significance of E-cadherin expression in gliomas showed that 
identification was rare in both low and high grade gliomas, which is to be expected 
due to glioma being a non-epithelial malignancy (31).     
 
Selectins are calcium-dependent transmembrane lectins that initiate the first step 
in leukocyte extravasation during an inflammatory response; the binding of 
leukocytes to the activated endothelium of blood vessel walls (32). Cancer cells 
take advantage of this cellular process and use their own surface selectins to 
bind to blood vessel walls and get extravasated in order to invade other tissues 
in the metastatic cascade. This mechanism is the most researched and most 
evident function of selectins in cancer progression (33).  
 
Integrins are large, complex heterodimeric glycoproteins that contain an a chain 
and a b chain. Integrins facilitate cell-cell adhesion, directly bind ECM 
components and  function as an anchorage system for cell migration and invasion 
(34). As well as these processes, integrins also activate growth factor receptors 
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and promote proliferation and cell survival. They also enable bidirectional 
signalling promoting changes in cell structure. Many human tumours arise from 
malignant transformation of epithelial cells, therefore as integrins are expressed 
on epithelial cells, they are also expressed on the transformed cancer cells and 
expression is correlated with metastasis and patient survival (5).  
 
Epithelial-mesenchymal transition (EMT) is a dynamic mechanism by which 
polarised epithelial cells undergo a number of conformational and biochemical 
changes which enable them to become motile by adopting a mesenchymal 
phenotype and invasive properties (5). Epithelial cells are highly polarised and 
are closely linked by a number of different cell-cell junctions including gap 
junctions, tight junctions, adherens junctions and desmosomes. A key step in 
EMT is the loss of these intimately connected junctions between neighbouring 
cells, allowing the dissociation of cells from the primary tumour. Therefore, EMT 
is typified by a loss of these junctions and their proteins, including E-cadherin, 
and a gain of mesenchymal markers including neural-cadherin (N-cadherin), 
vimentin and fibronectin (35). EMT also presents with reorganisation of the actin 
cytoskeleton and a loss of polarity resulting in the cells taking on an elongated 
migratory phenotype. This ‘cadherin switch’ is also a key characteristic of EMT 
and appears to be a necessity in the gain of invasive properties for tumour cells 
(36).  
 
1.3.2 Proteolysis of the ECM 
The ECM is a dynamic environment providing growth factors and matrix proteins 
to control cellular functions including remodelling and structural support. In order 
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to create a favourable environment for tumour cell proliferation and invasion, 
proteases remodel and degrade the ECM allowing room for these neoplastic 
processes (15). There are 5 groups of proteases that are known to remodel and 
degrade the ECM including serine, cysteine, aspartate, threonine and matrix 
metalloproteinases (MMPs) (18).  
 
A third of all proteolytic enzymes are the serine proteases. They are involved in 
a vast number of different biological processes including development, 
fertilisation, digestion and blood coagulation (37). The well-known digestive 
serine protease trypsin has been implemented in various cancers to promote 
proliferation, invasion and metastasis. In colorectal cancer, expression of trypsin 
is correlated with poor prognosis and survival (38). Another serine protease, 
urokinase-type plasminogen activator (uPA), has a membrane-bound receptor 
(uPAR), which induces the degradation of two ECM proteins, fibronectin and 
laminin, causing structural changes to the ECM resulting in channels for invading 
cells (39).  
 
Cysteine proteases are characterised by an active site cysteine residue. These 
proteases are involved in intracellular protein catabolism and signalling molecule 
activation (including interleukins and protein kinase C), as well as the degradation 
of the extracellular proteins laminins and collagen (38). A unique feature of 
cathepsin cysteine proteases is the ability to degrade both extracellular and 
intracellular matrix proteins. Their extracellular activity permits cancer cells to 
invade surrounding tissues and thus are said to be promising anti-cancer targets 
(40).       
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Aspartate proteases possess a catalytic site consisting of two aspartate residues. 
Cathepsin-D (Cath-D), an aspartic endo-protease, is found universally in all 
lysosomes and works to degrade them (40). It is overexpressed and over-
secreted in breast cancer and has been used as a marker for poor prognosis due 
to its role in promoting cancer cell proliferation, angiogenesis and metastasis. It 
was shown that Cath-D is a rate limiting factor in tumorigenicity, outgrowth and 
lung colonisation in breast cancer cell lines (38). 
 
Threonine proteases play an important role in the degradation of cellular proteins. 
They are catalysts in a complex mechanism called polyubiquitinisation, whereby 
a series of ubiquitin molecules bind to the same target protein. This is a trigger 
signal that leads to the degradation of proteins in the proteosome. This 
mechanism has been linked to cancer invasion and studies into threonine 
protease inhibitors have been suggested as a cancer therapy (38). Inhibition of 
threonine proteases have been shown to induce accumulation of pro-apoptotic 
proteins in tumour cells, but not in normal cells, leading to programmed cell death 
to be induced in cancer cells. The first US FDA-approved inhibitor drug of this 
kind, Bortezomib, was used for the treatment of multiple myeloma, 
relapsed/refractory multiple myeloma and mantle cell lymphoma (41). 
 
Matrix metalloproteinases (MMPs) are enzymes which have the capability to 
degrade all types of ECM protein. Because of their action, they can create tracks 
for cancer cells to migrate along, therefore promoting invasion and progression 
(18). Studies have shown a direct correlation between MMP expression and 
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tumour invasiveness. In addition to this role, MMPs also promote cell 
proliferation, differentiation and angiogenesis (42).  
 
1.4 Actin polymerisation 
The driving force that propels cell migration is built from the actin cytoskeleton; 
the largest cell organelle. By assembly and disassembly, the actin cytoskeleton 
can completely change the morphology of a cell with ease and flexibility. Differing 
from other large protein complexes, the actin filaments that make up the 
cytoskeleton vary in length, abundance and organisation (43). The ability to 
create networks and bundles of cross-linked filaments in a flexible and rapid 
manner underlines the importance of actin in cell migration and explains its well 
established place in this field of research.  
 
In terms of mass, actin is the most abundant protein in the majority of cell types, 
partaking in more protein-protein interactions than any other known protein. Its 
ability to shift between two states, globular and filamentous, makes actin an 
important player in many cellular functions apart from motility including cell shape 
and polarity (44). When globular actin (G-actin) polymerises into filamentous actin 
(F-actin) it can result in a range of different organisational arrangements including 
branched, cross-linked bundles and contractile structures. It is these mechanical 
assemblies that drive shape changes within the cell and promote cell motility (45).  
 
When the concentration of actin monomers (G-actin) reaches a certain level, 
polymerisation into F-actin occurs. These F-actin strands link each other in a 
double-helical structure and form distinct ends to the polymer; a barbed end and 
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a pointed end (46). Because the subunits of the polymer all have the same 
orientation and directionality, actin filaments are polar. The monomers are 
preferentially added onto the barbed end and lost at the pointed end. However, 
as actin polymerisation is an equilibrium process, either activity can occur at both 
the barbed or pointed end of the polymer. It is the kinetics of the polymerisation 
process that differ, i.e., a more rapid growth of the barbed end of the filament 
than the pointed end (10). Within an internal cleft of monomeric actin, ATP is 
bound to stabilise the globular structure. Shortly after filament assembly, the 
actin-bound ATP gradually releases the terminal phosphate from the bound ATP 
through hydrolysis (47). This process does not regulate actin polymerisation but 
acts as an internal clock that is keeping track of the filament’s age. It activates 
the disassembly of actin filaments within the cell when the filament’s lifespan is 
at an end (48).  
 
When an actin polymer is not in the process of shortening or lengthening, it is 
said to be in equilibrium. When it is in this state it is constantly dissociating actin 
monomers at the pointed end and associating monomers at the barbed end. As 
a result of this, an actin monomer added at the barbed end will ultimately move 
along the filament until it is dissociated at the pointed end. This continuous 
progression is known as treadmilling (49). Treadmilling is made possible by the 
free energy created by the hydrolysis of ATP. It may seem that this energy is 
being lost to a process that has little advantage to the cell, however, treadmilling 
provides the cell with a way in which to control the cytoskeletal organisation (50). 
This means if there is a requirement for filaments in a different region of the cell, 
disassembly of existing actin filaments is instantaneous as is the re-assembly of 
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the new actin filaments due to the rapidly diffusing actin monomers. This spatial 
and flexible arrangement allows cellular control over actin filament location and 
overall cellular structure (43). 
 
1.4.1 Actin polymerisation activators  
Recent evidence linking Rho GTPases to a range of diseases has raised interest 
in the signalling pathways and downstream processes, including actin 
polymerisation, as potential targets for pharmacological intervention. Continuing 
studies into the identification and functions of vital players involved in actin 
polymerisation is key to developing new therapeutic treatments for cancer 
progression and many other diseases (51).  
 
Potential key players in this process are members of a large family of over 30 
genes called the ARHGAPs. ARHGAP genes have been described in scientific 
literature as being associated with a number of diseases; the main one being 
cancer. However, the detail on this is minimal. The ARHGAP genes encode a 
group of proteins called Rho GTPase activating proteins (RhoGAPs), which 
interact with Rho GTPases. They are primarily known for their role in regulating 
the actin cytoskeleton and, therefore, are involved in cell migration (52). 
 
1.4.2 RhoA transcriptional signalling pathway 
Rho GTPases make up one of five distinctive families in the Ras superfamily. 
Included in the 23 members of the Rho family subgroup are Rho, Rac and Cdc42; 
three of the best characterised Rho GTPases. Rho-like proteins are highly 
conserved and act as molecular switches, regulating signal transduction 
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pathways by cycling between an inactive (GDP-bound) and an active (GTP-
bound) state (11). Rho GTPases are activated via stimulation of cell surface 
receptors known as G-protein coupled receptors (GPCRs). This family of 
receptors produces a multitude of cellular functions when activated by 
extracellular stimuli, such as hormones, cytokines, lipids, proteases and 
neurotransmitters (53). The G-proteins consist of the protein subunits Ga, Gb and 
Gg to form a heterodimer. When activated, the Ga subunit exchanges GDP for 
GTP, whilst the Gb and Gg disassociate. The now activated GTP-bound Ga and 
Gbg can interact with their corresponding effectors and generate various 
downstream effects such as cytoskeletal changes, cell motility, cell growth and 
gene transcription (54). The Rho family of GTPases is best known for its 
involvement in cytoskeletal changes, which promote cell motility. The three main 
subgroups (Rho, Rac and Cdc42) are responsible for this through their control of 
focal adhesions, stress fibres and cell protrusions (lamellipodia and filopodia).  
 
The activation of Rho GTPases is regulated by a number of other protein families. 
Guanine nucleotide exchange factors (GEFs) catalyse the exchange of GTP for 
GDP thus activating Rho GTPases and promoting the downstream effects. The 
RhoGAPs do the opposite, thus inactivating Rho GTPases by hydrolysing GTP 
(Figure 3). Guanine nucleotide dissociation inhibitors (GDIs) extract Rho 
GTPases from membranes and solubilise them in the cytosol, preventing their 
activation and membrane localisation (55).  
  
18 
 
 
 
 
 
 
 
 
 
RhoGEFs are activated by G12/13 signalling of GPCRs. There are four mammalian 
RhoGEFs that are known to be regulated by G12/13 and link the activation of 
GPCRs to the small Rho GTPase, RhoA. These are p115-RhoGEF, PSD-
95/Disc-large/ZO-1 homology-RhoGEF, leukaemia-associated RhoGEF and 
lymphoid blast crisis-RhoGEF (56). RhoA promotes reorganisation of the actin 
cytoskeleton and regulates cell shape, attachment and motility. It mediates the 
activation of Rho Kinases (ROCK1/2) which leads to the phosphorylation of focal 
adhesion kinase (FAK). FAK induces the formation of actin stress fibres and the 
activation of serum response factor (SRF); a widely expressed and highly 
conserved, single copy transcription factor (57). In the nucleus, SRF binds to 
serum response element (SRE) sequences in the promotor of specific genes, 
regulating their transcription. SRF has a crucial role in cell migration and the actin 
cytoskeleton. Genomic studies have revealed that out of the 200+ SRF target 
Figure 3. The Rho GTPase Cycle. Rho GTPases cycle between an inactive GDP-bound 
state and an active GTP-bound state. They are regulated by RhoGEFs and RhoGAPs. 
Active GTPases then interact with an effector protein to initiate a response and promote 
downstream effects.   
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genes, over half of them encode proteins with functions that relate to actin 
dynamics, contraction, lamellipodia/filopodia formation and integrin-cytoskeleton 
coupling. It is therefore an essential part of the actin cytoskeleton and contractile 
homeostasis (57). 
 
SRF interacts with a number of transcriptional coactivators in order to stimulate 
gene expression. In the RhoA signalling pathway, a key SRF interactant is 
megakaryoblastic leukaemia 1 (MKL1) (58). MKL1 (also known as 
megakaryocytic acute leukaemia [MAL] and myocardin-related transcription 
factor A [MRTF-A]) was originally identified in acute megakaryoblastic 
leukaemias of infants and children through its fusion to RBM15 (RNA binding 
motif protein 15); a unique interaction found in leukaemias. More recently, MKL1, 
along with its other family members MKL2 and myocardin, have been shown to 
be coactivators to SRF and have a vital role in the activation of SRF target genes 
(59). Within the cell, MKL1 is bound to monomeric G-actin. When actin 
polymerisation is induced, MKL1 is released from G-actin and is imported from 
the cytoplasm into the nucleus by an importin a/b heterodimer where it forms a 
complex with SRF and activates the target genes (60).               
 
1.4.3 RhoA transcriptional signalling pathway and cancer 
The link between Rho proteins and cancer was not discovered for some time due 
to lack of evidence of activating mutations within the coding sequences of these 
proteins. Now it is well known that Rho GTPases play a fundamental role in many 
aspects of tumorigenesis such as cell migration, invasion and metastasis. Rho 
proteins are found to be overexpressed in numerous tumour types (43). For 
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example, overexpression of RhoA was found in breast, colon and lung, Rac1 is 
overexpressed in breast, lung and testicular and Cdc42 is also overexpressed in 
breast and testicular cancers (61).  
 
As well as overexpression of the Rho GTPase itself, the mis-regulation of these 
proteins can also occur in cancer through irregular changes in RhoGEFs, 
RhoGAPs and GDIs. For example, MyoGEF, a RhoGEF, has been shown to drive 
invasive breast cancer through its activation of RhoA and RhoC (62). Another 
GEF, known as Tiam1 (Rac specific), was identified as a promotor of T lymphoma 
invasion as well as being overexpressed in breast cancer (63). Deleted in liver 
cancer 2 (DLC2) is a GAP that is found to be under-expressed in many types of 
hepatocellular cancers and also in fibrosarcoma of bone. ARHGAP35 is a well-
known tumour suppressor in gliomas and has been found to be deleted in 50-
80% of oligodendrogliomas. When overexpressed in these cancers, ARHGAP35 
reduced proliferation and expression of nestin; a neural precursor marker (64). 
With RhoGDIs, there are conflicting data on their alterations in cancer with studies 
showing both increased and decreased expression in a number of different 
cancer types (61). An imbalance of Rho and RhoGDIs has been shown in breast 
cancer with an excessive level of Rho and a reduced level of RhoGDIs. This 
results in the inability to switch off Rho, leading to increased invasion. This 
correlates with the fact the RhoGDI-2 mRNA was found to be expressed in low-
invasive breast cancers but not high-invasive (65). In contrast, the same RhoGDI-
2 is upregulated in ovarian cancer, showing the contradictory action of RhoGDIs 
in cancer (66).  
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Arguably, one of the most prominent Rho effectors that has a role in cancer 
progression is the Rho-associated protein kinase (ROCK). ROCK, like its 
activators, RhoA and RhoC, is overexpressed in a number of different cancer 
types (67) including pancreatic cancer, oesophageal squamous cell carcinoma 
and hepatocellular carcinoma (68–70). ROCK has been shown, both in vitro and 
in vivo, to be associated with metastasis in the B16 melanoma models, HT1080 
lung cancer and MDA-MB-231 breast cancer cell lines (71,72). Through the use 
of 3D-Matrigel matrix assays, ROCK has been shown to be a key player for in 
vitro cell invasion in rounded blebbing cells (amoeboid) vs elongated cells 
(mesenchymal) (73). In addition, ROCK has been implicated in the regulation of 
MMPs in hepatocellular carcinoma and colon cancer cells. This means that 
ROCK has the ability to regulate MMP-dependent types of cell migration in certain 
cancer types and could therefore function as a successful therapeutic target for 
cancer treatment (74).  
 
1.4.4 Targeting the RhoA transcriptional pathway 
The RhoA transcriptional signalling pathway has been thoroughly studied in 
cancer progression, however, very few inhibitors have been developed to target 
it. The inhibition of carboxy-terminal isoprenylation of active Rho GTPases has 
been the focus of most inhibitor studies of this pathway. Carboxy-terminal 
isoprenylation is a modification of lipids and is vital for the membrane localisation 
of Rho GTPases and their functions (75). However, the drugs used to inhibit this 
lipid modification, including inhibitors of farnesyl transferase and geranylgeranyl 
transferase as well as statins, are not selective for the Rho family or GTPases or 
the RhoA transcriptional signalling pathway (76). 
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ROCK has also been the subject of many inhibitor studies for this pathway. 
Compounds, including Y-27632, fasudil and WF-536, have achieved promising 
results in both in vitro and in vivo anti-invasion experiments (69,70). However, 
one of the drawbacks of these drugs is their limited inhibitory effects targeting 
only one branch of the RhoA signalling pathway (Figure 4). As a consequence, 
these inhibitors may be ineffective against tumours that rely upon the 
transcriptional branch (branch II) of the same pathway (77). 
 
 
In addition to the ROCK inhibitors, two specific inhibitors of the Rho GTPase 
signalling pathway (NSC23766 and EHT-1864) have been shown to directly 
Figure 4. A simplified schematic diagram of the RhoA signalling pathway. Branch I shows 
the RhoA pathway that results in morphological changes to promote migration. Branch II 
shows the transcriptional pathway of RhoA whereby MKL1 is imported into the nucleus to 
form a complex with SRF. This promotes cancer cell migration and invasion by gene 
production of motility proteins following gene transcription.    
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inhibit the Rho GTPase, Rac1 (78) (79). As with the other inhibitors, these drugs 
do not target the RhoA transcriptional signalling pathway and so would become 
ineffective. The need for inhibitors that target specific regulators and effectors of 
the RhoA transcriptional pathway is still evident in order to target the progression 
of cancer and stop invasion and metastasis. 
 
1.4.5 Anti-invasion and anti-metastatic treatments  
In solid tumours, invasion and metastasis account for 90% of the fatalities in 
cancers, yet there is a lack of anti-invasion and anti-metastatic drugs in treatment 
regimens (80). Candidate drugs for anti-cancer treatments are still mainly 
evaluated on their efficacy to reduce tumour size by their cytotoxic effect on 
cancer cells. This approach is understandable, however, tumour shrinkage is 
rarely sustainable and is not a predictor of an anti-invasive effect (81).  
 
Another difficulty in anti-cancer treatments is drug resistance. This is a 
recognised problem as a result of a disease becoming tolerant to a 
pharmacological intervention. Drug resistance was first studied in bacteria with 
antibiotic resistance but is also now documented in other diseases including 
cancer. Some processes of drug resistance can be specific to certain diseases 
but others are evolutionally conserved, such as drug efflux in drug-resistant 
human cancers. A family of proteins known as ATP-binding cassette (ABC) 
transporters facilitate efflux and are important biological regulators at plasma 
membranes in healthy cells. ABC transporters push toxins out of cells in order to 
prevent toxin accumulation. Although this is a normal process in healthy cells, in 
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cancer cells this is a recognised mechanism of drug resistance and results in 
protection against chemotherapy (82). 
 
Recently there has been an increase in the number of studies on anti-invasion 
drugs in order to address the high cancer mortality rate associated with cancer 
invasion and metastasis. First attempts to target cancer invasion by using 
synthetic MMP inhibitors showed promising results in vitro. Following in vivo 
studies also produced effective inhibition of growth and invasion and increased 
survival in treated mice compared to control mice (83). However, when taken 
forward to clinical trials no benefits with MMP inhibitors were observed in a variety 
of cancers, including pancreatic, glioblastoma, lung, ovarian and renal, and 
toxicity was also associated with this type of treatment (84). It is now 
acknowledged that pharmacological inhibition of MMP activity or integrin function 
is associated with a cellular motility shift, i.e., switching from one mode of 
migration to the other. Mesenchymal-amoeboid transition (MAT) or amoeboid-
mesenchymal transition (AMT) can be promoted by environmental or epigenetic 
factors (85). These changes create an advantageous state for cancer cells to 
metastasise (86). It is also important to note that non-migrating cells, for example 
epithelial cells, can undergo EMT to become mesenchymal migratory cells (87). 
From here the cells can then undergo transition again via MAT (25). 
 
L-type calcium channels have been identified as regulators of filopodia; 
cytoplasmic projections extending at the leading edge of a migrating cell. Studies 
in p53 mutation breast cancers have demonstrated that L-type calcium channels 
are present and functional in cancer cells, uncovering a novel role for these 
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channels in tumour progression. Blocking the channels with FDA-approved 
calcium channel blockers has proved to have an anti-migratory effect in cancer 
cells by inhibiting the formation of filopodia (88). 
 
Studies using in silico screens have uncovered that cell migration can be reduced 
by using drugs that affect the fluidity of the cell membrane. Over-expression of 
ABCA-1, a regulator of membrane fluidity and cholesterol, in breast cancers has 
been associated with cancer metastasis (89). Drugs targeting this cholesterol 
efflux regulatory protein, through either pharmacological or genetic inducers, 
allow the manipulation of metastatic processes. In vivo mouse models showed 
that reducing the fluidity of the cell membrane prevents metastasis and inhibits 
and/or reverses epithelial-mesenchymal transition (EMT) which is commonly 
associated with cancer invasion and metastasis (90).  
 
An increasing number of experimental techniques have been developed recently 
that aim to screen and identify anti-invasion drugs for improved cancer patient 
survival. One such technique is a high-throughput three-dimensional invasion 
assay, involving the embedding of a tumour spheroid in collagen, which provides 
a 3D environment for the cells to migrate and invade into (91). By using a 3D 
matrix, the natural 3D tumour environment can be mimicked rather than using a 
2D assay before validation in in vivo studies. Drug development based on testing 
drugs on 2D cell monolayers has been shown to not effectively translate to clinical 
trials resulting in a high rate of trial failure due to limited drug efficacy (92). Live 
cell imaging of tumour cell generated spheroids allows insights into cell dynamics 
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of migrating cells, modes of migration by different cell types and the effects of 
drugs on cell morphology.  
 
Immunocytochemistry can also be employed on the collagen-embedded 
spheroids adding another level of assessment of drug efficacy (93). Large scale 
screening of such 3D-based assays will enhance accuracy of research findings 
and increase the chance of identifying drugs to progress towards trial phases. 
A new trend in cancer invasion research has been introduced known as 
migrastatics; a term used to describe drugs that interfere with cancer cell 
migratory mechanics and their ability to metastasise. Migrastatics have been 
proposed to specifically focus on inhibiting metastasis and invasion and to 
distinguish between drugs of a cytostatic nature that target proliferation and those 
that are specifically for anti-invasion purposes. For a successful launch of 
migrastatics, regulations for the approval of anti-cancer drugs targeting invasion 
need to be modified so that, in the absence of tumour shrinkage, candidate drugs 
can still be clinically evaluated. There is also an urgent need for large-scale 
testing of drug archives as well as testing new drugs that interfere with cell 
migration and invasion (81).  
 
1.5 Brain tumours - World Health Organisation classification of tumours of 
the central nervous system 
There are over 120 different types of brain and central nervous system tumours, 
all with different histological patterns, cell phenotypes, behaviours and 
mechanisms of progression and survival. This poses a great problem for neuro-
oncologists, neuro-pathologists and research scientists, alike, for diagnosis, 
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treatment and development of new treatments, as variances between the types 
of brain cancer can be slight but can have an important impact on tumour 
progression (94). In 2016, the World Health Organisation (WHO) published a 
reclassification of tumours of the central nervous system to introduce a more 
precise classification system in neuro-oncology and to reflect the heterogeneity 
of these tumours. The 2016 WHO classification of tumours of the central nervous 
system classifies brain tumours by cell origin, cell behaviour and least aggressive 
(benign) to most aggressive (malignant). Invasive tumour types are given a grade 
based on their rate of growth from least aggressive (Grade I) to most aggressive 
(Grade IV). By grading and classifying an individual tumour, predictions can be 
made on how the tumour is likely to behave (95). The information gathered and 
formed into the new classification combines histology with molecular biology, 
providing a tool that enables clinicians to deliver more accurate diagnoses, 
prognoses and treatment plans for patients. The new classification will also 
improve research and contribute to the development of novel treatments for this 
set of tumours as it allows scientists to be more selective and target particular 
tumour types. Eventually this will ensure that patients are matched to clinical trials 
according to the molecular make-up of their tumour and will receive targeted 
therapeutic intervention that will have the most advantageous effect. Another 
benefit of the updated classification is the effect on basic research. It will provide 
a platform for more accurate analysis and interpretation of experimental results, 
allowing for the identification of causes of tumour progression (96). By 
incorporating the integrated classification of molecular characteristics and 
histopathology, the brain tumour field will be able to progress to the same level 
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as other well-researched cancers, resulting in the development of highly targeted 
treatments for personalised care plans for brain tumour patients.  
 
1.6 Gliomas 
The 120 different types of brain tumour are generally named after the type of cell 
from which they originate. Gliomas develop from glial cells and account for 30% 
of all brain and central nervous system tumours (97). Gliomas can develop in the 
spine or the brain, the latter being the most common accounting for 80% of all 
malignant brain tumours. In 2013, 10624 new brain tumour cases were 
diagnosed in the UK with just 19% of patients surviving 5 years or more (98). 
Worldwide, 256 000 people were diagnosed with a primary brain tumour in 2012 
(99). There are three types of glioma; ependymomas, oligodendroglioma and 
astrocytoma. Astrocytomas account for 50% of all brain tumours and are graded 
from I to IV, IV being the most severe and known as glioblastoma (GBM) (100). 
These cancers are especially prevalent among children and the young adult, 
accounting for the biggest loss in life due to a cancer among all cancer types. In 
addition, personality changes frequently observed in glioma patients place a big 
strain on relatives and carers. 
 
1.7 Glioblastoma 
The location and infiltrative nature of GBM means surgery alone cannot cure it 
as it cannot be completely resected, unlike other cancers that can be completely 
cured by surgery such as non-melanoma skin cancer and testicular cancer. In 
addition, the characteristic of GBM resistance to therapeutic intervention stems 
from the complex disposition of the tumour itself (101). One of the main 
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contributors to the poor prognosis of GBM is its cellular heterogeneity. 
Phenotypical heterogeneity is evident in GBMs as they are composed of cell 
populations that express markers of both differentiated and undifferentiated cells. 
The level of differentiation and cell type varies between tumours, which exposes 
a fundamental difference in the progenitor cells of individual tumours (102).  
Sottoriva et al. (2013) demonstrated that GBM exhibits a multitude of 
heterogeneous mutations across the whole genome, backing the concept that 
individually tailored treatments need to be developed based on a range of 
biopsies from the same GBM (103).  
 
This heterogeneity has been associated with glioblastoma stem cells (GSCs), 
which in themselves, are a distinct subpopulation in GBM that are responsible for 
hierarchal cellular organisation. GSCs can be functionally defined by their self-
renewal properties and ability to give rise to a mass of heterogeneous tumour cell 
progeny (104). Whilst GSCs have been found to have a high tumorigenic 
potential, their proliferation rate remains low, presenting a similar phenotype to 
normal stem cells, including CD133 gene expression and other commonly 
expressed genes in neural stem cells. GSCs coordinate a number of other 
biological aspects of GBM including therapy resistance, cellular invasion and 
recurrence of tumour. Due to the failures of therapies to completely eliminate 
GBM tumours, the remaining cancer cells will greatly consist of those in a stem 
cell state, leading to tumour recurrence and regrowth. This underlines the need 
for stem cell specific targeting within therapies to prevent the regrowth of cancer 
cell populations (105). 
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The heterogeneous GBM cell populations take advantage of their surroundings 
by detecting and responding to external signals from the environment. Direct 
interactions of tumour-associated parenchymal cells and GBM cells control the 
progression of the disease and make up the tumour micro-environment that has 
a pathological impact on malignant brain tumours (106). Microglia are the most 
prevalent inflammatory cells that are able to penetrate GBMs by degrading the 
ECM. By doing so, these tumour-associated macrophages enhance the invasion 
of GBM cells into the surrounding brain. This infiltration of microglia is conducted 
by the tumour itself via the release of chemo-attractive cytokines, in order for it to 
take advantage of degradation carried out by the macrophages (107).  
 
Angiogenesis is a physiological process whereby new blood vessels form from 
pre-existing ones (108). It is a key factor in the progression and growth of GBM 
with microvasculature proliferation being linked to tumour aggression and 
recurrence. Microvessel density can be used as a postoperative prognostic 
marker. Through the use of the immunohistochemical stain Von Willebrand 
Factor on paraffin embedded samples of GBM, a direct correlation has been 
shown between microvessel density and patient survival (105). The strong 
vasculature network of neurogenic niches has been shown as the site for stem 
cell production for both malignant and normal brain tissue (109). Malignant 
gliomas are one of the most vascularised tumour types. They inhabit perivascular 
niches and depend on these to control the balance between self-renewal and 
differentiation. These niches support the tumours by providing nutrients and 
removing metabolic by-products (110). 
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The treatment of GBM is difficult and there are no curative approaches. Research 
leading to a better understanding of the molecular mechanisms and genetic 
mutations of GBM, as well as clinical trials, is pointing towards more tailored 
therapeutic approaches. However, an array of challenges still remains, including 
tumour location, relapse and as previously mentioned, tumour heterogeneity. The 
current standard of care consists of surgical resection followed by radiotherapy 
and adjuvant chemotherapy with temozolomide (111). Nearly all patients will 
develop a recurrent tumour, despite therapy, and treatment options are limited to 
palliative care. For some, a second resection may be beneficial but for the 
majority of patients, chemotherapy remains the treatment of choice for 
recurrence. For patients with a decreased performance status (criteria used by 
clinicians to assess the progression of the disease) solely palliative care options 
could be more appropriate (112).  
 
1.7.1 GBM subtypes  
The Cancer Genome Atlas Network compiled recurrent genomic aberrations in 
GBM and classified them based on gene expression. This molecular 
classification forms four GBM subtypes; Proneural, Classical, Mesenchymal and 
Neural. Multidimensional genomic information was integrated into this 
classification to determine patterns of somatic mutations (113). By classifying 
GBM into subtypes, a foundation for improved molecular knowledge of GBM 
signalling pathways has been established that will potentially lead to personalised 
treatment plans for patients suffering from this devastating disease and improve 
survival rates.  
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Proneural GBM is characterised by IDH/TP53 mutations, normal 
EGFR/PTEN/Notch signalling and is positive for the glioma-CpG island 
methylator phenotype (G-CIMP). The G-CIMP phenotype seems to be a common 
trait in low grade gliomas and provides a molecular classification for secondary 
GBMs, much like IDH mutation. Proneural GBM has neuronal differentiation and 
is commonly seen in young adults. This subtype of GBM is related to a better 
prognosis (114). 
 
The mesenchymal subtype of GBM is characterised by aberrant EGFR 
amplification, PTEN loss, NF1 and TP53 tumour suppressor gene mutations and 
Akt signalling. It has mesenchymal differentiation and is common in older adults 
with an association with worse prognosis, however with very aggressive 
treatment regimens, significant increases in survival are seen in patients with this 
type of GBM (115).   
 
Classical GBM tumour types are characterised by aberrantly high levels of EGFR, 
the highest of all the subtypes. In contrast, the TP53 gene, which is the most 
common gene to be mutated in GBM, is not mutated in classical GBM tumours. 
In response to aggressive treatment regimens, patients with classical GBM 
tumours survived the longest when compared to the other GBM subtypes (115).    
 
The neural GBM subtype has many of the same gene mutations as the other 
subgroups, with no particular mutation being shown as having a higher or lower 
frequency than the other groups. Neural GBM tumours are therefore 
characterised by the expression of standard genes of normal, non-cancerous 
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brain neurons and nerve cells.  Patients with this type of GBM are normally older 
and do not respond as positively to aggressive treatment compared to the 
classical and mesenchymal subtypes (115).  
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1.8 Project rationale  
GBM is the most common and most aggressive type of primary brain tumour. It 
is associated with very poor prognosis and a high mortality rate. The invasive 
phenotype of this cancer contributes to the low therapeutic response rate of 
patients and highlights the need for novel compounds that can target migration 
and invasion of these tumours. The work contained within this thesis aims to 
identify new targets of migration and develop novel approaches in which to stop 
invasion in GBM.         
 
1.8.1 Aims and objectives  
1. Characterise the migrational properties of established glioma cell 
lines and assess the effect of known actin polymerisation and RhoA 
signalling pathway inhibitors on these cell lines 
Glioma cell lines U87 and U251 will be tested to evaluate their migratory 
properties in vitro using a range of 2D and 3D assays. A panel of actin 
polymerisation and migration inhibitors will be used to assess their effect on the 
candidate cell lines. This will lead to novel findings on characterisation of 
migratory abilities among glioma cell lines and on the activity inhibitors on glioma 
cell migration.  
 
2. Select candidate inhibitor from the panel and determine mechanisms 
of inhibition in the actin polymerisation pathway 
The study will focus on the activity of an inhibitor selected from the initial panel to 
assess for effect on cell migration in terms of motility and morphology in detail. 
This will uncover new mechanisms and pathways that promote GBM cell 
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migration and to focus on for the development of novel strategies to improve GBM 
survival rates.  
 
3. Establish advanced 3D technologies for the assessment of drug 
activity for improved accuracy of in vitro drug development     
There is a need for more representative in vitro assays and data analysis for anti-
migratory drug development as most drugs taken forward to clinical trials fail in 
this field of brain tumour research. By developing a new technique that mimics 
the physiological environment within the brain, candidate drugs are selected 
more efficiently for application in preclinical trials.  
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Chapter 2: Inhibitors of the actin polymerisation pathway and 
their effects on glioma cell migration   
2.1 Introduction 
Actin polymerisation is a key process in cell migration. As previously mentioned, 
it drives rearrangements of the actin cytoskeleton allowing cells to rapidly change 
their morphology to respond to external cues for efficient migration. Inhibition of 
G-actin monomer polymerisation into an actin filament prevents actin 
rearrangements resulting in loss of cell migration (116).  
 
2.1.1 Inhibitors of the actin polymerisation pathway 
Pharmacological inhibitors that interfere with actin polymerisation, 
depolymerisation and actin cytoskeletal rearrangements are commonly used to 
investigate the role of actin dynamics in a number of different cellular processes. 
These inhibitors can be grouped into several different classes (117). The most 
prominent class of inhibitors includes those targeting actin polymerisation. 
Examples of drugs in this class include latrunculin, which directly sequesters the 
free G-actin monomers preventing their polymerisation onto the filament chain, 
and cytochalasin, which binds with high affinity to the barbed end of the actin 
filament stopping the addition of G-actin (118,119). Another class of actin 
inhibitors comprises compounds that prevent the disassembly of actin filaments. 
An example of this class is the drug jasplakinolide, which is commonly used as a 
stabilising drug for actin filament polymerisation (120). However, at high 
concentrations, it can interfere with depolymerisation by joining the majority of 
free G-actin monomers to the filament and lowering the dissociation rate (121). A 
further class of actin inhibitors includes drugs that have an effect on actin 
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rearrangement. Myosin II is a motor protein involved in the reorganisation of the 
actin network causing cells to shift from generating protrusions to contraction 
(122). Blebbistatin is a small molecule inhibitor that blocks myosin in an actin-
detached state preventing acto-myosin crosslinking (123). Other drugs in this 
class inhibit myosin II activators such as the ROCK inhibitor Y-27632 (124).  
 
Actin inhibitor studies have not only allowed the identification of actin 
cytoskeletal-dependent cellular processes but have also become a useful tool in 
investigations in clinical studies (Table 2). There have been a number of 
successful clinical trials with actin inhibitors. In the field of optometry, such studies 
include latrunculin B and cytochalasin B. In a phase I clinical trial using latrunculin 
B it was observed that the inhibitor reduced intraocular pressure in glaucoma 
patients through its inhibition of ROCK, which induces muscle relaxation (125). 
Cytochalasin B was used in a phase I clinical trial to investigate its effect in 
patients after a coronary angioplasty. This study showed that delivering 
cytochalasin B directly to the arterial walls decreases restenosis (an abnormal 
recurrence of narrowing of the artery or valve wall after corrective surgery) by 
preventing the depolymerisation in vascular smooth muscle cells that occurs as 
a result of balloon angioplasty trauma (118). Another successful actin inhibitor 
clinical trial includes the drug HA-1077 (fasudil), another ROCK inhibitor and 
vasodilator (126). It was found that fasudil significantly reduces cerebral 
vasospasm and cerebral infarction occurrence in patients with subarachnoid 
haemorrhage, improving the clinical prognosis of these patients. The initial study 
based on a small sample size produced promising results, with further validation 
envisaged in a larger clinical trial (127).  
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In GBM research, a drug repurposing study identified fluvoxamine, a clinically 
used anti-depressant, to be a potent inhibitor of the actin polymerisation pathway, 
with the capability to block GBM cell invasion through the inhibition of FAK and 
Akt. It was shown that fluvoxamine did not produce a direct effect on actin or 
Arp2/3 (a protein complex involved in the regulation of the actin cytoskeleton) as 
it did not inhibit Arp2/3-dependent actin polymerisation. This shows that actin 
polymerisation inhibition by fluvoxamine is induced via the inhibition of actin 
polymerisation-related proteins in the brain cytosol and not by the direct inhibition 
of Arp2/3 or actin itself (128).  
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Actin 
Polymerisation 
Inhibitor 
Chemical 
Formula Target 
Clinical 
Trials Applicability 
Latrunculin A C22H31NO5S  Globular actin N/A N/A 
Latrunculin B C20H29NO5S Globular actin Glaucoma 
Decreased 
intraocular 
pressure which 
leads to 
glaucoma (10) 
CCG-1423 C18H13ClF6N2O3  MKL1 N/A N/A 
Y-27632 C14H21N3O.2HCl  ROCK1/2 N/A N/A 
Cytochalasin B C29H37NO5  
Filamentous 
actin 
Coronary 
angioplasty 
and 
restenosis 
 
Can be safely 
administered, 
further study 
needed for 
efficacy in 
reducing 
restenosis (14) 
Cytochalasin D C30H37NO6  
Filamentous 
actin N/A N/A 
CK666 C18H17FN2O  
Arp2/3 
complex N/A N/A 
Wiskostatin 
 
C17H18Br2N2O 
 
N-WASP N/A N/A 
HA-1077 
(Fasudil) 
C14H17N3O2S.HCl 
 ROCK 
Cerebral 
vasospasm 
Current 
treatment for 
the disease 
(11) 
NSC23766 C24H38CI3N7  Rac1 N/A N/A 
Table 2. Examples of inhibitors targeting different effectors of the actin polymerisation 
pathway, their application in clinical trials and applicability in practice. 
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2.1.2 Selection of candidate inhibitors of the actin polymerisation pathway  
For initial assessment of compound activity on actin polymerisation, a panel of 
commercially available inhibitors was chosen that target different steps in the 
pathway (Figure 5). The panel included 5 inhibitors of the actin polymerisation 
pathway and the Rho signalling pathway. The chosen inhibitors included 6-
bromoindirubin-oxime (BIO) and lithium chloride (LiCl), which both target GSK-3, 
Y-27632, which targets ROCK, latrunculin A which targets G-actin and CCG-
1423, which targets MKL1.  
 
The first candidate drug in the panel of inhibitors, BIO, is part of the indirubin 
family; a family of bis-indole isomers, isolated from various natural sources 
Figure 5. A simplified schematic diagram of the actin polymerisation pathway and the RhoA 
signalling pathway. Inhibitor targets are shown circled in red. BIO and LiCl target GSK3, Y-
27632 targets ROCK, LatA targets actin monomers and CCG-1423 targets MKL1.       
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including varieties of marine mollusc, recombinant bacteria and mammalian urine 
(130). They are the active ingredient of Danggui Longhui Wan, a traditional 
Chinese medicine that has been successfully used for treatment of chronic 
myelocytic leukaemia (131). The cell permeable compound indirubin-3’-
monoxine possesses anti-mitotic properties, pushing cells into endoreplication 
and cell death (132). Indirubins have been shown to be potent inhibitors of 
glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase which targets 
actin cytoskeletal dynamics through its regulation of RhoGAPs and actin 
polymerisation (133). The indirubins have been of great interest for the 
development of pharmacological interventions in a number of neurological 
diseases. In both sporadic and familial types of Alzheimer’s disease, over-activity 
of GSK-3 has been implied in hyper-phosphorylation of tau, increased β-amyloid 
production, memory impairment and microglial-mediated inflammatory response 
to local plaques, all hallmarks of Alzheimer’s disease (134). By utilising the 
indirubins’ potential to inhibit GSK-3, the development of pharmacological 
interventions for diseases such as Alzheimer’s can be investigated. Common to 
members of the indirubin family is a naturally occurring product, 6-
bromoindirubin, whose synthetic derivative is BIO. This cell-permeable indirubin 
has been shown to be an inhibitor of GSK-3 both in vitro and in vivo (135). Studies 
using BIO demonstrated reduced glioma cell invasion (in vitro and in vivo) and 
improved the survival of mice in intracranial xenograft models. In both intracranial 
and orthotopic xenograft models, it was also shown to reduce angiogenesis by 
blocking the migration of blood vessel endothelial cells (136). A study into 
colorectal cancer showed that BIO upregulated stemness, adhesion and 
chemoresistance. It was also shown that it is a non-specific inhibitor with targets 
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including JAK1, TYK2, GSK3α and, of course, GSK3. The molecular mechanisms 
causing increases in stemness, adhesion and chemoresistance in colorectal 
cancer cells after treatment with BIO still need to be further investigated (137).  
 
The second drug candidate in the inhibitor panel was LiCl, which also targets 
GSK-3. LiCl was one of the first GSK-3 inhibitors to be described and inhibits cell 
migration both directly and indirectly by increasing the inhibitory phosphorylation 
of GSK-3 (138). Its other targets include inositol monophophatase (IMPase), 
phosphomonoesterases and phosphoglucomutase, which are structurally similar 
to GSK-3, as well as the arrestin-2/Akt complex (139). Although there is a broad 
range of targets, Patel et al. showed that LiCl effectively inhibits GSK-3 as it 
activates glycogen synthase, increases intracellular β-catenin levels and reduces 
the phosphorylation of tau in neurons (140). LiCl has been used for the treatment 
of bipolar disorder as a mood stabiliser and, like BIO, has been evaluated for its 
use in neurodegenerative diseases such as motor neuron disease and 
Alzheimer’s disease (141–143). In glioma, LiCl was found to be a potent inhibitor 
of cell migration in spheroid, wound-healing and brain slice assays. Its effect was 
found to be specifically targeting cell migration, as it did not affect cell viability at 
predetermined concentrations used for cell migration studies. LiCl induced 
morphological changes, with cells becoming more rounded and concomitant loss 
of cell protrusions. Although LiCl has many targets, there is evidence that LiCl 
targets GSK-3 in glioma cell migration. Examination of LiCl different known 
targets, including inositol monophophatase (IMPase) and the large family of 
related phosphomonoesterases, showed that there was no effect on migration 
  
43 
upon the inhibition of IMPase whereas there was with inhibition of GSK-3 
(144,145). 
 
The third inhibitor in the panel was Y-27632; a selective ROCK inhibitor. Its 
inhibitory effect showed a 100x greater selectivity for ROCK over other kinases 
including protein kinase C, cAMP-dependent kinase and myosin light chain 
kinase (146). Y-27632 activity has been shown to reduce platelet shape change 
and activation (147,148), relax aortic smooth muscle contractions (149) and 
reduce hypertrophy of cardiomyocytes (150), amongst other effects. In cancer 
studies using rat MM1 hepatoma cells, Y-27632 has proven to be a promising 
tool in the pharmacological manipulation of the Rho pathway to control tumour 
invasion. In vitro and in vivo studies have shown that Y-27632 does not inhibit 
tumour growth, however, in an in vivo study for multiple myeloma involving an 
11-day treatment regimen in rats it considerably reduced tumour cell 
dissemination with no apparent adverse side effects, suggesting 
chemotherapeutic potential for preventing invasion and metastasis (151). Y-
27632 has also been shown to decrease breast cancer cell invasion in vitro and 
metastasis in vivo in a human breast to bone cancer metastasis model in mice 
(152). Other cancer types targeted by Y-27632 activity include ovarian, colon and 
hepatocellular carcinomas (153–155). In glioma in vitro research studies, Y-
27632 profoundly inhibited glioma cell migration as determined in transwell and 
brain slice assays (156). Y-27632 is not completely ROCK-specific or isoform-
specific and, at similar concentrations, it can block a wide range of kinases, which 
has been shown to result in a number of undesired side effects including 
hypotension and reduction in resting cerebral blood flow, which can lead to brain 
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hypo-perfusion. This has also been previously observed in mice treated with Y-
27632 during stroke (157).  
 
The inhibitor panel also included a naturally occurring macrolide, isolated from 
the Red Sea sponge Negombata magnifica, latrunculin A (LatA) (158). It was first 
identified as an inhibitor of actin polymerisation by its effects on cell morphology 
and actin filament distribution in non-smooth muscle cells (159). An in vitro study 
on the effects of LatA on the steady state of F-actin showed that its effects are 
consistent with direct sequestering of G-actin monomers (119). Its binding site 
was established based on an investigation into the effects of LatA on yeast actin 
mutations, which revealed that the binding site of LatA is on/near the actin 
nucleotide binding cleft (160,161). Currently, a clinical trial is under way to explore 
the ability of LatA to aid oocyte vitrification in humans and preserve fertility 
capabilities (162). Previous in vitro studies indicated that LatA activity induced 
stabilisation of the oocyte actin cytoskeleton promoting oocyte robustness prior 
to cryopreservation and increasing the survival rates of oocytes after thawing 
(163). LatA has also been found to aid normal chromosomal segregation by 
improving accurate F-actin formation in cloned mice embryos. As abnormal 
chromosome segregation is a major cause of developmental failure in cloned 
embryos, treatment with LatA improved the formation of F-actin and increased 
the birth rate of the cloned embryos (164). A further study revealed the potential 
of LatA for further investigation and application in cancer research by reducing 
peritoneal dissemination of gastric cancer. In vitro, LatA-induced a loss of the cell 
adhesion complex in the gastric cancer cell lines MKN45 and NUGC-4, leading 
to cell rounding. After a 72-hour treatment, cells treated with LatA lost focal 
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contact with concomitant shrinkage or bursting resulting in a LatA-induced 
morphological change. In vivo, mice inoculated with MKN45 and NUGC-4 
tumours exhibited a significant increase in survival when treated with LatA via 
intraperitoneal injection (165). In vitro glioma cell migration studies showed that 
LatA significantly reduces the movement and velocity of glioma cells and causes 
alterations in cell morphology, resulting in cell rounding and thinning of cell 
protrusions (166).  
 
The final drug in the inhibitor panel was a small molecule inhibitor called CCG-
1423, which elicits its effects downstream of both RhoA and actin polymerisation 
by blocking the nuclear import of MKL1 and preventing the activation of 
MKL1/SRF-dependent transcription (167). In doing so, CCG-1423 inhibits the 
production of CCN1 (also known as Cysteine-rich angiogenic inducer 61 or 
CYR61); a multifunctional matricellular protein involved in cell adhesion and 
mesenchymal cell migration (168). In vivo studies using CCG-1423 recognised 
its anti-fibrotic potential in skin, lung and vascular fibrosis mouse models. In all 
three cases, CCG-1423 was shown to reduce fibrosis in blood vessels, skin and 
lungs when injected intraperitoneally (169–171). A proof of concept study was 
carried out as a follow up to the initial studies which revealed that local delivery 
of CCG-1423 decreases scar tissue formation in a preclinical model of fibrosis 
(172). In cancer studies, CCG-1423 was found to significantly affect the Rho 
transcription signalling pathway in the aggressive human prostate cancer cell line 
PC-3, resulting in the inhibition of PC-3 invasion and the disruption of a number 
of biological processes including cell cycle, DNA repair and replication, apoptosis, 
G1/S checkpoints and endoplasmic reticulum stress. In addition, targets of the 
  
46 
E2F family (Rho targeted transcription factors) and genes related to melanoma 
progression and metastasis were strongly repressed by CCG-1423 (173). In 
glioma-associated studies on Wnt5a-induced GBM invasion CCG-1423 
treatment reduced Wnt5a-induced stress fibre formation and decreased GBM cell 
invasion in the U251 and T98MG GBM cell lines, assessed by the Boyden 
chamber assay with a pore size of 0.8µm, confirming the involvement of Wnt5a 
in promoting GBM invasion via the RhoA signalling pathway (174).   
 
2.1.3 Two-D vs 3D migration 
In their natural physiological environment, migratory cells connect with each other 
by cell-cell interactions, as well as with the ECM for mechanical support enabling 
the cells to move efficiently in all three dimensions. The traditional 2D in vitro 
environment - cell monolayers attaching to a plastic support - is not a true 
representation of such biological microenvironments; they do not reflect cellular 
processes occurring in vivo. These processes include gene expression, 
apoptosis and drug uptake and delivery, as well as cell migration (175). Using a 
3D model in vitro system provides a more accurate representation of the in vivo 
environment and represents the intermediate step between 2D and in vivo 
modelling. One fundamental difference between 2D and 3D in vitro systems is 
the absence of steric hindrance in 2D migration. Only frictional (drag) forces from 
the 2D surface and surrounding liquid need to be overcome in 2D migration 
resulting in a higher migration speed. In addition to the frictional forces, 3D 
migrating cells need to overcome the forces associated with the steric hindrance 
of the matrix network. Under these conditions cells are presented with two 
options, to distort themselves enough to fit through the pores or to 
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distort/manipulate the matrix to ensure that the size of the pore is large enough 
to pass through. The first option is now known as path-finding migration, whereas 
the second option as path-laying, which involves matrix degradation (176). 
 
A 2D tissue culture environment exerts a significantly different effect on cell 
morphology than a 3D culture. For example, breast cancer cell line BT474 
(ER/PR-positive, HER2-positive) grown in a 2D culture forms patches on a flat 
solid support. When grown in suspension culture conditions, cells from the same 
cell line grow as spheroids with a seemingly smooth surface. In contrast, 
HCC1954 cells (a ER/PR-negative, HER2-positive breast cancer cell line) do not 
grow in clusters but prefer to grow more spread out and independently when 
grown in 2D culture. In 3D, these cells form very tight spheroids with a rougher 
surface than BT474 (177,178). The differences between 2D and 3D culturing 
techniques present a problem when trying to determine drug efficacy. Drug 
development and lead selection is firstly based on 2D in vitro drug screens to 
identify candidate drugs from a large panel for further testing. However, 
comparisons of 2D and 3D in vitro methods using, for example, the anti-cancer 
drugs neratinib and docetaxel showed that cells grown in 3D cultures displayed 
greater drug resistance compared to the same cells grown in 2D. In addition to 
this, levels of specific proteins involved in cell survival and growth also targets of 
the drugs were all increased in cells grown in 3D. The increase in protein 
expression levels likely contributed to the observed drug resistance as 
overexpression of these proteins had previously been linked to the facilitation of 
acquired drug resistance (177).   
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Historically, 2D methods of cell culture and analysis have been favoured due to 
their feasibility, ease and as the gold standard of tissue culturing. However, 3D 
technologies and cultivation including the use of bioreactors and hydrogels, are 
now becoming more popular as they offer a more physiologically applicable 
environment in which to investigate the behaviours of cells and tissues. The 
increasingly expanding field of 3D cell culturing is continuously evolving to 
address the current challenges in research, particularly around drug 
development. Currently, it is still necessary to employ 2D screening methods 
because of associated cost implications and ease of performance, however, 3D 
studies do yield more accurate and reproducible results in terms of observed 
cellular processes and interactions in vivo  and can be carried out in combination 
with 2D testing (179). 
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2.2 Materials and methods 
2.2.1 Cell lines and media 
The adult glioma cell lines U87 (Grade IV, GBM) and U251 (Grade IV, GBM) were 
used in this study, originally established by Pontén and colleagues (180). These 
cells have been comprehensively characterised in terms of genomic alterations 
and gene expression patterns. Cells were grown in Dulbecco’s Modified Eagles 
medium (DMEM) (Sigma) with 10% heat-inactivated foetal calf serum (HI-FCS) 
(Labtech) and 0.5% penicillin-streptomycin (Sigma) (complete medium). They 
were free of mycoplasma contamination as confirmed by Sarah Perry (In house 
testing at LICAP) and had been genotypically profiled by University of Leeds in-
house services (Claire Taylor).  
 
2.2.2 Cell culture 
Cells were cultured in a Sanyo CO2 incubator at 37°C in a humidified atmosphere 
of 5% CO2 (in air). Cells were maintained in plastic tissue culture flasks (Corning) 
and harvested at or near confluence by washing with PBS and adding trypsin 
(10x solution, diluted 1:10 in Hanks Balanced Salt Solution, (Sigma)). Cells were 
viewed/imaged with a Nikon eclipse TS100 microscope and counted using an 
improved Neubauer haemocytometer (Weber Scientific).  
 
2.2.3 Chemicals 
Chemicals/inhibitors used were LiCl (Sigma), BIO (Calbiochem), ROCK Inhibitor 
Y-27632 (Abcam), RhoA Inhibitor CCG-1423 (Tocris) and Latrunculin A (Sigma 
Aldrich), all reconstituted as stock solutions in lab grade DMSO (Sigma). 
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2.2.4 Live cell imaging 
U251 and U87 cells were adjusted to a density of 1.5x103/ml in complete medium. 
100µl of U251 or U87 cell suspension was pipetted into each well of a flat 
bottomed 96 well plate (half a plate per cell line) and incubated for 24 hours at 
37°C. Following incubation, 100µl of complete medium (control) or known 
inhibitor (20mM LiCl, 5µM BIO, 10µM ROCK inhibitor, 500nM CCG-1423, 10µM 
LatA) was added. The plate was imaged using the IncuCyte Zoom System for 72 
hours at 37°C. Movies were generated using the IncuCyte Zoom System software 
and analysed in ImageJ.  
 
2.2.5 Two-D transwell migration assay 
The underside of 24 well, 8µm pore Transwell Inserts (Greiner Bio-one) were pre-
coated with 5µg/ml of fibronectin (Sigma) in PBS for one hour at 37°C. Cell lines 
were pre-treated with either 20mM LiCl, 5µM BIO, 10µM ROCK inhibitor, 500nM 
CCG-1423, 10µM LatA (all pre-determined anti-migratory concentrations) or 
control medium for one hour before 50µl 5x104 cells were placed into the 
transwell insert for each condition in triplicate and allowed to migrate for four 
hours. Migrated cells were fixed with 1% glutaraldehyde (Sigma) in PBS for 10 
minutes and, after several washes with PBS followed by H2O, visualised by 
staining with 0.1µg/ml 4',6-diamidino-2-phenylindole (DAPI) (Biotium).  
 
2.2.6 Three-D spheroid invasion assay in collagen 
Spheroids were formed by placing 5x103 cells/ml in an ultra-low attachment round 
bottom 96-well plate (Costar, Corning Lifesciences) and then incubated for 72 
hours at 37°C (93). The media was removed and 100µl of neutralised (1M NaOH, 
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supplemented with 5xDMEM) rat tail collagen 1 (BD Biosciences) was added to 
each well and allowed to polymerise at 37°C for 15 minutes to entrap the 
spheroid. For evaluation of the effects of inhibitors on migration, the collagen was 
then overlaid with 100µl of complete medium (control) or individual inhibitor in 
complete medium (2X 20mM LiCl, 5µM BIO, 10 µM Y27632, 500nM CCG-1423). 
Each condition was repeated in multiple repeats but at least in triplicate for each 
plate. Each experiment was repeated three times. Spheroid expansion and 
invasion into the collagen matrix was monitored for 72 hours using the EVOS cell 
imaging system (Advanced Microscopy Group, Life technologies) at x4 
magnification.  
 
2.2.7 Migration on nanofiber plates 
2x104/ml cells of GFP labelled U251 (obtained from Dr Nora Suas) were 
suspended in 20µl drops from the lids of petri dishes for 72 hours to allow the 
formation of cell spheroids. Cell spheroids were manually transferred into wells 
of aligned poly-e-caprolactone nanofiber coated culture plates (Nanofiber 
solutions), which promotes cell migration on a 3D scaffold stimulated by 
topographic cues. The spheroids were then incubated at 37°C in either 20mM 
LiCl, 5µM BIO, 10µM ROCK inhibitor, 500nM CCG-1423, 10µM LatA or complete 
medium (control) in triplicate and migration was monitored for 72 hours using the 
EVOS cell imaging system at x4 magnification.  
 
2.2.8 Data analysis  
Three-D spheroid invasion and nanofiber plate assays were analysed by creating 
a migration index using Volocity 3D Image Analysis software according to Cockle 
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et al, 2015 (181). ImageJ (http://rsbweb.nih.gov/ij) and Excel (Microsoft, USA). 
Live cell imaging distance and direction were analysed using the MTrackJ tool in 
ImageJ (http://rsbweb.nih.gov/ij). Transwell assays were analysed by quantifying 
the area covered by migrating cells using Velocity 3D Image Analysis software 
(Perkin-Elmer inc). Data was examined for normality using an online Shapiro-
Wilk test (http://sdittami.altervista.org/shapirotest/ShapiroTest.html).  Differences 
between control cells and treated cells were compared using a two-tailed T-test 
(Excel). P-values ≤0.05 were considered statistically significant.  
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2.3 Results 
2.3.1 Adult glioma cell lines display different migration patterns  
The cell lines used in this study were the established adult glioma cell lines U251 
and U87. The U251 cell line was derived from a malignant astrocytoma from a 
male patient and was established in the 1960s by the Wallenbery Lab in Uppsala, 
Sweden (182). This cell line is characterised by glial markers presenting as GFAP 
positive and b3-tubulin negative. In contrast, U87 presents as GFAP negative 
and b3-tubulin positive, thus representing a more neuronal phenotype. The U87 
cell line was also established in the Wallenbery Lab in the 1960s from a 44-year-
old female patient (183). Although these cell lines appear morphologically 
different, previous studies have shown that both migrate in a mesenchymal 
pattern, a key characteristic of invading GBM cells (184). U251 cells display this 
phenotype more distinctly, with pronounced lamellipodia at the leading edge, 
whereas U87 cells present with longer singular protrusions (Figure 6). 
 
U251 U87 
Figure 6. U251 and U87 display different patterns of migration. The cell lines were grown 
in complete DMEM medium and pictured at x10 magnification. Arrows indicate 
differences in the leading edges of U251 and U87, which are highlighted in the boxed 
images. Pronounced lamellipodia are a characteristic in U251 cells whereas single 
elongated protrusions are observed in U87. Scale bar = 400µm. 
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Cell morphologies changed in a 3D setting in collagen. Migrating cells in close 
proximity to the original spheroid core assumed a rounded morphology, which 
changed to an elongated morphology as the cells migrated away from the original 
core. U251 cells appeared to migrate in chains and prefer cellular contact with 
each other as they moved away from the original core with the cell furthest away 
in the chain seemingly detaching once a certain distance from the original 
spheroid was reached. U87 cells appeared to preferentially migrate as single 
cells (Figure 7). 
 
 
 
2.3.2 Inhibitors targeting different steps in the actin polymerisation pathway 
exert distinct effects on cell morphology and migration 
Live cell imaging of the two cell lines revealed distinct differences in cell 
morphology (Figure 8) and cell migration as measured by distance travelled and 
direction (Figure 9) after treatment with the different inhibitors. Directional 
U251 U87 
Figure 7. U251 and U87 spheroids in collagen were incubated in complete DMEM medium 
and imaged at x4 magnification at 72 hours. White arrows indicate rounded cells near the 
core and black arrows indicate elongated cells at the migration edge. Examples of the 
migratory phenotypes are highlighted in the boxes U251 cells migrated in interconnected 
strings with the cell furthest away from the original core detaching into the surrounding 
matrix, whereas U87 appeared to migrate as single cells. Scale bar = 1000µm. 
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migration as measured by cell displacement is promoted by the creation of a 
leading edge through intracellular signalling of Rho GTPases (185).  
 
After treatment with BIO, migration (both in terms of distance and displacement) 
was significantly reduced in both cell lines in comparison to the control. The 
effects of BIO were observed almost immediately, within minutes of treatment, in 
both cell lines and were maintained throughout the 72 hours of imaging. There 
was a notable change in morphology in U251 cells, with a shift to a more 
elongated morphology whereas U87 cells were characterised by mixture of both 
elongated and rounded cells. U251 treated with BIO travelled an average 
distance of 809.7µm +/- 40.2µm, which was significantly different to the control 
(3864.1µm +/- 162.5µm) (P=2.87x10-16). The displacement of U251 treated with 
BIO was 100.5µm +/- 12.5µm, which was significantly different to the control 
(451.9µm +/- 26.1µm) (P=4.30x10-11). U87 treated with BIO travelled an average 
distance of 513.2µm +/- 21.5µm, which was significantly different to the control 
(3061.6µm +/- 258.7µm) (P=7.96x10-9). The displacement of U87 treated with 
BIO was 77.4µm +/- 6.6µm, which was significantly different to the control 
(335.6µm +/- 6.4µm) (P=1.62x10-22). 
 
LiCl also had a significant inhibitory effect on glioma invasion. Cell rounding was 
observed in both cell lines, indicating an anti-migratory activity of LiCl. The effect 
of the inhibitor on cell morphology was firstly noted after 12 hours, post drug 
addition, for both cell lines but appeared more pronounced in U87 cells compared 
to U251 cells, with the majority of the cells seemingly retracting their protrusions 
and exhibiting a rounded morphology. The effect of LiCl on U87 appeared to 
  
56 
wane around the 48-hour mark, with the cells starting to recover and adopting 
their normal cell morphology. In comparison, U251 cells did not recover and 
remained rounded for the duration of the imaging. U251 treated with LiCl travelled 
an average distance of 934.8µm +/- 33.4µm, which was significantly different to 
the control (3864.1µm +/- 162.5µm) (P=8.09x10-16). The displacement of U251 
treated with LiCl was 87.4µm +/- 6.0µm, which was significantly different to the 
control (451.9µm +/- 26.1µm) (P=1.94x10-12). U87 treated with LiCl travelled an 
average distance of 551.1µm +/- 50.1µm, which was significantly different to the 
control (3061.6µm +/- 258.7µm) (P=1.56x10-8). The displacement of U87 treated 
with LiCl was 84.9µm +/- 8.6µm, which was significantly different to the control 
(335.6µm +/- 6.4µm) (P=8.48x10-20). 
  
A marked change in morphology was also observed in both cell lines when 
treated with Y-27632. The observed change was the most striking compared to 
the phenotypes seen after addition of the other inhibitors in the panel. The cells 
became extremely elongated taking on a very neuronal-like morphology, with the 
inability to retract the trailing tail when attempting to migrate. Y-27632 induced 
the observed changes after addition of drug within 24 hours and maintained its 
effect beyond the 72-hour imaging period for both U251 and U87, before the cells 
recovered. U251 treated with Y-27632 travelled an average distance of 717.9µm 
+/- 22.0µm, which was significantly different to the control (3864.1µm +/- 
162.5µm) (P=5.75x10-17). The displacement of U251 treated with Y-27632 was 
91.1µm +/- 3.7µm, which was significantly different to the control (451.9µm +/- 
26.1µm) (P=1.66x10-12). U87 treated with Y-27632 travelled an average distance 
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of 644.5µm +/- 11.5µm, which was significantly different to the control (3061.6µm 
+/- 258.7µm) (P=2.45x10-8). The displacement of U87 treated with Y-27632 was 
78.2µm +/- 0.8µm, which was significantly different to the control (335.6µm +/- 
6.4µm) (P=4.69x10-28). 
 
Treatment with CCG-1423 produced a mixed population of cells with a rounded 
and elongated morphology, which was observed in both cell lines after 12 hours 
and persisted for 72 hours, after which the cells recovered. Unlike the other 
inhibitors, the effect of the drug on distance travelled only just reached statistical 
significance for both U251 and U87. Significance was not reached in either cell 
line for displacement. U251 treated with CCG-1423 travelled an average distance 
of 3320.0µm +/- 78.1µm, which just reached significance in comparison to the 
control (3864.1µm +/- 162.5µm) (P=0.03). The displacement of U251 treated with 
CCG-1423 was 526.8µm +/- 29.6µm, which was not significantly different to the 
control (451.9µm +/- 26.1µm) (P=0.16). U87 treated with CCG-1423 travelled an 
average distance of 2030.8µm +/- 132.0µm, which reached significance in 
comparison to the control (3061.6µm +/- 258.7µm) (P= 0.013). The displacement 
of U87 treated with CCG-1423 was 427.4µm +/- 36.2µm, which was not 
significantly different to the control (335.6µm +/- 6.4µm) (P=0.07). 
 
LatA exerted an immediate anti-migratory effect in the two cell lines, leading to 
cell rounding instantaneously after drug addition, which was maintained for 72 
hours. However, observation beyond the 72-hour mark showed that the cells 
recovered as they returned to an elongated, migratory morphology. U251 treated 
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with LatA travelled an average distance of 595.6µm +/- 36.7µm, which was 
significantly different to the control (3864.1µm +/- 162.5µm) (P=2.79x10-17). The 
displacement of U251 treated with LatA was 73.4µm +/- 6.4µm, which was 
significantly different to the control (451.9µm +/- 26.1µm) (P=7.37x10-13). U87 
treated with LatA travelled an average distance of 270.6µm +/- 12.8µm, which 
was significantly different to the control (3061.6µm +/- 258.7µm) (P=8.88x10-10). 
The displacement of U87 treated with LatA was 57.5µm +/- 1.3µm, which was 
significantly different to the control (335.6µm +/- 6.4µm) (P=4.26x10-29). 
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Control	
(medium	only)	
Figure 8. U251 and U87 cell lines display morphological changes in response to treatment with the same inhibitors. Cell lines were grown in a 96 
well plate in complete DMEM medium in the presence of the inhibitors. They were imaged with the Incucyte Imaging system for 72 hours at x10 
magnification. Drugs were added at time point 0-hours. Movie stills were generated from exported movies. Specific morphological changes induced 
by addition of the various drugs were observed for both cell lines.     
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9A 
9B 
Figure 9. Cell migration is inhibited by a panel of inhibitors acting on different stages of the 
actin polymerisation pathway. Graphs show the effects of the inhibitors on cell migration 
as measured by distance travelled and cell displacement. 9A shows the effects of the 
inhibitors in U251 cells. 9B shows the effects of the inhibitors in U87 cells. Experiments 
were repeated in triplicate Asterisks indicate statistically significant results compared to 
the control (Med). *P≤ 0.05, ****P≤ 0.0001. 
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2.3.3 Inhibitors targeting the actin polymerisation pathway exert anti-
migratory effects in a 3D migration assay 
Tumour spheroids were generated using a 96-well round bottom low adherence 
plate. Both U251 and U87 readily formed spheroids within 72 hours with U87 
forming bigger spheroids due to a higher proliferation rate compared to U251 
(186). These spheroids are a more representative model of 3D tumours since 
they possess a 3D multicellular and morphological structure as reported for 
gliomas (187). Once embedded in collagen, cells migrated away from the original 
spheroid core into the surrounding collagen. The migration front and the migration 
edge were both measured and expressed as a migration index (MI) to analyse 
the ability of the cells to migrate under different treatment conditions. The 
migration front refers to 75% of the total migrated area of the cells. The migration 
edge refers to the outer most area where the furthest cells have migrated to. As 
results may be skewed as a result of individual cells migrating more efficiently 
compared to the majority, the MIs were determined for both the migration edge 
and front. Differences in the migratory performance of individual cells may also 
be important in terms of drug development targeting cell subpopulations with 
seemingly different migratory abilities. Therefore, both the migration front and the 
migration edge were measured. A migration index (MI) was then calculated by 
dividing the area of the tumour spheroid core by the area of the migration front or 
the migration edge. Treatment with the various inhibitors revealed that the ROCK 
inhibitor Y-27632 had the most pronounced anti-migratory effect on U87 
spheroids with almost no migration being observed away from the core (Figure 
10). The most effective inhibitor for U251 spheroid invasion appeared to be LiCl 
(Figure 10) as it led to the greatest reduction in migration.  
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U251 cells treated with LiCl had an average MI for the migration front, at 24-
hours, of 0.21 +/- 0.05 which was statistically significant compared to the control 
(0.51 +/- 0.03) (P=0.014). The MI for the migration edge of U251 cells treated 
with LiCl at 72 hours was 0.69 +/- 0.06 which was also significantly different 
compared to the control at 72 hours (0.83 +/- 0.02) (P=0.017). Significance was 
not reached for the 48-hour time point for the migration front. For the migration 
edge at the 24-hour time point, U251 cells treated with LiCl had an MI of 0.34 +/- 
0.08 which was statistically significant compared to the control (0.72 +/- 0.02) 
(P=0.004). At 48 hours, U251 cells treated with LiCl had an MI of 0.67 +/- 0.05 
which is significantly different to the control (0.72 +/- 0.02) (P=0.021). There was 
also statistical significance at the 72-hour time point with the average MI being 
0.81 +/- 0.01 compared to the control (0.72 +/- 0.02) (P=0.0002). U87 cells 
treated with LiCl had an average MI for the migration front, at 24-hours, of 0.54 
+/- 0.06 which reached statistical significance compared to the control (0.72 +/- 
0.04) (P=0.02). The MI for the migration edge of U87 cells treated with LiCl at 72 
hours was 0.70 +/- 0.05 which was also significantly different compared to the 
control at 72 hours (0.82 +/- 0.005) (P=0.002). Significance was not reached for 
the MI at the 48-hour time point for the migration front. For the migration edge at 
the 24-hour time point, U87 cells treated with LiCl had an MI of 0.71 +/- 0.07 
which was statistically significant compared to the control (0.87 +/- 0.004) 
(P=0.01). This was the only time point to reach statistical significance for the 
migration edge in U87 cells treated with LiCl.  
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Statistical significance was not reached for any of the time points for the MI of the 
migration front in U251 cells treated with BIO. For the MI of the migration edge, 
there was significant difference in all the time points (24 hours = 0.48 +/- 0.05, 48 
hours = 0.71 +/- 0.02, 72 hours = 0.83 +/- 0.01) compared to the control (24 hours 
= 0.72 +/- 0.02, 48 hours = 0.87 +/- 0.01, 72 hours = 0.93 +/- 0.01) (P=0.01, 
P=0.05, P=0.03). The MI of U87 cells treated with BIO reached statistical 
significance for the 72-hour time point only for the migration front (0.61 +/- 0.05) 
when compared to the control (0.82 +/- 0.005) (P=0.014). There was significant 
difference in all the time points for the migration edge (24 hours = 0.56 +/- 0.10, 
48 hours = 0.67 +/- 0.07, 72 hours = 0.73 +/- 0.03) compared to the control (24 
hours = 0.87 +/- 0.004, 48 hours = 0.87 +/- 0.004, 72 hours = 0.87 +/- 0.004) 
(P=0.01, P=0.05, P=0.03). 
 
The MI results for U251 cells treated with Y-27632 did not reach statistical 
significance for the migration front or the migration edge. The MI results for U87 
cells treated with Y-27632 reached high statistical significance for all time points 
of the migration front (24 hours = 0.06 +/- 0.04, 48 hours = 0.13 +/- 0.07, 72 hours 
= 0.11 +/- 0.06) compared to the control (24 hours = 0.72 +/- 0.01, 48 hours = 
0.76 +/- 0.006, 72 hours = 0.82 +/- 0.005) (P=2.03x10-10, P=5.5x10-7, P=9.9x10-
9). The MI of U87 cells treated with Y-27632 reached high statistical significance 
for all time points of the migration edge (24 hours = 0.09 +/- 0.06, 48 hours = 0.15 
+/- 0.08, 72 hours = 0.13 +/- 0.07) compared to the control (24 hours = 0.87 +/- 
0.004, 48 hours = 0.87 +/- 0.004, 72 hours = 0.87 +/- 0.004) (P=6.84x10-12, 
P=2.6x10-8, P=9.3x10-9).  
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The MI of U251 cells treated with CCG-1423 did not reach statistical significance 
for the migration front or the migration edge when compared to the control. The 
MI of U87 cells treated with CCG-1423 also did not reach statistical significance 
at the 24-hour time point for the migration front when compared to the control. At 
the 48-hour time point for the migration front in U87 cells treated with CCG-1423, 
the MI was 0.47 +/- 0.08 which was significantly different compared to the control 
(0.76 +/- 0.006) (P=0.04).  At the 72-hour time point for the migration front in U87 
cells treated with CCG-1423, the MI was 0.45 +/- 0.01 which was also significantly 
different compared to the control (0.82 +/- 0.005) (P=0.015). For the migration 
edge, the MI of U87 cells treated with CCG-1423 was 0.40 +/- 0.1 at the 24-hour 
time point which was significantly different to the control (0.87 +/- 0.004) 
(P=0.003). At the 48-hour time point, the MI was 0.55 +/- 0.09 for the migration 
edge, which was also significantly different to the control (0.87 +/- 0.02) 
(P=0.001). The MI at the 72-hour time point of the migration edge was 0.50 +/- 
0.10, which, again, was significantly different to the control (0.87 +/- 0.02) 
(P=0.01).  
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Figure 10. The anti-migratory effect of various inhibitors on cell migration in a 3D invasion assay. Graphical illustration of the effects of inhibitors 
in a 3D collagen invasion assay for cell lines U251 and U87. Spheroids were embedded in collagen with or without inhibitor and allowed to migrate 
over 72 hours. At 24 hour intervals images of the individual spheroids and migratory cells were taken. The migration front indicates the distance 
travelled by 75% of the migrating cell population. The migration edge indicates the furthest point of migration. Results were obtained from at least 
three individual repeats. Differences in anti-migratory activity of the individual drugs were observed in both cell lines. Asterisks indicate statistically 
significant results. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001 ****P≤ 0.0001. 
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2.3.4 Inhibitors targeting the actin polymerisation pathway display reduced 
anti-migratory activity on cells in a 2D transwell and nanofiber migration 
assay in comparison to random cell migration and 3D invasion assays 
Inhibition of cell migration was observed in the 2D transwell assay in the presence 
of all the chosen inhibitors in both cell lines (Figure 11). For treatment of U251 
cells with BIO, the average number of cells to migrate through the transwell insert 
was 49 +/- 9, which was significantly different to the control (162 +/- 33) (P=0.03). 
The average number of U251 cells to migrate through the insert when treated 
with LiCl was 43 +/- 7, which was, again, significantly different to the control (162 
+/- 33) (P=0.02). For treatment with Y-27632, the number of cells to migrate 
through the insert was 43 +/- 8, which was significantly different to the control 
(162 +/- 33) (P=0.02). Treatment using CCG-1423 was also significantly different 
with the number of cells migrating through the insert being 51 +/- 12 compared to 
the control (162 +/- 33) (P=0.03). LatA treatment was the most effective inhibitor 
of migration in U251 through the transwell insert. The number of cells that 
migrated through the insert with LatA treatment was 25 +/- 4 which was 
significantly different to the control (162 +/- 33) (P=0.01).      
 
For treatment of U87 cells with BIO, the average number of cells to migrate 
through the transwell insert was 33 +/- 4, which was significantly different to the 
control (213 +/- 17) (P=0.0005). The average number of U87 cells to migrate 
through the insert when treated with LiCl was 34 +/- 3, which was, again, 
significantly different to the control (213 +/- 17) (P=0.0005). Y-27632 treatment 
was the most effective inhibitor against the migration of U87 through the transwell 
insert. The number of cells that migrated through the insert with Y-27632 
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treatment was 19 +/- 3, which was significantly different to the control (213 +/- 
17) (P=0.0003). Treatment using CCG-1423 was also significantly different with 
the number of cells migrating through the insert being 36 +/- 7 compared to the 
control (213 +/- 17) (P=0.0007). The number of cells that migrated through the 
insert with LatA treatment was 20 +/- 3 which was significantly different to the 
control (213 +/- 17) (P=0.0004).      
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Figure 11. Effect of various inhibitors on migration through a transwell. Graphs showing the 
results for the 2D transwell migration assay for U251 and U87 cell lines treated with the 
chosen inhibitors. All inhibitors had an anti-migratory effect on U87 and U251 cell migration. 
The results were obtained from at least three repeat experiments. Asterisks indicate 
statistically significant results. *P≤ 0.05, ***P≤ 0.001. 
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GFP-labelled U251 cells were used to generate tumour spheroids according to 
the hanging drop cell culture protocol and placed onto aligned nanofiber plates. 
They were allowed to attach to the nanofibers and then treated with the inhibitors 
at the predetermined concentrations. Images were taken at 24 hour intervals for 
72 hours. U251 cells displayed migratory activity away from the original spheroid 
along the nanofiber tracks for all treatments (Figure 12). BIO and LiCl treated 
cells displayed the least migration after 72 hours compared to the control and 
CCG-1423 treated cells showed the greatest migratory activity, even greater than 
the control (Figure 13). 
 
The MI for U251 cells treated with BIO after 24 hours was 0.39 +/- 0.05 which 
was significantly different to the control (2.32 +/- 0.34) (P=6.53x10-6). After 48 
hours of BIO treated, the MI of U251 cells was 0.80 +/- 0.07 which was also 
significantly different to the control (4.8 +/- 0.46) (P=4.7x10-6). At the 72-hour time 
point the MI was 1.28 +/- 0.09 which was, again, significantly different to the 
control (6.33 +/- 0.51) (P=1.65x10-5).  The MI for U251 cells treated with LiCl after 
24 hours was 1.18 +/- 0.08 which was significantly different to the control (2.32 
+/- 0.34) (P=0.002). After 48 hours of LiCl treated, the MI of U251 cells was 2.06 
+/- 0.13 which was also significantly different to the control (4.8 +/- 0.46) 
(P=0.0003). At the 72-hour time point the MI was 2.66 +/- 0.1 which was, again, 
significantly different to the control (6.33 +/- 0.51) (P=0.0002). Statistical 
significance was not reached for any of the time points for U251 cells treated with 
Y-27632 or CCG-1423. For treatment with LatA, statistical significance was 
reached for the 24-hour time point. The MI was 1.24 +/- 0.08, which was 
significantly different to the control (2.32 +/- 0.34) (P=0.05).  
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Changes in the spheroid core size over the 72-hour treatment period were 
observed. Interestingly, the control spheroids seemingly disintegrated structurally 
over time with all cells being lost from the original core and migrating away.  When 
treated with inhibitors the cells maintained the original rounded spheroid core 
structure which appeared to increase in size over time. After 24 hours, change in 
U251 spheroid core size treated with BIO did not reach statistical significance 
compared to the control. At the 48-hour time point, the average size of the cores 
treated with BIO was 19561µm3 +/- 1283µm3 which was significantly different to 
the control (9339µm3 +/- 3537µm3) (P=0.02). At the 72-hour time point, the 
average size of the cores treated with BIO was 21827µm3 +/- 1700µm3 which was 
significantly different to the control (4918µm3 +/- 4180µm3) (P=0.001).  
 
After 24 hours, U251 spheroid cores treated with LiCl did not reach statistical 
significance compared to the control. At the 48-hour time point, the average size 
of the cores treated with LiCl was 20167µm3 +/- 1264µm3 which was significantly 
different to the control (9339µm3 +/- 3537µm3) (P=0.003). At the 72-hour time 
point, the average size of the cores treated with LiCl was 23366µm3 +/- 2009µm3 
which was significantly different to the control (4918µm3 +/- 4180µm3) 
(P=0.0005).  
 
After 24 hours of treatment with Y-27632, U251 spheroids had an average core 
size of 49289µm3 +/- 7419µm3 which was significantly different to the control 
(19271µm3 +/- 2848µm3) (P=4.23x10-5). At the 48-hour time point, the average 
size of the cores treated with Y-27632 was 33938µm3 +/- 6056µm3 which was 
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significantly different to the control (9339µm3 +/- 3537µm3) (P=2.72x10-5). At the 
72-hour time point, the average size of the cores treated with Y-27632 was 
49260µm3 +/- 10265µm3 which was significantly different to the control (4918µm3 
+/- 4180µm3) (P=7.18x10-6).  
 
After 24 hours of treatment with CCG-1423, U251 spheroids had an average core 
size of 28632µm3 +/- 2053µm3 which was significantly different to the control 
(19271µm3 +/- 2848µm3) (P=4.23x10-5). At the 48-hour time point, the average 
size of the cores treated with CCG-1423 was 24473µm3 +/- 2367µm3 which was 
significantly different to the control (9339µm3 +/- 3537µm3) (P=0.0009). At the 72-
hour time point, the average size of the cores treated with CCG-1423 was 
29964µm3 +/- 3737µm3 which was significantly different to the control (4918µm3 
+/- 4180µm3) (P=0.0001).  
 
After 24 hours of treatment with LatA, U251 spheroids had an average core size 
of 40305µm3 +/- 3071µm3 which was significantly different to the control 
(19271µm3 +/- 2848µm3) (P=0.0003). At the 48-hour time point, the average size 
of the cores treated with LatA was 38846µm3 +/- 5031µm3 which was significantly 
different to the control (9339µm3 +/- 3537µm3) (P=0.001). At the 72-hour time 
point, the average size of the cores treated with LatA was 35310µm3 +/- 7132µm3 
which was significantly different to the control (4918µm3 +/- 4180µm3) (P=0.001). 
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Figure 12. Effect of various inhibitors on cell migration along nanofiber tracks. GFP labelled U251 tumour spheroid cell migration on nanofiber plates 
imaged at 24 hour intervals over a 72-hour period with different inhibitor treatments. Representative examples for each treatment are shown. Imaged 
on the EVOS cell imaging system at x4 magnification. Scale bar = 1000µm. 
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13A 
13B 
Figure 13. Effect of various inhibitors on cell migration along nanofiber tracks and spheroid 
core size. U251 tumour spheroid cell migration on nanofiber plates over 72 hours with 
inhibitor treatments. 13A. Migration away from the core as presented by the MI and the 
changes over 72 hours with different inhibitor treatments. 13B. The core size area measured 
in µm3 and the changes over 72 hours with different inhibitor treatments.  Different effects 
on cell migration in both cell lines by the inhibitors were observed. At least three repeats of 
the experiment were carried out. Asterisks indicate statistically significant results. *P≤ 0.05, 
**P≤ 0.01, ***P≤ 0.001 ****P≤ 0.0001. 
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2.4 Discussion 
Cell migration is an integral feature of tumour dissemination and metastasis in 
cancer. The glioma cell lines U87 and U251 were demonstrated to be highly 
migratory as established by 2D random migration and 3D invasion assays. 
Although both cell lines were originally isolated from high grade gliomas they 
intriguingly differed in the way they migrated in 2D and 3D. Whereas U87 adopted 
a spindle-like morphology with pronounced single protrusions in 2D and preferred 
to migrate as single cells in a 3D environment, U251 was characterised by the 
formation of elaborate lamellipodia and the presence of a pronounced tail region 
in 2D and chain-like migration with eventual cell budding in 3D; these 
observations highlight the heterogeneity found within high grade gliomas (186). 
Both cell lines displayed a mesenchymal migratory phenotype as observed by 
live cell imaging, however, U87 adopted a more neuronal cell-like morphology 
when compared to the U251 cell line. The range of assays used here were 
chosen to reproduce biological processes or represent components of the brain 
environment. Live cell imaging of random cell migration provided insight into the 
inert migratory ability of glioma cells without external cues and a first assessment 
of morphological changes that can be induced with different anti-migratory 
inhibitors. By using a 3D invasion assay, the brain environment can be replicated 
more accurately as the cells have to actively migrate through a matrix (i.e. 
collagen in the assay), which is not achieved when growing cells on monolayers 
in culture. Utilisation of a model more representative of the brain environment will 
result in more biologically relevant results supporting the advancement in our 
understanding of cell migration in brain tumour research (93). The transwell 
assay captures the ability of cells to migrate towards a chemoattractant. It is 
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believed that glioma cells follow action potentials generated by axons acting as a 
signal or chemoattractant to migrate towards (188), which is mimicked in the 
transwell assay and highlights the capacity of cells to migrate towards signals in 
their external environment. The nanofiber assay replicates the migration method 
of glioma cells following blood vessels or white matter tracts in the brain, using 
them as a guide to migrate along (189). The nanofiber plates consist of synthetic 
aligned fibres that run vertically in the wells, providing tracks for cells to follow, 
thus replicating blood vessel and white matter tract structure.  
 
2.4.1 Inhibiting glioma cell migration in 2D and 3D assays 
Live cell imaging of random cell migration suggested morphological changes over 
72-hours as well as the effect on the rate of migration in response to inhibitors, 
which was drastically reduced with treatment of all the inhibitors except for CCG-
1423, where the rate of migration was only slightly reduced (U251 = 3320.0µm 
+/- 78.1µm, U87 = 2030.8µm +/- 132.0µm) compared to the control (U251 = 
3864.1µm +/- 162.5µm P=0.03, U87 = 3061.6µm +/- 258.7µm P= 0.013). In terms 
of drug development, this gives a first insight into the mechanisms that could be 
manipulated in order to stop glioma cell migration.  
 
It is now well established that cells grown utilising a 3D in vitro cultivation 
technique form structures that more closely resemble tissues than those grown 
in 2D. In 2D cells are maintained on a flat plastic surface leading to unnatural cell 
attachments to a synthetic surface (190). In tissues and organs, cell-cell 
attachments and attachments to the ECM allow important biological instructions 
to be communicated between the cells. This enables effective cell processes 
  
76 
such as proliferation and motility. In addition, drug activity on and penetrance of 
3D structures is a more representative approach for the selection and testing of 
candidate drugs before they are considered for in vivo testing. Growing cells into 
a 3D structure creates a more natural environment and produces advantages 
over 2D generated monolayers. Cells in monolayers in a 2D environment are 
directly affected by a drug upon exposure unlike cells maintained within a 3D 
structure, which are more resistant due to their multicellular structure (179). 
Again, this provides a closer imitation to in vivo (191). The observations made 
from the MIs of the 3D collagen invasion assay and the distance travelled (µm) 
in the live cell imaging corresponded with this as the inhibitors had a much more 
pronounced effect on both U251 and U87 cells in the 2D live cell imaging than on 
the tumour spheroids in the 3D invasion assay in terms of cell motility. This may 
be due to the easy uptake of inhibitors by cells attached to a matrix in a monolayer 
than cells that are connected and integrated in a dense structure such as a 
spheroid. Studies using HepG2 liver cancer cells showed a greater cell viability 
and a reduced sensitivity to cytotoxic compounds when grown in 3D cultures 
compared to 2D monolayers (192). Biological barriers in vivo are not sufficiently 
imitated in 2D monolayers nor is the diffusion distance for drugs into a monolayer 
of cells which is reasonably short when compared to in vivo tissue environments 
(193). Studies into a 3D culture system that mimics the histology of GBM, 
demonstrated a reproducibility of the clinical results of 3 molecular targeted 
therapies, showing a vast improvement and reliability over 2D methods that have 
failed to predict drug efficacy (194). 
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It has been reported that glioma cells prefer to migrate along white matter tracts 
in the brain as well as blood vessels (189). When following anatomical structures 
that resemble fibres, glioma cells migrate much further as they have a 
topographic cue (195). Nanofiber plates mimic this providing tracks for cells to 
follow, allowing a more accurate representation of the brain environment (43). In 
the nanofiber experiments migration was observed with all the inhibitors after 
treatment of the spheroids, although the greatest reduction was observed after 
treatment with LiCl or BIO in comparison to the control. The cells readily attached 
to the fibre tracts and migrated away from the core, in a directed manner, along 
the vertical axes of the plate. The cells became elongated as they migrated along 
the tracks responding to the specific pattern of the topographic cue. The observed 
continued migration, despite inhibitor treatment, may be explained by the ability 
of the cells to compensate the effects of the inhibitor due to the external cues 
presented in this assay. Cells can be prompted to migrate not only through 
chemotaxis, but also by haptotaxis (along a gradient of chemoattractants or 
adhesion sites), durotaxis (in response to rigidity gradients), mechanotaxis (in 
response to mechanical cues such as fluidic shear stress) and galvanotaxis 
(migration towards or away from electrical currents) (196–200). In the other 
migration assays, the cells had no directional cues, thus the drugs had fewer 
cellular processes to overcome and therefore their effects were more apparent. 
This demonstrates how drug efficacy can be overestimated in 2D assays and a 
reason for failure of drug development at the clinical trial stage.  
 
The GSK3 inhibitors BIO and LiCl have been used in many glioma invasion 
studies. LiCl is known to be a potent and reversible inhibitor and was discovered 
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by Nowicki et al to cause a near complete block of cell invasion in vitro using the 
3D collagen invasion assay. To confirm these findings a wound healing assay 
was used, which supported the anti-migratory drug activity of LiCl at 20mM, the 
same working concentration used here (144). BIO, along with LiCl, was shown to 
increase the activity of b-catenin transcriptional co-activation. Among other 
cellular functions, b-catenin is known for its role in the Wnt signalling cascade; it 
is an important effector responsible for stimulating transcription of Wnt-specific 
genes involved in numerous cellular processes including cell fate, polarity and 
migration (201,202). A study by Williams et al using the glioma cell lines U251, 
U87 and GBM9, showed that by knocking down b-catenin, glioma cell migration 
increases. This suggested that the activation of GSK3 increases cell migration 
through the phosphorylation and downregulation of b-catenin. Therefore 
inhibiting GSK3 with BIO or LiCl will increase levels of b-catenin and reduce 
glioma cell migration (136). In the data presented here, U251 and U87 reacted 
differently to BIO and LiCl treatments. In the 3D invasion assay, BIO inhibited 
U87 cell migration more effectively than U251 and LiCl inhibited U251 cell 
migration more effectively than U87. This suggests that although these inhibitors 
share the same target, the cell lines respond to drug activity in different ways and 
can overcome inhibition through different cellular mechanisms. When comparing 
protein expression levels in U251 and U87, it has been shown that U251 has 
lower protein expression levels in 263 different proteins when compared to U87 
(203). This demonstrates that, although both glioma cell lines, there are 
significant differences between the two cell lines, which could lead to differences 
in cell signalling pathways such as efflux pathways and drug metabolism.  
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In gliomas, the ROCK inhibitor Y-27632 has been used to study the expansion of 
glioblastoma stem cells (GSCs) in vitro. Because ROCK inhibitors suppress 
apoptosis, they have been used to increase stem cell numbers for cloning 
efficiencies (204). Y-27632 is a myosin-II-based contractility inhibitor (117). This 
means that the traction forces exerted by myosin II at the retracting ends of 
migrating cells are blocked, and the cells can no longer migrate (205). These 
effects of Y-27632 were evident in the studies undertaken here, as a lack of 
migrating cells was observed coinciding with an increase of the original tumour 
core when analysing the nanofiber images. The MI of U251 cells treated with Y-
27632 failed to reach statistical significance, when compared to the control, for 
all times points (24 hours P=0.62, 48 hours P=0.40, 72 hours P=0.94), however, 
the size of the area of the core reached extreme significance when compared to 
the control for all time points in the nanofiber assay (24 hours P=4.23x10-5, 48 
hours P=2.72x10-5, 72 hours P=7.18x10-6). Y-27632 has been previously shown 
to stimulate proliferation of bovine corneal endothelial cells and prevent 
apoptosis. When used on spheroids, it decreased cell death inside the spheroid 
core and promoted proliferation of the cells on the edge of the spheroid (206,207). 
This corresponds with the above results. By reducing cell death and migration 
and enhancing proliferation, Y-27632 stimulates an increase in spheroid size. 
Different results were also observed in the 3D invasion assay between the two 
glioma cell lines as U87 migration was significantly affected by treatment with Y-
27632. This suggests that U87 migration in 3D is regulated by cell signalling 
pathways different to those employed by U251; potentially based on their 
phenotypic background and the differences in protein expression between U251 
and U87 as previously stated (203).  
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LatA disrupts actin filament organisation by sequestering G-actin in a 1:1 
complex, preventing the formation of F-actin (208). LatA has been used in a 
number of studies to inhibit actin polymerisation. It was found to inhibit 
asymmetric segregation of Neuroglia antigen 2 (NG2) cells (209). NG2 is a rat 
integral membrane proteoglycan commonly found in GBM tumours. GBM NG2+ 
cells are associated with aggressive tumorigenicity by the overexpression of 
proteins involved in mitosis and cell cycling (210). LatA has also been shown to 
effectively inhibit transwell migration in the C6 glioma cell line, which correlates 
with our own studies using this type of migration assay (156). 
 
CCG-1423 has been shown to reduce the expression of CCN1, thus inhibiting 
cell migration and proliferation (211). CCG-1423 is also a potent inhibitor of EMT, 
which is closely associated with cancer progression (212). This inhibition is 
caused by the blockage of MKL1, which is a key element in EMT, however, the 
inhibitory effect of CCG-1423 in this respect is restricted to conditions in which 
the G-actin pool is depleted (213). Cell migration is stimulated by many different 
factors, including proteins such as CCN1. It is secreted by cells and regulates cell 
migration as well as proliferation, angiogenesis and cell survival. CCN1 
expression is stimulated by G-protein coupled receptor (GPCR) agonists leading 
to activation of RhoA; a key driver of actin polymerisation (214). It is able to 
interact with the cell it is secreted from as well as surrounding cells through 
autocrine-paracrine signalling. It applies its mechanism through its interaction 
with 5 integrins, αvβ3, αvβ5, α6β1, αIIbβ3, αMβ2, and heparan sulphate proteoglycans 
(215). In GBM cells, CCN1 is frequently overexpressed and rapidly secreted, 
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which may contribute to the invasive nature of the disease (216). CCG-1423 
exerted a different effect on each cell line in the 3D invasion assay. It appeared 
to have no anti-migratory activity in U251 cells but a significant effect on U87 
cells, suggesting that different or compensating signalling pathways are activated 
by U251 resulting in continued migration. Different responses to drugs between 
these two cell lines have been previously reported. Studies on glioma cell 
proliferation and migration showed that drugs that target purine metabolism have 
a higher toxicity to U251 cells than U87 cells. It was these studies that showed 
the 263 proteins that are expressed lower in U251 are involved in drug resistance 
to platinum based drugs (203). In addition, U251 and U87 possess different 
genetic mutations in p53, p21, CDKN2A and PTEN, which also affect the anti-
cancer properties in drugs containing platinum (217). This highlights the 
importance of personalised treatments for patients with brain tumours as cell 
heterogeneity can cause chemoresistance and different cellular reactions to 
drugs.  
 
2.4.2 The effect of CCG-1423 activity on glioma cell migration   
Considering the overall anti-migratory effect of all inhibitors on cell migration, 
CCG-1423 stands out as being the least effective at preventing cell migration. 
This is surprising given that it has been reported to be a potent inhibitor of cell 
migration in other cancer types including prostate cancer and melanoma (167). 
CCG-1423 displayed a varied ability to inhibit migration depending on the assay 
used. In the 3D spheroid migration assay, CCG-1423 had no anti-migratory effect 
on U251 cells but did exert some reduction in migration in U87. CCG-1423 
showed little or no inhibitory effect in the live cell imaging random migration and 
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nanofiber assays, however, it efficiently inhibited migration in the transwell assay. 
An explanation for these results could be that CCG-1423 is driving MAT in the 
cells. As previously stated CCG-1423 inhibits the production of CCN1, which 
promotes mesenchymal migration. As the cells continue to migrate after 
treatment in most assays, they could be doing so by a switch to an amoeboid 
migration phenotype. This type of migration is characterised by a more rounded 
cell morphology and may be adopted by cancer cells when faced with adverse 
external cues such as inhibitors targeting mesenchymal migration (218). The 
same cell shape may be preventing the cells from being able to physically pass 
through a transwell insert of this size, thus presenting the drug as a potent 
inhibitor in the transwell insert assay. In a previous study, CCG-1423 was shown 
to inhibit migration in U251 cells, however, the assay used for assessing invasion 
was the Boyden chamber assay that also used pores with a 0.8µm diameter 
(212). This could be due to drug-induced changes in lamin-A, a nucleoskeletal 
protein filament that is responsible for the stabilisation and stiffening of the 
nucleus through the assembly of juxtaposed networks within nuclei. This has 
been shown to contribute to cell survival in such migration assays that involve 
constrictive microspores. High levels of lamin-A promote nucleus stiffness and 
suppress nuclear distortion, therefore preventing cells from being physically able 
to squeeze through pores (219). 
  
This work reports, for the first time, the migratory behaviour of glioma cell lines in 
different environments, the effect of anti-migratory inhibitors targeting the actin 
polymerisation pathway on cell migration and the potential ability of glioma cells 
to change from one migratory behaviour to another in response to external cues 
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such as treatment with inhibitors (Table 3). MAT is an important consideration for 
the development of novel anti-migratory drugs. Anti-migratory combination 
treatments to prevent tumour cells migrating to healthy parts of the brain will have 
to be developed to circumvent a potential migratory switch from one phenotype 
to another.  
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  Live Cell Imaging 3D Invasion Assay Transwell Assay Nanofiber Assay 
BIO 
U251/U87 = 
↓ Migration 
Rounded 
Morphology 
U251 = 
Migration slightly ↓ 
U87 = 
↓ Migration 
U251/U87 = 
↓ Migration 
U251 = 
↓ Migration 
LiCl 
U251/U87 = 
↓ Migration 
Rounded 
Morphology 
U251 = 
Migration slightly ↓ 
U87 = 
↓ Migration 
U251/U87 = 
↓ Migration 
U251 = 
↓ Migration 
Y-27632 
U251/U87 = 
↓ Migration 
Elongated 
Morphology 
U251 = 
Migration unaffected 
U87 = 
↓ Migration 
U251/U87 = 
↓ Migration 
U251 = 
Migration slightly ↓ 
CCG-1423 
U251/U87 = 
Migration unaffected 
Rounded 
Morphology 
U251 = 
Migration unaffected 
U87 = 
↓ Migration 
U251/U87 = 
↓ Migration 
U251 = 
Migration unaffected 
LatA 
U251/U87 = 
↓ Migration 
Rounded 
Morphology 
N/A U251/U87 = ↓ Migration 
U251 = 
Migration slightly ↓ 
Table 3. A table summarising the panel of inhibitor effects on U251 and U87 cells in different migration assays. 
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Chapter 3: The small molecule inhibitor CCG-1423 and its effects 
on glioma cell migration     
3.1 Introduction 
The intriguing results gained with CCG-1423 led us to focus on this inhibitor to 
look more closely at its mechanism. Potentially, CCG-1423 could be utilised as a 
tool to induce MAT allowing for the identification of key molecules involved in this 
process and therefore potential targets for inhibitor development. There are very 
few pharmacological compounds that specifically target the Rho signalling 
pathways in cancer treatment. A lot of work has focussed on the inhibition of 
COOH-terminal isoprenylation of Rho GTPases, which is a necessary 
modification made to lipids in order to allow localisation of activated Rho proteins 
to the cell membrane resulting in cell proliferation, migration, adhesion and 
invasion. Common inhibitors that prevent this lipid modification include statin 
drugs, geranylgeranyltransferase and farnesyltransferase, however, these drugs 
are non-specific and therefore their effects cannot be accurately analysed as Rho 
GTPase inhibitors (220). Studies have also been conducted to inhibit ROCK, a 
Rho effector kinase molecule, which is involved in regulating cell shape and 
movement. Inhibitors of this molecule, such as Y-27632, have shown favourable 
anti-metastatic effects, however, there are some contrasting studies that have 
stated Y-27632 has a pro-invasive effect in some cancer cell types in  3D invasion 
assays (2, 3). One inhibitor has been identified as being specific to Rho GTPases. 
NSC23766 is a specific inhibitor of Rac1, but with only low potency, which poses 
a problem for cancer treatment (79).  
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With a clear need for specific inhibitors of the Rho signalling pathway, the small 
molecule inhibitor CCG-1423 was identified at the University of Michigan through 
a transcription based high-throughput serum response element-luciferase 
screening assay. A selective probe of RhoA-induced gene transcription in the 
form of a modified SRE luciferase reporter that lacked the ternary complex factor 
binding sites was utilised. The Rho signalling pathway was then stimulated at 
different steps to determine the site of CCG-1423 action (223). This process 
identified CCG-1423 as a specific inhibitor that elicits its effects downstream of 
RhoA and actin polymerisation, targeting MKL1 and importation into the nucleus 
to form the MKL/SRF complex (167).   
 
3.1.1 The mechanism of CCG-1423 
MKL1 is a protein that shuttles between the cytoplasm and nucleus in cells. In 
the nucleus, it acts as a transcriptional co-activator with SRF, where they form a 
complex that activates the transcription of SRF-dependent genes (224). In the 
cytoplasm, MKL1 is bound to G-actin via its N-terminal basic (NB) domain 
between the RPEL motifs 2 and 3. When actin polymerisation is activated via the 
Rho signalling pathway, MKL1 disassociates with G-actin to allow for the 
formation of actin filaments, leaving MKL1 unbound in the cytoplasm. Once 
unbound, MKL1 can be imported into the nucleus by the transporter protein 
complex importin a/b, which binds to the NB domain of MKL1. Once in the 
nucleus, it then forms the transcription complex with SRF (6, 7). 
 
CCG-1423 acts upon the free cytoplasmic MKL1, where it binds to the NB 
domain, preventing the binding of importin a/b and, consequently, the nuclear 
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import of MKL1 (Figure 14). This action causes a build-up of MKL1 in the cell 
cytoplasm and inhibits the transcription of SRF-dependent genes (225). This site 
of action was determined by activating the Rho signalling pathway at multiple 
different points in the prostate cancer cell line PC-3. Through control experiments 
to assess the effect of CCG-1423 on membrane activator proteins, it was shown 
that the compound shows non-specific binding between the membrane-
associated heterotrimeric G proteins, Ga12 and Ga13. Other up-stream steps were 
also eliminated as being the target of CCG-1423 through the use of  RhoA and 
RhoC G14V mutants (167). The activation of these proteins does not depend on 
upstream activators of the Rho signalling pathway. CCG-1423 inhibited RhoA-
G14V and RhoC-G14V activity, suggesting its action lies downstream (226). It 
was also shown that ROCK was not the target of this inhibitor as its activity was 
unaffected in vitro. Further investigations were focused on the effectiveness of 
CCG-1423 downstream targeting of the transcriptional processes. The effects of 
transcription induced by numerous different transcription factors and co-
activators determined that CCG-1423 inhibited transcription induced by MKL1 co-
activation with SRF (167).        
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Figure 14. A schematic diagram showing the Rho signalling pathway and the mechanism of the small molecule inhibitor CCG-1423. In the cytoplasm, 
MKL1 is bound to G-actin via its N-terminal basic (NB) domain between the RPEL motifs 2 and 3. When actin polymerisation is activated via the Rho 
signalling pathway, MKL1 disassociates with G-actin to allow for the formation of actin filaments, leaving MKL1 free in the cytoplasm. Once free, MKL1 
can be imported into the nucleus by the transporter protein complex importin α/β, which binds to the NB domain of MKL1. Once in the nucleus, it then 
forms the transcription complex with SRF and activates the transcription of SRF-dependent genes. The actions of CCG-1423 target the free 
cytoplasmic MKL1, where it binds to the NB domain, preventing the binding of importin α/β and, consequently, the nuclear import of MKL1. This action 
causes a build-up of MKL1 in the cell cytoplasm and inhibits the transcription of SRF-dependent genes, including CCN1. 
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3.1.2 The cell adhesion protein CCN1   
CCG-1423 selectively elicits its effects on transcription stimulated by the Rho 
signalling pathway. One such transcription product affected by this is the 
multifunctional matricellular protein called CCN1 (also known as cysteine-rich 61 
[CYR61]). This protein has an essential role in a number of different biological 
processes including embryogenesis, wound healing, fibrogenesis and 
inflammation (168). CCN1 is a member of the CCN protein family, which contains 
6 members in mammals. The name CCN is derived from the first 3 members of 
the family CYR61, CTGF (connective tissue growth factor) and NOV 
(nephroblastoma overexpressed). The 6 members of the CCN family have been 
renamed in order of their discovery CCN1-6 (227). The function of CCNs was 
originally thought to be regulating cell proliferation having been identified through 
their stimulation by oncogenes, mitogenic growth factors and transformation. It is 
now known that they closely associate with the ECM upon secretion and directly 
bind to integrin receptors aiding cell adhesion (228). Although CCN1 does not 
solely promote cell proliferation, it does enhance the DNA synthesis that is 
stimulated by other mitogens (229). 
 
The tight association of CCN1, the ECM and the surface of cells supports cell 
adhesion and stimulates adhesive signalling. From these interactions, focal 
adhesions form and activation of focal adhesion kinase (FAK), paxillin and Rac 
is induced leading to reorganisation of the actin cytoskeleton and lamellipodia 
and filopodia formation (14, 15). CCN1 stimulates the migration of fibroblasts, 
endothelial cells, smooth muscle cells and some types of cancer cells (232). It 
can also promote proliferation induced by growth factors in PC-3 prostate cancer 
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cells and ovarian cancer cells through its synergy with other mitogenic growth 
factors, resulting in an increase of growth-factor induced DNA synthesis (233).   
 
Rac1 is a member of the GTPase family and promotes invasion and metastasis 
(234). The activities of Rac1 are moderated by CCN1 in a number of different 
cancers including pancreatic, lymphoma and prostate (233). It has been shown 
that Rac1 is an important downstream effector of integrins, and that its activation 
is considerably augmented when CCN1 expression is enhanced (235). The 
elongated movement of mesenchymal migration is driven by Rac1 activation, 
which promotes WASP-family verprolin-homologous protein 2 (WAVE2)-
mediated actin polymerisation (236). This signalling pathway also suppresses 
rounded movement in cells by reducing the contractibility of actomyosin (237).  
 
3.1.3 CCN1 in cancer 
Dysregulated CCN1 expression has been identified in a number of different 
diseases including cancer. In tumour progression, CCN1 has been shown to 
promote invasion, angiogenesis, cell proliferation, cell survival and metastasis 
(168). Silencing CCN1 expression in HeLa cells in vitro, for example, leads to 
loss of invasion supporting an important role for CCN1 in cancer metastasis and 
invasion (231). In addition, in immunodeficient mice implanted with human gastric 
adenocarcinoma cells, overexpression of CCN1 effectively induces 
angiogenesis, which increases tumour vascularisation and promotes tumour 
growth (238). Consequently, further studies based on CCN1 overexpression 
have shown increases in tumour growth in xenografts of prostate (233), ovarian 
(239), breast (240) and squamous carcinoma cells (241). Consistent with these 
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findings, a decrease in tumour growth was demonstrated in xenografts of prostate 
(233) and pancreatic cancer cells when CCN1 expression was silenced (242). 
These findings have been supported by clinical observations correlating CCN1 
expression with tumour, size, stage, lymph node positivity and poor prognosis in 
cancers including glioma (243), prostate (244) and breast (240,245). A 
particularly striking example of the effects of CCN1 in cancer includes the breast 
cancer cell line MCF7, which is dependent on oestrogen for growth. When CCN1 
is overexpressed in these cells, they become oestrogen-independent and 
extremely resistant to apoptosis, partly due to the upregulation of XIAP; an anti-
apoptotic protein (246–248). This anti-apoptotic role of CCN1 is facilitated 
through the integrin receptor αvβ3. The expression of this integrin receptor is also 
stimulated by CCN1 (249).  
 
Interestingly, CCN1 also has the ability to induce cell senescence and apoptosis, 
two key processes of tumour suppression. CCN1 activity may regulate 
proliferation of damaged cells, thereby preventing tumorigenesis (250,251). For 
example, as previously mentioned, CCN1 can stimulate the proliferation of 
prostate cancer cells and therefore tumour growth, however, it can also induce 
apoptosis when in the presence of TRAIL; an immune surveillance cytokine 
involved in inducing apoptosis (233,252). In addition to this, CCN1 expression is 
high in prostate cancer cells that possess mutant or null p53 and low in cells that 
express wild-type p53, which suggests that together, CCN1 and p53 can promote 
apoptosis in tumour cells and that high CCN1 levels can, in fact, be tolerated in 
cells that possess mutant p53 (253).  
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3.1.4 CCN1 in gliomas    
CCN1 has been found to be highly expressed in primary gliomas, as well as in 
high-grade glioma cell lines (243). It has been shown to be highly expressed in 
the astrocytoma cell lines U87, U373 and T98G and only weakly expressed in 
the less invasive U343 cell line. In a study by Xie et al, expression of CCN1 was 
quantified using real-time PCR for 98 primary brain cancer samples and four 
normal brain tissues. The results revealed overexpression of CCN1 in 68% of the 
GBM samples, 22% in the astrocytomas and 14% in the less invasive 
oligodendrogliomas suggesting that CCN1 plays a role in tumour progression in 
GBM (254). Mirroring the observations in the previously mentioned study with the 
breast cancer cell line MCF7 (246), forced expression of CCN1 in U343 cells 
increased proliferation, angiogenesis and tumorigenicity in vivo. Cells 
overexpressing CCN1 migrated more readily and produced larger, more 
vascularised tumours in nude mice (254).  
 
CCN1 induces its effects through its involvement in a number of different 
pathways. It has been shown that CCN1 induces tumorigenesis in gliomas 
through its activation of the Akt pathway and by stabilising β-catenin and its 
nuclear import. This results in the activation of the β-catenin-TCF/Lef signalling 
pathway, a key pathway in cell proliferation (254,255). In addition, CCN1-
expressing glioma cells activate the PI3K pathway through integrin-linked kinase 
(ILK) and also inhibit GSK3 in U343 cells through its phosphorylation, as well as 
promote the nuclear translocation of β-catenin. These effects are most likely 
produced through the activation of ILK, which has been previously shown, in 
breast epithelial cells, to inhibit GSK3 by its direct phosphorylation, causing the 
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nuclear translocation of β-catenin (256). β-catenin is an important regulator of the 
Wnt signalling pathway. It acts as a co-activator to form a key complex with 
TCF/Lef transcription factors to induce transcription of a number of different target 
genes that are involved in cell proliferation (257). These genes include those that 
code for cyclin D1, E-Cadherin, c-Jun and c-Myc (258–260).  
 
Abnormal expression of receptor tyrosine kinases (RTK) is involved in a number 
of different mechanisms that stimulates malignant processes. The RTK known as 
c-Met, along with its ligand hepatocyte growth factor (HGF), are overexpressed 
in a number of different tumour types, correlating with poor prognosis (261,262). 
Activation of the c-Met/HGF pathway results in numerous biological processes 
including proliferation, angiogenesis and migration/invasion (263–265). Studies 
into this pathway found that CCN1 is, in part, responsible for the activation and 
mediation of the c-Met/HGF pathway and that intra-tumour levels of CCN1 
directly correlate with c-Met levels. Furthermore, inhibiting the CCN1 gene 
overrides Akt-dependent cell signalling as well as the biological processes that 
respond to c-Met/HGF activation. More specifically, CCN1 siRNAs were shown 
to inhibit HGF-dependent cell migration and growth in the glioma cell lines U87, 
U373 and SNB-19, both in vitro and in vivo using nude mice. These findings show 
that the activation of CCN1 prolongs HGF-stimulated Akt-dependent signalling 
and the downstream effects. In addition, CCN1 protein levels in gliomas could be 
used as a biological marker of c-Met/HGF inhibition in tumours that are 
dependent on HGF (243).  
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The Cancer Genome Atlas (TCGA) includes a dataset of primary brain tumour 
samples from approximately 400 GBM patients (266). TCGA generated a Kaplan-
Meier plot to determine association of CCN1 expression and survival of GBM 
patients. The dataset revealed a statistically significant lower survival rate 
(P=3.84x10-4) in GBM patients with high expression of CCN1 compared to those 
with low expression (Figure 15). Another online dataset, the Repository for 
Molecular Brain Neoplasia Data (REMBRANDT), is a joint project of the National 
Cancer Institute and the National Institute of Neurological Disorders and Stroke 
consisting of clinically annotated data created through the Glioma Molecular 
Diagnostic Initiative. It consists of 874 glioma samples containing 566 gene 
expression arrays, 834 copy number arrays and 13,472 clinical phenotype data 
points (267). The REMBRANDT data for CCN1 gene expression reveals elevated 
levels in GBM samples compared to lower grade gliomas and normal brain tissue 
(Figure 16). This suggests that CCN1 expression plays an important role in 
glioma biology with clinical relevance and applicability as proposed by this 
research. 
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Figure 15. A Kaplan-Meier plot graph taken from TCGA showing percentage patient survival 
in GBM patients with high expression of CCN1 and low expression of CCN1 over months 
following their initial diagnosis. This data was taken from approximately 400 GBM patients and 
revealed a statistically significant lower survival rate (P=3.84x10-4) in GBM patients with high 
expression of CCN1 compared to those with low expression (50).   
Figure 16. A gene expression plot taken from REMBRANDT showing CCN1 (CYR61) 
expression in glioma subtypes; GBM, oligodendroglioma, astrocytoma and normal brain 
tissue. REMBRANDT consists of 874 glioma samples containing 566 gene expression arrays, 
834 copy number arrays and 13,472 clinical phenotype data points (51). The data for CCN1 
gene expression shows elevated levels in GBM samples compared to lower grade gliomas 
and normal brain tissue, suggesting that CCN1 expression plays an important role in glioma 
biology with clinical relevance and applicability as proposed by this research. 
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3.1.5 CCG-1423 and MAT  
CCG-1423 appears to promote distinct cellular responses in highly migratory 
glioma cells. This small molecule inhibitor targets the RhoA transcription 
signalling pathway (167) and seemingly induces MAT in treated cells. 
Mesenchymal and amoeboid modes of migration are interchangeable as 
switching between the two can be induced in cancer cells in response to changes 
in the extracellular environment including external pressures such as drug 
selection (85). This cellular switch may potentially allow the identification of 
pathways involved in this mechanism and enhance drug development. This is 
extremely important as a combination approach targeting both migration modes 
may be favoured to fully stop migratory activity in cancer cells. A high-resolution 
method of imaging and analysis is needed in order to observe and assess the 
characteristics of a phenotypic switch that occurs in MAT in cells treated with 
CCG-1423, especially in a 3D environment, as well as to confirm the previous 
results of this thesis. The limitations of 2D analysis in 3D cellular imaging impair 
the accuracy of research findings in biological studies. An approach of 3D 
analysis for advanced data acquisition and interpretation is needed to improve 
the accuracy and reliability of results gained for drug development.  
 
3.1.6 Three-D analysis of 2D images  
Traditionally cancer drug screens rely on the assessment of drug activity on 2D 
cell monolayers recording cytotoxic effects. The advantages of this approach are 
clear and include high throughput screening, determination of direct effects on 
cell viability and advancing our understanding of cancer biology (268). However, 
the disappointing hit rate of drug discovery 
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highlighted the importance to target cancer cells in a setting more appropriate for 
recapitulating the 3D structure of an original tumour (269). In addition, there has 
been a steady increase in the development of anti-migratory drugs as adjuvant 
treatment to target the dissemination of highly invasive cancers such as gliomas. 
Screening of cells migrating in a 3D environment aids a more representative 
assessment of drug activity than within a 2D environment (270). Initial 
assessment of MAT so far has relied on the interpretation of 2D images created 
by light microscopy from, for example, 3D spheroid invasion assays. However, 
interpretation of such images has to be treated with caution as there are 
limitations to assessing images with a 3D background captured on 2D images. 
Images generated by 2D image capture suggest that drugs have distinctive 
effects on migratory cells, but, so far, a more accurate high resolution analysis of 
3D generated imagery is in its infancy. As such, standard microscopy may miss 
important details of drug activity because of imaging, for example, one focal plane 
at a given time. This can lead to imprecise data interpretation such as 
overestimation of drug efficacy.  
 
3.1.7 Instant structured illumination microscopy (iSIM)  
Structured illumination microscopy (SIM) has an improved resolution of twofold 
over that of widefield microscopy. It also provides a much faster acquisition rate 
and computationally discards out of focus light that emerges from anywhere but 
the focal plane. These advantageous properties allow for optically-sectioned 
super-resolution imaging from hundreds of 3D time-points (271). SIM uses a 
moderately low number of widefield images in order to capture the information 
needed to increase resolution, as well as causing less irradiation to the samples 
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compared to other such techniques, thus deeming it more useful for imaging live 
samples (272). It is also compatible with all the fluorophores commonly used with 
confocal and widefield microscopy and can be used to produce depth-sectioning 
with an excitation pattern structured in three dimensions (273). To extract high 
spatial frequency information using SIM, multiple images of the sample must be 
obtained using a number of different orientations, which then need to be 
processed to acquire the final image (274).  
 
The speed of image acquisition using SIM was improved upon by multifocal SIM 
(MSIM) to several frames per second by the use of a digital mirror device which 
generates numerous excitation foci scanned across the sample. The generated 
foci are then ordered into a pattern. Every time this pattern is translated by the 
digital mirror device, a fluorescence image is produced. This image is then 
processed in a software that pinholes the fluorescence from each excitation spot. 
This is achieved by setting the pinhole to 0, past a certain radius, in order to reject 
light outside the focal plane. This is repeated until the entire field of view has been 
scanned. All the images are then scaled by a factor of 0.5 and summed to 
produce one frame (275).  
 
This was then developed further into iSIM. iSIM uses optical hardware which 
performs automatic summing of all images resulting in an ‘instant’ visualisation of 
a high-resolution image (271). A lenslet array generates a set of beamlets that 
are focussed onto the sample. This causes a fluorescence image to be generated 
which is then passed through a set of pinholes in order to reject light outside the 
focal plane. The image is then passed through a second lenslet array which 
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causes the beamlets to focus, resulting in each image from each excitation spot 
to be scaled by a factor of 0.5. These resulting images are then scanned by a 
mirror, which also scans the excitation across the sample to provide a single 
image comprised of all the fluorescence images that are generated. The 
resulting, instantly presented single image has an increased resolution to 
previous imaging techniques and an extremely rapid image attainment of more 
than 100 frames per second (274). A z-stack can be generated, with an interval 
of 10ms between slices, using iSIM whereby the optimum start and end points 
can be chosen manually. The start point is then set to 0, the end point to the value 
of the final desired frame. Each image is then automatically captured and saved 
as a 16-bit TIFF single file containing the multiple slices of the z-stack (274).   
 
The advanced technology of iSIM was chosen to capture MAT in glioma cells 
treated with CCG-1423. The super-resolution of iSIM and extremely fast image 
acquisition was deemed capable of visualising the change from elongated 
morphology to rounded morphology in CCG-1423 treated U251 cells migrating 
away from the core of tumour spheroids set in a collagen bed. With a twofold 
improvement on widefield microscopy for 3D resolution, this method could 
provide more accurate and reliable results for drug efficacy studies. By pairing 
this technology with other experimental assays, the mechanisms of CCG-1423 
on glioma cells can be more accurately explored, allowing for a more detailed 
understanding of the abilities of these invasive cells.   
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3.2 Materials and methods  
3.2.1 Cell lines and culture medium 
The adult glioma cell lines U87 (Grade IV, GBM) and U251 (Grade IV, GBM) were 
used in this study, originally established by Pontén and colleagues (180). These 
cells have been comprehensively characterised in terms of genomic alterations 
and gene expression patterns. Cells were grown in Dulbecco’s Modified Eagles 
medium (DMEM) (Sigma) with 10% heat-inactivated foetal calf serum (HI-FCS) 
(Labtech) and 0.5% penicillin-streptomycin (Sigma) (complete medium). They 
were free of mycoplasma contamination as confirmed by Sarah Perry (In house 
testing at LICAP) and had been genotypically profiled by University of Leeds in-
house services (Claire Taylor).  
 
3.2.2 Cell culture 
Cells were cultured in a Sanyo CO2 incubator at 37°C in a humidified atmosphere 
of 5% CO2 (in air). Cells were maintained in plastic tissue culture flasks (Corning) 
and harvested at or near confluence by washing with PBS and then adding trypsin 
(10x solution, diluted 1:10 in Hanks Balanced Salt Solution, (Sigma)). Cells were 
viewed/imaged with a Nikon eclipse TS100 microscope and counted using an 
improved Neubauer haemocytometer (Weber Scientific).  
 
3.2.3 MTT assay  
U251 and U87 cells were seeded at a density of 2.5x103 per well in a 96 well 
plate (Corning) and incubated overnight at 37°C. One row was kept clear of cells 
as a background control. The supernatant of the cells was then removed and 
replaced with either 100µl of fresh medium or 100µl of medium containing CCG-
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1423 (Tocris) in serial dilutions of 50µM, 5µM, 0.5µM, 0.05µM, 0.005µM or 
0.0005µM. A control of 0.5% DMSO (Sigma) was also used as well as the empty 
wells just containing medium. The plate was then incubated for 72 hours at 37°C. 
The supernatants were removed and replaced with 100µl of medium with 10µl of 
MTT reagent (Sigma) and incubated at 37°C for 3 hours. All media was removed 
and replaced with 100µl of lab grade DMSO (Sigma) and read on a colorimetric 
plate reader (Thermo Fisher) at 540nm.  
 
3.2.4 Enzyme-linked immunosorbent assay (ELISA)  
U251 and U87 cells were cultured at a density of 2x103 in 6 well plates (Costar, 
Corning Lifesciences, USA) and incubated for 24 hours at 37°C. Following 
incubation, the media was removed and replaced with 2ml of complete medium 
(control) or medium with 500nM of CCG-1423 (Tocris). The cell supernatants 
were collected at 24, 48 and 72-hour time points. A commercially available 
Human CYR61/CCN1 Quantikine ELISA kit (R&D Systems) was used for the 
solid phase sandwich ELISA for CCN1. Forty-eight microplate well strips were 
removed from the plate frame (3 wells per time point per cell line and 8 for the 
standard curve) and 100µl of assay diluent was added to each well, followed by 
50µl of cell supernatant, control or standard. The wells were covered with a plate 
sealer and incubated on a plate shaker at room temperature for 2 hours. The 
wells were aspirated and washed 3 times with wash buffer. 200µl of human CCN1 
conjugate was added to each well and incubated for 2 hours on a plate shaker. 
The wells were washed 3 times with wash buffer before adding 200µl of substrate 
buffer to each well. The wells were incubated for 30 minutes at room temperature 
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covered with foil. 50µl of stop solution was added to each well and the plate was 
immediately read on a plate reader at 540nm (Thermo Fisher).  
 
3.2.5 Immunofluorescence staining   
U251 cells were cultured at a density of 2x103 on sterile 25x25 coverslips in 6 
well plates (Costar, Corning Lifesciences, USA) and incubated for 24 hours at 
37°C. Following incubation, the media was removed and replaced with 2ml of 
complete medium (control) or medium with 500nM of CCG-1423 (Tocris). The 
plates were incubated for a further 48 hours at 37°C. The cells were fixed using 
4% PFA (Thermo Scientific) and blocked for 1 hour using 5% normal goat serum 
(Abcam). The cells were stained by immunofluorescence for MKL1 (anti-MKL1 
Rb, Abcam) at 1:100 and incubated for 24 hours at 4°C. The cells were washed 
3 times with PBS and incubated for an hour at room temperature with the 
secondary antibody anti-rabbit Alexa fluor 488 (Abcam) at 1/500. The cells were 
washed 3 times in PBS and mounted on glass slides using Mowiol with Hoechst 
(Sigma). The slides were imaged on a Bioimaging Zeiss LSM880 Inverted 
Confocal microscope (Zeiss).   
 
3.2.6 Western blotting  
Cell lysates were obtained from cells grown in 25 cm2 plastic tissue culture flasks 
(Corning) treated with 500nM of CCG-1423 (Tocris) for 24, 48 and 72 hours. Cells 
were placed on ice and washed twice with ice cold PBS. The cells were collected 
and centrifuged at 400g for 5 minutes. The PBS was removed and the pellet was 
resuspended in 0.5ml of Tris-HCl lysis buffer 25 µl/ml protease inhibitor (Sigma-
Aldrich) for 5 minutes. The cells were centrifuged at 400g for 10 minutes. 
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Supernatants containing the cytoplasmic extract were collected and transferred 
into clean tubes.  
 
Protein concentration of each cell lysate was determined by Bradford protein 
assay (Bio-Rad), whereby 2µl of protein sample was added to 700µl of Bradford 
protein assay solution in a cuvette (Sigma). Included in this was a ‘blank’ 
consisting of 2µl of Tris-HCl buffer in 700µl Bradford protein assay solution. The 
samples were measured at 595nm on a spectrophotometer and normalised to 
the lowest concentrated lysate using Tris-HCl buffer.   
 
10µl of Laemmli buffer (Bio-Rad) was added to the cell lysates, which were boiled 
for 5 minutes at 95°C in a dry bath. Fifty microlitres of cell lysate was loaded into 
wells in a 4-20% TGX stain-free precast gel (Bio-Rad) with a pre-stained protein 
ladder (Bio-Rad) to estimate protein size. Proteins were separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at 120V for 
approximately 90 minutes in a tank filled with running buffer (Bio-Rad). They were 
transferred to PVDF membranes at 250mAmp over 90 minutes in a tank filled 
with transfer buffer (Bio-Rad). Once unpacked, the PVDF was washed in Tris-
Buffered Saline and Tween®20 (TBST) and blocked in 5% milk in TBST for 45 
minutes. The PVDF was probed with an antibody against MKL1 (1:300, Abcam) 
in 5% milk in TBST overnight. PVDF was washed 3 times in TBST and exposed 
for 90 minutes to the secondary antibody HRP-conjugated donkey anti-rabbit IgG 
antibody (1:1000, GE Healthcare). Following a further 3 washes with TBST, 
proteins were detected by SuperSignal West Femto maximum sensitivity 
substrate (Thermo Fisher), according to the provided protocol and visualised 
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using a ChemiDoc MP imaging system (Bio Rad) and Image Lab software 
(BioRad). Protein band intensity was analysed using Image J software. The 
intensity of each band was normalised to the corresponding β-actin control.  
 
3.2.7 Three-D spheroid generation and invasion assay  
For inhibitor studies, U251 cells were seeded at 1x103/well in low adherence 96 
well plates (Nunc, UK) as previously described (Cheng et al., 2015). Three days 
after seeding, spheroids contained within the wells were embedded in rat tail 
collagen V (Corning Life Science, US), polymerisation was achieved with 1M 
NaOH. The inhibitor CCG-1423 (Tocris Bioscience, US) was resuspended in 
DMSO and was added at a predetermined anti-migratory concentration at 2X 
(500nM). Some spheroids were mock-treated with DMSO-supplemented medium 
only. Invasion into collagen was observed over 72 hours at 24-hour interval and 
images captured with the EVOS Cell Imaging System (Advanced Microscopy 
Group) at 4x magnification. 
 
3.2.8 Preparation of spheroids and migratory cells for iSIM imaging  
We have previously reported the staining of collagen embedded spheroids and 
associated migratory cells with fluorescent dyes such as phalloidin and DAPI 
(Cheng et al., 2015). Here, this technique was improved and amended to allow 
antibody labelling. The whole procedure was adapted so that it can be carried out 
in the original low adherence 96-well plate (Nunc, US). After completion of the 
invasion assay, the wells were carefully washed with PBS three times; this was 
achieved using 200µl pipette tips and pastettes to add and remove fresh PBS. 
The collagen plugs were fixed using 4% PFA for 40 minutes. For permealisation, 
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0.5% Triton-X100 was added for 30 minutes; three washes of PBS were followed 
by blocking with 0.01% Marvel skimmed milk powder in PBS for five minutes. The 
collagen plugs were incubated with Alexa Fluor 488 phalloidin at 1/500 (Molecular 
probes, Invitrogen US) and anti-acetylated tubulin antibody (1/500) (Abcam, UK), 
which had been prepared in the blocking solution (0.01% Marvel skimmed milk 
powder) and spun down for 5 minutes at 13,000 rpm. After a two-hour incubation, 
the collagen plugs were washed three times with PBS for five minutes each; the 
secondary antibody, Alexa Fluor 488 (conjugated to Alexa Fluor 488 phalloidin) 
(1/500; Molecular probes, Invitrogen US), was added at a 1/500 concentration 
along with DAPI (1/500, according to manufacturer instructions), prepared as for 
the primary antibody solution. Incubation was for 1 hour after which the collagen 
plugs were washed three times with PBS. The collagen plugs were carefully lifted 
out of the wells and transferred onto glass slides. Fluoromount G (Thermo Fisher 
Scientific, UK) was added to the plugs and coverslips were gently lowered onto 
the collagen plugs. 
 
3.2.9 iSIM imaging  
The iSIM used for this study was built and housed at the University of Leeds (Dr 
Alistair Curd). The objective lens used was a x60 NA 1.2 objective (Olympus). 
This iSIM has a frame rate of 100 frames per second (fps) with lateral sampling 
at 56nm per pixel. Deconvolution was performed on all final images using the 
Image plugin DeconvolutionLab (Biomedical Imaging Group, EPFL, Switzerland).  
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3.2.10 Data analysis  
MTT and ELISA assays were analysed using a plate reader and ascent computer 
software (Thermo Fisher). For the ELISA, the optical density of each sample was 
read at 540nm. The standard curve was generated in Excel and used to calculate 
the concentration of each sample in pg/ml. Immunofluorescence for MKL1 was 
analysed using particle analyser in the ImageJ software (http://rsbweb.nih.gov/ij). 
The data generated using ImageJ was collected by generating an outline of a 
single cell (minus the nucleus) and an outline of the nucleus using the DAPI 
image. These were then used to measure the mean gray value of the fluorescent 
MKL1 in the cytoplasm and the nucleus. This method ensured that there was no 
overlap of particles in either measurement, creating accurate results. For all 
experiments, differences between control cells and treated cells were compared 
using a two-tailed T-test (Excel). P-values ≤0.05 were considered statistically 
significant.  
 
3.2.11 ImageJ plugin for data analysis 
A novel ImageJ plugin was developed together with Dr Arndt Rohwedder to 
specifically measure the number of filopodia and major protrusions, of treated 
and untreated U251 cells, from the images captured with iSIM. The plugin takes 
the current image/image stack and generates an internal copy for the analysis. In 
the case of an image stack, each slice is evaluated individually. Firstly, a black 
and white image is generated using auto-threshold. To remove small single pixel 
(‘noise’), a rank filter is applied to the image using median and bright outliers 
filters. The function ParticleAnalyser is then used for isolating the cells/cell 
cluster. This is achieved with the options EXCLUDE_EDGE_PARTICLES, 
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requiring objects not touching the frame, INCLUDE_HOLES, resulting in the 
detection of the outer objects border only and CENTER_OF_MASS for analysing 
of lateral shifts. Size limits are calculated in percentage from the minimum 
coverage value from the menu and a reduced width and height value for 
maximum. The particle analyser will try to find an object based on those values 
first. When it fails, it starts reducing the minimum size value until an object is 
identified. When an object is found, the resulting ROI is stored for analysis as a 
linear array.  
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3.3 Results 
3.3.1 MTT assay for assessing cell viability following CCG-1423 treatment  
The effect of CCG-1423 on cell viability was confirmed by using an MTT assay 
(Figure 17). Viable cells with metabolic activity convert MTT into a purple 
formazan product. This reduction reaction reflects the amount of living cells in the 
well (276). By using this technique on cells that have been treated with CCG-
1423, we can assess at which concentration the drug is killing the cells rather 
than exerted its anti-migratory effects. In previous studies, CCG-1423 had been 
used at 500nM. Concentrations were therefore chosen above and below 500nM. 
The concentrations were 50µM, 5µM, 0.5µM (500nM), 0.05µM, 0.005µM and 
0.0005µM. The results of the MTT assay were expressed as a percentage of the 
control.  
 
CCG-1423 did not significantly affect cell viability of U251 cells at 0.0005µM 
(98.2% +/- 3.9%) (P=0.37), 0.005µM (96.8% +/- 3.3%) (P=0.07) or 0.5µM (95.9% 
+/- 6.2%) (P=0.38), when compared to the control. At a concentration of 0.05µM, 
CCG-1423 did not affect cell viability of U251 cells (96.5% +/- 1.8%), however, 
slight statistical significance was reached when compared to the control (P=0.02). 
CCG-1423 at a concentration of 5µM, significantly affected cell viability of U251 
cells (13.4% +/- 1.2%) when compared to the control (P=2.06x10-7). CCG-1423 
also significantly affected U251 cell viability at a concentration of 50µM (6.1% +/- 
1.0%) when compared to the control (P=1.84x10-8) (Figure 17A). 
 
CCG-1423 did not significantly affect cell viability of U87 cells at 0.0005µM 
(99.2% +/- 5.5%) (P=0.11), 0.005µM (99.2% +/- 7.4%) (P=0.13), 0.05µM (99.1% 
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+/- 7.8%) (P=0.21) or 0.5µM (97.3% +/- 7.0%) (P=0.46), when compared to the 
control. CCG-1423 at a concentration of 5µM, significantly affected cell viability 
of U87 cells (6.3% +/- 0.3%) when compared to the control (P=5.8x10-10). CCG-
1423 also significantly affected U87 cell viability at a concentration of 50µM (6.1% 
+/- 0.23%) when compared to the control (P=1.81x10-11) (Figure 17B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17A 
17B 
Figure 17. Cell viability of U251 and U87 monolayers treated with CCG-1423. Serial 
dilutions of CCG-1423 were added to U251 cells (17A) and U87 cells (17B). Cell viability 
was confirmed by a MTT assay and was expressed as a percentage of the control. This 
was carried out before continuing further CCG-1423 studies to confirm that the 
recommended inhibition concentration was correct and that observed rounding effects of 
CCG-1423 on glioma cell lines was not due to cell death. Experiments were repeated in 
triplicate. Asterisks indicate statistical significance where **** = p≤0.0001.   
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3.3.2 ELISA for the detection of CCN1 secretion  
To investigate the effects of CCG-1423 on CCN1 secretion in the cell lines, a 
sandwich ELISA was used to detect the presence of secreted CCN1 in the 
supernatants of U251 and U87 cell cultures over 72 hours. The cells were seeded 
at a density of 2x103 in 6 well plates and incubated for 24 hours at 37°C. The 
medium was then replaced with fresh medium (control) or medium containing 
500nM of CCG-1423. The supernatants were then removed at time points of 24, 
48 and 72 hours and tested by ELISA. The optical density was obtained from 
running the plate on a colorimetric plate reader at 540nm. The concentration of 
CCN1 in the medium did not increase in the treated cells, whereas there was a 
detectable increase in CCN1 levels in the supernatants from untreated cells over 
time (Figure 18). At the 24-hour time point, the supernatant of U251 cells treated 
with CCG-1423 had a CCN1 concentration of 0.47pg/ml +/- 0.51pg/ml, which was 
not significantly different to the control (2.19pg/ml +/- 0.17pg/ml). At the 48-hour 
time point, the concentration of CCN1 in the supernatant of U251 cells treated 
with CCG-1423 was 1.33pg/ml +/- 0.87pg/ml, which was significantly different to 
the control (16.88pg/ml +/- 0.86pg/ml) (P=0.04). At the 72-hour time point, the 
concentration of CCN1 in the supernatant of U251 cells treated with CCG-1423 
was 4.79pg/ml +/- 1.2pg/ml, which was significantly different to the control 
(50.15pg/ml +/- 3.08pg/ml) (P=0.03).  
 
At the 24-hour time point, the supernatant of U87 cells treated with CCG-1423 
had a CCN1 concentration of 4.0pg/ml +/- 0.17pg/ml, which was not significantly 
different to the control (4.38pg/ml +/- 0.32pg/ml). At the 48-hour time point, the 
concentration of CCN1 in the supernatant of U87 cells treated with CCG-1423 
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was 4.38pg/ml +/- 0.69pg/ml, which was significantly different to the control 
(17.79pg/ml +/- 0.51pg/ml) (P=0.02). At the 72-hour time point, the concentration 
of CCN1 in the supernatant of U87 cells treated with CCG-1423 was 2.47pg/ml 
+/- 85pg/ml, which was significantly different to the control (29.29pg/ml +/- 
1.2pg/ml) (P=0.015).  
 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18A 
18B 
Figure 18. An ELISA was carried out to determine CCN1 levels in the supernatants of U251 
and U87 cell lines over a 72-hour period. Cells were incubated for 24, 48 and 72 hours +/- 
CCG-1423. The supernatants were collected for each time point and tested for CCN1 by 
ELISA. CCN1 concentration levels were reduced in the supernatants of treated U251 (18A) 
and U87 cells (18B), at the 48 and 72-hour time points, when compared to the untreated 
controls as indicated by decreased concentration. Experiments were repeated in triplicate. 
Asterisks indicate statistical significance where * = p≤0.05.      
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3.3.3 The effects of CCG-1423 on MKL1 nuclear import   
The reduction in CCN1 secretion by cells treated with CCG-1423 is thought to be 
a result of the inhibition of MKL1 nuclear import, based on published data (225). 
Immunofluorescence was used to visualise a potential build-up of MKL1 in the 
cytoplasm of cells treated with CCG-1423 in comparison to untreated control 
cells.  From observation of the confocal images, there appeared to be a marked 
increase in cytoplasmic MKL1 in cells treated with CCG-1423 with a concomitant 
loss of nuclear MKL1 (Figure 19). To quantify these observed results, the mean 
gray value of 30 imaged cells per repeat was calculated for cytoplasmic staining 
and nuclear staining of MKL1 using ImageJ (Figure 20). The mean gray value for 
nuclear staining of MKL1 in U251 cells treated with CCG-1423 was 54.54 +/- 
1.75, which was significantly different to the control (99.35 +/- 4.33) (P=4.65x10-
19). For cytoplasmic staining of MKL1, the mean gray value for treated U251 cells 
was 62.11 +/- 2.08, which was also extremely significant compared to the control 
(36.24 +/- 1.66) (P=1.25x10-16). 
Figure 19. Immunofluorescence staining of MKL1 in untreated U251 cells (19A) and 
U251 cells that have been treated with CCG-1423 (19B) for 48 hours. Arrows show a 
build-up of MKL1 in the cytoplasm of treated cells compared to the control cells which 
show pronounced nuclear staining. Imaged on a confocal microscope at a magnification 
of x60. Green fluorescent stain = MKL1; Scale bar = 10µm.   
U251 Control   U251 CCG-1423   
10µm 10µm 
19A 19B 
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To confirm the results from the immunofluorescence imaging of MKL1, western 
blots were carried out to determine cytoplasmic protein levels of MKL1 in 
untreated (control) and CCG-1423 treated U251 cells over a 72-hour period. 
During sample preparations of cell lysates, nuclear-associated components were 
discarded, therefore the results from the western blot are representative 
cytoplasmic MKL1. The U251 cell line showed an increase in MKL1 build-up in 
the cytoplasm when treated with CCG-1423 (Figure 21). The intensity of the 
MKL1 band at the 24-hour time point was 1.44 +/- 0.39, which was significantly 
different to the control (0.46 +/- 0.04) (P=0.04). At the 48-hour time point, the 
intensity of the CCG-1423 treated MKL1 band was 1.81 +/- 0.39, which was 
significantly different to the control (1.22 +/- 0.07) (P=0.05). At the 72-hour time 
point, the intensity of the CCG-1423 treated MKL1 band was 0.54 +/- 0.11, which 
was not significantly different to the control (0.48 +/- 0.08). 
 
Figure 20. Quantification of immunofluorescence staining of MKL1 to determine 
differences in nuclear and cytoplasmic MKL1 localisation in untreated (control) U251 
cells and U251 cells treated with CCG-1423. The images were analysed using ImageJ 
where a mean gray value was calculated for the nucleus and the cytoplasm of each cell. 
A total of 90 cells were analysed over 3 repeat experiments. Asterisks indicate statistical 
significance where **** = p≤0.0001. 
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Figure 21B. Western blot analysis of the effects of CCG-1423 on glioma cell lines. Glioma 
cell line U251 was treated ± 500nM CCG-1423. Following 24, 48 and 72-hour incubations, 
cell lysates were obtained. Expression of cytoplasmic MKL1 was determined by western 
blotting including a β-actin control to evaluate protein loading and transfer. MKL1 band 
intensity was quantified and normalised to the β-actin control using Image J software. 
Graphs show mean ± SEM of 3 individual experiments. Asterisks show statistical 
significance where * = p≤0.05. 
Figure 21A. The U251 cell line was treated with 500nM of CCG-1423 and incubated 
for 24, 48 and 72 hours before cell lysates were obtained. Protein levels of MKL1 were 
then determined by western blot. A beta-actin control was included as a protein loading 
and transfer control. 
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3.3.4 iSIM technology generates high-resolution 3D single cell images  
Previous results suggest the induction of MAT in glioma cells by treatment with 
CCG-1423. To visualise this transition, iSIM was used to capture morphological 
changes from elongated (mesenchymal) to rounded (amoeboid); a notable sign 
of MAT. Following the newly established and optimised staining technique, the 
fixed and fluorescently labelled tumour spheroids and single migratory cells 
embedded in collagen were successfully imaged using iSIM (Figure 22). High-
resolution images were created allowing the detailed visualisation of cell 
morphology and actin cytoskeletal changes. Z-stacks generated from the iSIM 
data, with applied colour depth, provides the means to accurately analyse effects 
of anti-migratory inhibitors on glioma cells in a 3D setting.  
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22A 
22B 
Figure 22. A. Brightfield images of U251 glioma cells after 72h incubation, embedded in 
collagen, in 96-well low adherent plates. Untreated spheroid and spheroid treated with 
CCG-1423. In the untreated spheroids elongated cells are visible migrating into the 
collagen, whereas in the treated spheroids the morphology has seemingly changed to a 
more rounded phenotype. Scale bar = 1000µm. 
B.  High resolution 3D iSIM imaging of fixed spheroids and migrating cells within collagen 
plugs. Left image: a single cell in untreated spheroids emanating from the original spheroid 
core. Asterisks show filopodia. Right image: the elongated shape disappears after 
treatment with inhibitor and is replaced by a rounded phenotype. Fluorescent label = Alexa 
Fluor 488 phalloidin. Scale bar = 10µm. Colour bar: sample depth. 
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3.3.5 CCG-1423 reduces the formation of major protrusions and increases 
filopodia formation in treated U251 cells 
The images obtained by iSIM were imported into ImageJ and analysed using the 
novel, newly developed ImageJ plugin to calculate the number of major 
protrusions and filopodia (Figure 23). The frequency of these cellular extensions 
differs in mesenchymal and amoeboid migratory cells and as such may be used 
as an indicator of MAT. The average number of filopodia in U251 cells treated 
with CCG-1423 was 27.14 +/- 3.60 which was significantly different to the control 
(21.41 +/- 2.21) (P= 1.40x10-15). The average number of major protrusions in 
U251 cells treated with CCG-1423 was 0.55 +/- 0.25 which was also significantly 
different to the control (1.48 +/- 0.67) (P=7.14x10-15). This data was generated 
from 90 cells per treatment type, over 3 repeats. 
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23A 
23B 
Figure 23. A graph showing the difference in the number of filopodia (23A) and major 
protrusions (23B) in untreated U251 cells compared to cells treated with CCG-1423. 
A total of 90 cells per treatment were analysed using a novel ImageJ plugin from the 
Z-stack images captured by iSIM. The plugin calculates the number of filopodia and 
major protrusions of each image in the Z-stack and generates an overall number. 
Asterisks indicate statistical significance where **** = p≤0.0001.    
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3.4 Discussion 
3.4.1 CCG-1423 inhibits the nuclear import of MKL1  
CCG-1423 was investigated for its role in migration in gliomas and as a potential 
inducer of MAT. It is evident that CCG-1423 has a marked effect on glioma cell 
lines. Immunofluorescence staining of MKL1 revealed a striking relocalisation of 
this co-transcriptional activator from nuclear to cytoplasmic when U251 cells were 
treated with CCG-1423. Quantification of the images confirmed these 
observations with high statistical significance being reached for both nuclear 
(P=4.65x10-19) and cytoplasmic (P=1.25x10-16) MKL1 in treated cells, when 
compared to the control. The clear build-up of MKL1 in the cytoplasm of cells 
treated with CCG-1423 is consistent with previous inhibitor studies using NIH3T3 
cells. These studies showed that the action of CCG-1423 was promoted by its 
binding to MKL1 and the inhibition of MKL1 and importin a/b interactions and not 
MKL1 and G-actin interactions, resulting in the prevention of MKL1 nuclear import 
(167,213).  The immunofluorescence results presented here were confirmed by 
western blot using U251 cells. Like the immunofluorescence results, a build-up 
of MKL1 in the cytoplasm of cells treated with CCG-1423 at 24 and 48-hour time 
points was determined. It appeared that the cells recovered after 72 hours as the 
control and treated bands were not significantly different in their intensity at the 
72-hour time point. This is consistent with the live cell imaging results in which 
cells treated with CCG-1423 started to recover at the 72-hour time point and is 
also consistent with the original CCG-1423 studies conducted by Evelyn et al. 
using PC-3 cells, whereby the cells recovered following withdrawal of CCG-1423 
(167).  
 
  
120 
3.4.2 CCG-1423 affects CCN1 secretion and migration in glioma cells  
The results from the ELISA assays showed a significant decrease in CCN1 
secretion in cells treated with CCG-1423. In both U251 and U87, the reduction in 
CCN1 concentration in cell culture supernatants at the 48 and 72-hour time points 
were statistically significant (U251 48-hour [P=0.03], 72-hour [P=0.03], U87 48-
hour [P=0.02], 72-hour [P=0.01]) compared to the control. Potentially, the 
reduced levels of CCN1 secretion are a consequence of the inhibition of MKL1 
nuclear import by CCG-1423 activity as evidenced by the western blot and 
immunofluorescence results and as CCN1 gene transcription is a product of the 
MKL1/SRF complex. By inhibiting CCN1 secretion, Rac1 activation is inhibited 
resulting in reduced mesenchymal migration and loss of focal adhesions with a 
concomitant increase in rounded cell movement (235). The extensions of the 
plasma membrane in lamellipodia of cells is primarily driven by Rac-activated 
actin polymerisation. In vivo, protruding lamellipodia are extended at one part of 
the plasma membrane of a single migrating cell and at the front of the leading 
cells during collective migration, which allows the cells to ‘crawl’ along a migratory 
surface (277). For example, lamellipodia in dendritic cells are used to crawl 
towards lymph nodes along lymphatic endothelial vessels (278). An essential part 
of migration involving lamellipodia is integrin-mediated adhesion, as this 
maintains activated Rac in a positive feedback loop whereby integrins at the 
leading edge of a cell stimulate Rac activation (279). Rac recruits activated 
integrins to the leading edge to promote cell migration (280). Among these is the 
integrin αvβ3, whose expression is stimulated by CCN1 (249). By inhibiting 
CCN1, integrin αvβ3 will not be activated and therefore, will not be recruited by 
Rac to stimulate the positive feedback loop and promote elongated cell migration. 
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Because of this reduced Rac activation, rounded motility of cells will be elevated 
via a bleb-driven cell migration, such as, amoeboid migration. This motility type 
correlates with a high level of active RhoA/ROCK signalling and is driven by 
cortical actomyosin contractility (281). This migratory activity is often seen in vivo 
and in low-adhesion in vitro systems. Cells have the ability to readily transition 
between bleb-based migration (amoeboid) and lamellipodia-based migration 
(mesenchymal) in vivo in order to adapt to their surroundings as they migrate 
(282).  
 
CCG-1423 activity targets events downstream of the RhoA signalling pathway 
but upstream of CCN1 production and therefore Rac activation. Not only does 
this explain the reduction in CCN1 cell secretion but also the changes in 
phenotype from elongated to rounded described in the previous chapter. This 
correlates with the concept that CCG-1423 is inducing MAT in these cells in vitro, 
allowing them to continue to migrate after treatment with CCG-1423 by amoeboid 
migration. To investigate this transition and the associated changes of cell 
morphology in more detail, it was necessary to develop an integrated workflow of 
specimen preparation, high-resolution imaging and data processing for 
quantification. 
 
3.4.3 iSIM advances accurate and reliable MAT analysis in single migrating 
glioma cells at subcellular level 
The advanced technology of iSIM allows high resolution imaging and captures z-
stacks with an interval of 10ms between slices (274). iSIM technology was 
investigated for applicability to image CCG-1423 treated glioma cells seemingly 
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adopting a more rounded (amoeboid) morphology in stark contrast to their normal 
elongated (mesenchymal) migratory morphology. As there was no existing 
protocol for the preparation of migratory cells encased in collagen for use with 
the iSIM technology, a staining methodology was developed, which allowed the 
labelling of the original spheroid and migratory cells trapped in the surrounding 
collagen whilst still maintained within the original 96 well low adherence plate. All 
washing steps and antibody incubations were carried out in the plate without loss 
of, or damage to the specimen. 
 
iSIM was used to generate Z-stacks of single migratory cells moving away from 
the original spheroid core to allow detailed characterisation of changes in 
migratory phenotypes. Single migratory cells were detected at high resolution 
with this technology, as well as morphological features, such as, for example, 
single actin fibres (Figure 22A and B). iSIM associated features allowed us to 
improve our understanding of the mechanisms of CCG-1423 drug activity on cell 
migration and confirmed the previous results and hypothesis that the inhibitor is 
causing the cells to adopt a rounded phenotype. A novel ImageJ plugin was 
developed to quantify these observations. The plugin was used to calculate the 
number of major protrusions, such as lamellipodia, and filopodia in the cells under 
treated versus untreated conditions. Lamellipodia and filopodia formation is 
regulated by the activity of small RhoGTPases, Rac1 and Cdc42, orchestrators 
of MAT (85).  There was a distinct loss of major protrusions/lamellipodia in treated 
cells compared to the control cells, which was concurrent with an increase in the 
number of filopodia in treated cells compared to control cells, a striking feature of 
MAT (Figure 23). These results support a direct effect on actin dynamics and cell 
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morphology indicative of MAT when cells are treated with CCG-1423. Liu et al. 
investigated how adhesion and confinement affect MAT in a number of different 
cancer cells including HeLa cells (human cervix cancer cells), MDA-MB231 cells 
(human breast adenocarcinoma), HT29 cells (human colon adenocarcinoma), 
A375P and A375M2 cells (human melanoma) and HT1080 cells (human 
fibrosarcoma). They found that under confinement conditions and in the absence 
of focal adhesions, mesenchymal cells can spontaneously transition to an 
amoeboid phenotype. They also identified two distinct types of amoeboid 
migration or ‘fast-migration’, namely A1 and A2, A2 being the faster of the two. It 
was discovered that transformed cells were more disposed to adopting the A2 
migration mode. However, it was also shown that the various modes of amoeboid 
migration can be observed in a single cell line by slight changes in the levels of 
confinement and adhesion. This is a significant observation, which suggests that 
physical properties of the tumour environment, for example, the confining space 
around the tumour caused by surrounding tissue, could induce MAT resulting in 
a faster mode of cell migration and an invasive cancer (25). This could also 
explain why studies into the inhibition of MMPs fail, due to an increase in tumour 
confinement resulting in the promotion of MAT (283). If cells can spontaneously 
undergo MAT to escape a primary tumour in response to the physical 
environment around them with no pharmacological intervention or genetic 
alteration, it is more than likely that these strategies can also be adopted by the 
cells in response to drug treatment, such as CCG-1423.  
 
The use of iSIM has allowed visualisation of the phenotypic changes that occur 
in MAT. The combined workflow of sample preparation, image acquisition with 
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this advanced technology and application of a novel ImageJ analysis plugin has 
confirmed the previous findings of this thesis and supports the proposed 
phenotype switch in migrating glioma cells after treatment with the inhibitor CCG-
1423 in 3D environments. The combined iSIM and plugin technologies may be 
applicable to other investigations of detailed protein localisation, phenotypic 
changes and protein co-localisation in a 3D setting; in cancer research, it will 
advance pharmacological intervention by producing more accurate predictions of 
drug efficacy. 
 
In the context of this research, confirmatory and additional information has been 
generated to support the theory of MAT in glioma cells induced by CCG-1423 
and has highlighted the need for combination treatments to target both 
mesenchymal and amoeboid cell migration to fully prevent glioma cell migration 
and invasion. 
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Chapter 4: Clinical relevance of CCG-1423   
4.1 Introduction  
The results presented in the previous chapters support CCG-1423 as a MAT 
inducer in glioma cell lines and suggest a potential switch between the two 
migratory modes through the inhibition of CCN1 secretion. The pro-migratory 
effects of this drug via the RhoA signalling pathway could provide an explanation 
as to why anti-migratory drugs have a high failure rate when taken to clinical trial. 
Drug activity of other inhibitors may potentially be exerting similar effects and 
instead of targeting migration, they are promoting cell migration via induction of 
different cellular pathways. This highlights the importance and necessity of 
adopting combination treatments for cancer patients. In addition, new and 
advancing technologies provide a platform on which to gain a more accurate 
insight into the effects that drugs will have when moving forward towards clinical 
trial, including novel 3D technologies for drug investigation and screening, as well 
as advances in mass spectrometry for accurate detection of drug localisation and 
diffusion in tissue samples. 
 
4.1.1 CCN1 and its role in cancer 
CCG-1423 inhibits the Rac signalling pathway through the inhibition of CCN1. 
Previous studies have shown CCN1 to be associated with cancer progression 
and invasion. Holloway et al (2005) investigated ECM proteins associated with 
tumour cell metastasis and described CCN1 expression in peritoneal metastases 
of pancreatic tumours. Analysis of gene expression profiles from a high-density 
microarray in metastases compared to the primary tumour, showed that there 
was a greater than two-fold increase in CCN1 expression in the metastases. At 
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the protein level, immunohistochemistry studies with pancreatic adenocarcinoma 
cells also showed an increase in CCN1 protein and a persistent expression of the 
integrin αvβ3 in the peritoneal metastases, suggesting that the interaction 
between CCN1 and αvβ3 promotes metastasis in pancreatic cancer (284).    
 
In ovarian cancer, CCN1 expression has been found to be abnormally expressed 
in a large number of ovarian tumours as well as in normal ovarian tissue. In 
normal ovaries, it was shown that CCN1 plays a role in the formation and 
regression of the corpus luteum which involves vascular network changes. This 
process is extremely similar to angiogenesis, which was observed in ovarian 
tumour formation and is associated with high levels of CCN1. This suggests that 
CCN1 is a key regulator of biological processes in both normal and cancerous 
ovaries. Furthermore, CCN1 has been linked to chemoresistance in ovarian 
cancer. High levels of CCN1 protein was found in cisplatin-resistant ovarian 
cancer cells when compared to cells that had been sampled before the patient 
received cisplatin chemotherapy (239). In addition to ovarian cancer, CCN1 has 
been associated with chemoresistance in MCF-7 breast cancer cells. As CCN1 
activates the CCN1 integrin αvβ3, it has been suggested that the observed 
upregulation of CCN1 in breast cancer may induce the metastatic phenotype by 
autocrine signalling whereby proliferation is activated by the ERK/MAPK pathway 
and apoptosis is inhibited by the AKT pathway, therefore influencing breast 
tumour cells to develop chemoresistance (248).   
 
In gliomas, CCN1 has similar role to breast cancers promoting proliferation and 
inhibiting apoptosis. In agreement with other cancer types, it is also more highly 
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expressed in the more invasive tumour types, again, suggesting that CCN1 is 
involved in tumour progression and metastasis. In other studies, CCN1 was found 
to be highly expressed in the invasive glioma cell lines U87, T98G and U373 and 
with low expression in the less invasive U343 cell line. When forced expression 
was induced in U343 cells, a marked increase in their proliferation and 
vascularisation was observed. When used in in vivo studies, these cells produced 
much larger and highly vascularised tumours in nude mice, which more readily 
migrated as assessed by immunohistochemistry (254).  
 
4.1.2 CCG-203971  
Following the identification of CCG-1423 by Evelyn et al., it was shown that 
although it was a significantly potent inhibitor, it was also highly cytotoxic (167). 
This led to several molecular modifications of the lead compound CCG-1423 in 
order to reduce cytotoxicity and improve its potency and selectivity. One 
molecular modification, CCG-203971 (Figure 24), was successful in reducing 
cytotoxicity and improving potency in the PC-3 cell line and the melanoma cell 
lines A275M2 and SK-Mel-147 when assessed for cell migration inhibition by a 
scratch wound assay. Studies into the mechanisms of CCG-203971 indicated 
that it too prevents the nuclear localisation of MKL1. This analog of CCG-1423 
was taken forward to an in vivo tolerability study in normal mice, which showed 
that CCG-203971 was well-tolerated in doses up to 100mg/kg/day injected 
intraperitoneally for 5 days (225).   
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4.1.3 Mass spectrometry imaging  
Mass spectrometry imaging (MSI) is a technique that allows for unlabelled 
analyses of the spatial distribution of a variety of molecules in different samples, 
including lipids, peptides, metabolites and proteins. Characterisation of biological 
samples can be chemically analysed through the combination of the vast 
information produced by mass spectrometry and the actual visualisation of 
molecular distribution in thin sections of samples (285). Sample preparation is a 
crucial step in MSI and must be done carefully and accurately to obtain 
informative results. Consequently, a grid is defined over the sample surface for 
the mass spectrometer to follow. The mass spectrometer then ionises molecules 
on the sample surface and for each pixel, collects a mass spectrum. The resultant 
spatial resolution is dependent on the size of each pixel. The specialised 
computer software of the mass spectrometer is then used to select the mass-to-
24A – CCG-1423 
24B – CCG-203971 
Figure 24. The chemical structures of CCG-1423 (24A) and its analog CCG-203971 (24B). 
The structural changes occurred as a result of a series of modifications to the aromatic 
rings and purification by acidic Amberlyst-15 resin. 
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charge (m/z) value of interest and extract the intensity of that m/z at each pixel. 
All the m/z intensities are collected together to form a heat map image showing 
the distribution of the m/z on the sample (285,286). Figure 25 shows a typical 
MSI workflow.  
 
    
There are several different techniques for ionisation with MSI, each involving a 
different sample preparation process. One of the more prevalent techniques is 
matrix-assisted laser desorption/ionisation (MALDI) due to its widespread 
capabilities in molecular species and weights (287). However, in order to create 
proper ionisation of samples, it requires a matrix, which has led to the 
Figure 25. MSI workflow. Following sample collection from the animal, the sample is 
embedded in optimal cutting temperate (OCT) compound for sectioning onto slides (A). 
The slides are placed into the mass spectrometer for spectra acquisition whereby a grid 
is positioned on the sample and a spectrum is extracted at each pixel on the sample 
surface by a laser which ionises the molecules (B). After spectra acquisition, the 
distribution of selected molecules can be visualised. From there, identification of the m/z 
values and statistical analysis between different images can occur (C). 
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development of unique matrixes and laserspray ionisation to ensure different 
molecules can be detected. As different molecules require different methods for 
successful results, the optimisation process for MALDI is extremely important, 
with most of the focus being on the matrix application process (288). When using 
MALDI for molecule ionisation, a matrix is required to allow for accurate ionisation 
of the desired molecule. Once applied, the matrix crystallises causing analytes to 
be extracted from the sample and co-crystallise with it. With MALDI, it is unlikely 
that analytes will be ionised if they are not within this crystal structure that is 
created by the matrix. For the best MALDI results, the matrix should produce a 
small crystal size, homogeneous application and appropriate analyte extraction 
(289). Examples of popular matrixes include 2,5-dihydroxybenzoic acid (DHB), 
α-cyano-4-hydroxycinnamic acid (CHCA) and 2,4,6-trihydroxyacetophenone 
monohydrate (THAP). Researchers used to spray the matrixes by hand using 
airbrush sprayers, however, based on inter-personal and institutional 
inconsistencies, automated sprayers were developed, which improved 
reproducibility of results, showing the importance of sample preparation when 
using this MSI technique (290).  
 
Another MSI technique, called liquid extraction surface analysis (LESA), allows 
for the detection of analytes directly from the sample surface by the formation of 
a liquid microjunction from a solvent droplet placed directly on the tissue. The 
analytes in the tissue are dissolved into the solvent droplet, which is then 
suctioned up and sprayed directly into the mass spectrometer for spectra 
acquisition. The area of detection can be manually chosen through computer 
software, whether this be specific dots in precise regions of the sample or a grid 
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over the whole sample. LESA does not require a matrix as the solvent is dropped 
directly onto the tissue surface (291).    
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4.2 Materials and methods 
Several experiments included in this chapter were undertaken during a 3-month 
secondment at Harvard Medical School (HMS). These experiments include 
western blots for cell lines G9, G44, GL261, CNS1 and U251, the aortic ring 
assay, MALDI and LESA experiments and the animal studies.   
 
4.2.1 Cell lines and media 
The primary human glioma cell lines G9 and G44, the murine glioma cell line 
GL261 and the rat glioma cell line CNS1 were all obtained and grown in the 
Neurosurgery department at HMS, Brigham and Women’s Hospital. G9 and G44 
were grown as neurospheres suspended in neurobasal medium (Gibco) 
containing B27 supplement, 0.5% penicillin-streptomycin (Gibco), glutamine 
(Gibco), EGF and FGF (Gibco). GL161 and CNS1 were grown in Dulbecco’s 
Modified Eagles medium (DMEM) (Sigma) with 10% heat-inactivated foetal calf 
serum (HI-FCS) (Labtech) and 0.5% penicillin-streptomycin (Sigma) (complete 
medium). They were free of mycoplasma contamination as confirmed by in house 
testing at HMS.  
 
4.2.2 Western blots  
Cell lysates were obtained from cells grown in 25 cm2 plastic tissue culture flasks 
(Corning) treated with 500nM of CCG-1423 (Tocris) for 24, 48 and 72 hours. Cells 
were placed on ice and washed twice with ice cold PBS. The cells were collected 
and centrifuged at 400g for 5 minutes. The PBS was removed and the pellet was 
resuspended in 0.5ml of Tris-HCl lysis buffer 25 µl/ml protease inhibitor (Sigma-
Aldrich) for 5 minutes. The cells were centrifuged at 400g for 10 minutes. 
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Supernatants containing the cytoplasmic extract were collected and transferred 
into clean tubes.  
 
Protein concentration of each cell lysate was determined by Bradford protein 
assay (Bio-Rad), whereby 2µl of protein sample was added to 700µl of Bradford 
protein assay solution in a cuvette (Sigma). Included in this was a ‘blank’ 
consisting of 2µl of Tris-HCl buffer in 700µl Bradford protein assay solution. The 
samples were measured at 595nm on a spectrophotometer and normalised to 
the lowest concentrated lysate using Tris-HCl buffer.   
 
10µl of Laemmli buffer (Bio-Rad) was added to the cell lysates, which were boiled 
for 5 minutes at 95°C in a dry bath. Fifty microlitres of cell lysate was loaded into 
wells in a 4-20% TGX stain-free precast gel (Bio-Rad) with a pre-stained protein 
ladder (Bio-Rad) to estimate protein size. Proteins were separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at 120V for 
approximately 90 minutes in a tank filled with running buffer (Bio-Rad). They were 
transferred to PVDF membranes at 250mAmp over 90 minutes in a tank filled 
with transfer buffer (Bio-Rad). Once unpacked, the PVDF was washed in Tris-
Buffered Saline and Tween®20 (TBST) and blocked in 5% milk in TBST for 45 
minutes. The PVDF was probed with an antibody against MKL1 (1:300, Abcam) 
in 5% milk in TBST overnight. PVDF was washed 3 times in TBST and exposed 
for 90 minutes to the secondary antibody HRP-conjugated donkey anti-rabbit IgG 
antibody (1:1000, GE Healthcare). Following a further 3 washes with TBST, 
proteins were detected by SuperSignal West Femto maximum sensitivity 
substrate (Thermo Fisher), according to the provided protocol and visualised 
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using a ChemiDoc MP imaging system (Bio Rad) and Image Lab software 
(BioRad). Protein band intensity was analysed using Image J software. The 
intensity of each band was normalised to the corresponding β-actin control.  
 
4.2.4 Immunohistochemistry (IHC) of patient samples 
Patient GBM samples were collected, processed and stored by the Leeds 
Multidisciplinary Routine Tissue Banking (RTB) service from GBM patients 
undergoing surgery at the Leeds General Infirmary (ethical approval no. RTB 
15/YH/0080). Tumour tissues were embedded in paraffin wax, sectioned on a 
microtome (Leica) at 8µm and placed on glass slides to dry for 24 hours. The 
slides were dewaxed by 2x 1-minute washes in xylene (Sigma), followed by 2x 
1-minute washes in ethanol (Sigma) and 3x 1-minute washes in water. Antigen 
retrieval was completed using Tris EDTA pH9 (Abcam) in a pressure cooker for 
2 minutes. The slides were incubated for 1 hour with the primary antibody anti-
CYR61/CCN1 rabbit polyclonal at a concentration of 1:250 (Abcam). The slides 
were washed 3x 1 minute in PBS and incubated for 30 minutes with the 
secondary antibody anti-rabbit IgG HRP polymer (ready to use) (Vector). After 
secondary incubation, the slides were washed 3x 1-minute in PBS and stained 
using the chromogen DAB (Abcam) for 10 minutes. The slides were washed 
again 3x 1-minute in PBS and a glass coverslip applied. The slides were analysed 
by calculating and combining two scores for the CCN1 staining; as above, 
staining intensity and percentage covered. Strength of staining was scored from 
0-3 with 0 being no staining and 3 being strong staining. Percentage of staining 
was scored out from 0-4 with 0 being 0% covered, 1 being 1-25% covered, 2 
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being 26-50% covered, 3 being 51-75% covered and 4 being 75%+ covered. The 
final score is out of 7. The samples were randomised to avoid biased scoring.               
 
4.2.5 Patient blood sample ELISA 
Matched GBM patient blood samples were collected, processed and stored by 
the Leeds Multidisciplinary Routine Tissue Banking (RTB) service from GBM 
patients undergoing surgery at the Leeds General Infirmary (ethical approval no. 
RTB 15/YH/0080). A commercially available Human CYR61/CCN1 Quantikine 
ELISA kit (R&D Systems) was used for the solid phase sandwich ELISA for 
CCN1. 100µl of assay diluent was added to each well of the microplate, followed 
by 50µl of patient blood serum, control blood serum or standard. The wells were 
covered with a plate sealer and incubated on a plate shaker at room temperature 
for 2 hours. The wells were aspirated and washed 3 times with wash buffer. 200µl 
of human CCN1 conjugate was added to each well and incubated for 2 hours on 
a plate shaker. The wells were washed 3 times with wash buffer before adding 
200µl of substrate buffer to each well. The wells were incubated for 30 minutes 
at room temperature covered with foil. 50µl of stop solution was added to each 
well and the plate was immediately read on a plate reader at 540nm (Thermo 
Fisher).  
 
4.2.6 Aortic ring assay  
An aorta was isolated from a C57BL/6 mouse and transferred into a petri dish 
containing PBS. Under a dissection microscope (Nikon SMZ1000), all the 
extraneous fat, tissue and branching vessels were removed with forceps and a 
scalpel. The aorta was then cut into approximate 0.5mm rings and set aside. 
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Matrigel (Corning) was thawed on ice. Once thawed, 50µl of Matrigel was added 
per well to 21 wells of a flat bottomed 96 well culture plate (Greiner Bio-One) and 
incubated at 37°C for 15 minutes to allow polymerisation of the Matrigel. One 
aortic ring per well was placed on top of the Matrigel followed by another 50µl of 
Matrigel on top. The plate was then incubated at 37°C for 15 minutes to allow 
polymerisation of the second Matrigel layer. Once set, 100µl of endothelial cell 
medium (ScienCell) with human VEGF (Abcam) was then added to each well and 
the plate was incubated at 37°C overnight. Concentrations of 0.1µM, 1µM and 
10µM of CCG-1423 and CCG-203971 (Tocris) were prepared in endothelial cell 
medium. The medium in the wells was then replaced with 100µl of drug or with 
fresh endothelial cell medium. Each concentration and control were carried out 
in triplicate. The plate was then imaged after 1 week using a confocal microscope 
(Nikon Eclipse Ti) to assess the effect of CCG-1423 and CCG-203971 on blood 
vessel formation. 
 
4.2.7 Preparation, optimisation and detection using MALDI  
CCG-1423 and CCG-203971 (Tocris) was reconstituted in DMSO (Sigma) to a 
stock concentration of 10mM. Concentrations of 1mM, 100µM, 10µM, 5µM, 1µM 
and 100nM of CCG-1423 and CCG-203971 were then made up for detection with 
MALDI (Bruker Rapiflex). 0.3µl of each drug concentration was spotted onto an 
Indium-Tin-Oxide (ITO) coated slide (Sigma) directly onto the glass and directly 
on to mouse brain homogenate (for optimisation of MALDI settings) sectioned at 
8µm. This was repeated 3 times on half a slide for optimisation of 3 different 
MALDI matrices. The slides were then dried in a slide desiccator for 1.5 hours. 
The 3 different matrices were made up in 70% methanol with 0.1% trifluoroacetic 
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acid (TFA) and 1% DMSO (Sigma). 2, 5-Dihydroxybenzoic acid (DHB) (Sigma) 
was made up to 160mg/ml, a-cyano-4-hydroxycinnamic acid (CHCA) (Sigma) 
was made up to 5mg/ml and 2, 4, 6- trihydroxyacetophenone monohydrate 
(THAP) (Sigma) was made up to 40mg/ml. These were then sonicated and 
sprayed onto half a slide each using a TM sprayer (HTX Imaging). The DHB slide 
then underwent recrystallization by heating in a lab oven (HeraTherm, Thermo 
Fisher) for 2 minutes at 85°C followed by a further 6 minutes of heating at 85°C 
in a glass chamber with an acetic acid-soaked paper towel. The slides were then 
dried and ready for detection by MALDI.  
 
4.3.8 Preparation, optimisation and detection using LESA  
CCG-1423 and CCG-203971 (Tocris) was reconstituted in DMSO (Sigma) to a 
stock concentration of 10mM. Concentrations of 1mM, 100µM, 10µM, 5µM, 1µM 
and 100nM of CCG-1423 and CCG-203971 were then made up to be tested for 
detection with LESA (Bruker Rapiflex). 0.3µl of each drug concentration was 
spotted onto a glass slide (Thermo Fisher) directly onto the glass and directly on 
to mouse brain homogenate sectioned at 8µm. The slides were then dried in a 
slide desiccator for 1.5 hours and ready for detection by LESA.   
 
4.2.9 Animal studies  
All animal experiments were performed in 6-8-week-old female immunodeficient 
athymic mice (FoxN1 nu/nu, n=6, Envigo, South Easton, MA), in compliance with 
all relevant ethical regulations applied to the use of small rodents and with 
approval by the Institutional Animal Care and Use Committees (IACUC) at the 
Brigham and Women’s Hospital and Harvard Medical School. For intracranial 
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tumour implantation, a stereotactic frame was used to insert 50,000 G9 cells (re-
suspended in 2μl PBS) in each animal’s right striatum (2mm right lateral and 
0.5mm frontal to the bregma at 3.5mm depth). CCG-203971 (Tocris) 
reconstituted in a 1:4 1-methyl-2-pyrrolidinone (MPRL) (Sigma), Kollisolve PEG 
E 300 (Sigma) mix was administered in vivo by intraperitoneal injection at a 
concentration of 100mg/kg for 5 consecutive days starting from the 7th day after 
intracranial tumour implantation. The control mice were intraperitoneally injected 
with the control vehicle (MPRL/Kollisolve) for 5 consecutive days starting on the 
7th day after intracranial tumour implantation. Mice were euthanized 2 hours after 
the final CCG-203971 injection on day 5 by carbon dioxide overdose followed by 
tissue dissection to isolate the brain and liver, which were frozen immediately in 
liquid nitrogen. The brains and livers were embedded in optimal cutting temperate 
(OCT) compound (Leica) and sectioned at 8µM on a cryostat (Leica) and placed 
onto glass slides (Thermo Fisher) for LESA and on ITO coated slides (Sigma) for 
MALDI.     
 
4.2.10 Data analysis 
Western blot protein band intensities were analysed using ImageJ software. The 
intensity of each band was normalised to the corresponding β-actin control. For 
the ELISA, the optical density of each sample was read at 540nm. The standard 
curve was generated in Excel and used to calculate the concentration of each 
sample in pg/ml. The aortic ring assays were analysed by creating a migration 
index using Velocity 3D Image Analysis software according to Cockle et al, 2015 
(doi: 10.1038/bjc.2015.16), ImageJ (http://rsbweb.nih.gov/ij) and Excel 
(Microsoft, USA). For all experiments, differences between control cells and 
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treated cells were compared using a two-tailed T-test (Excel). P-values ≤0.05 
were considered statistically significant. For MALDI and LESA, data was 
analysed using the Bruker Rapiflex software system.   
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4.3 Results  
4.3.1 CCG-1423 and CCG-203971 activity on a panel of glioma cell lines  
To confirm the effects of CCG-1423 on patient-derived glioma cell lines as well 
as on murine and rat glioma cell lines for in vivo studies, western blots were 
carried out on the patient derived cell lines G9 and G44, the murine glioma cell 
line GL261 and the rat glioma cell line CNS1 (Figures 26-27). G9 is of the 
mesenchymal GBM subtype, which is associated with poor prognosis and high 
invasiveness (115). G44 is of the proneural GBM subtype and is associated with 
better prognosis (114). GL261 is an orthotopic model for murine glioma. Although 
invasive, this cell line is not known to metastasise and is considered a lot less 
invasive than other GBM cell lines (292). CNS1 is a highly invasive rat glioma cell 
line that very closely simulates the growth patterns of human gliomas (293).  
 
During sample preparations of cell lysates, nuclear-associated components were 
discarded, therefore the results from the western blots are representative 
cytoplasmic MKL1. All data obtained from the western blot experiments were 
normalised to β-actin. The G9 cell line showed an increase in MKL1 build-up in 
the cytoplasm when treated with CCG-1423. The intensity of the MKL1 band at 
the 24-hour time point was 1.04 +/- 0.16, which was significantly different to the 
control (0.48 +/- 0.08) (P=0.008). At the 48-hour time point, the intensity of the 
CCG-1423 treated MKL1 band was 1.24 +/- 0.12, which was significantly different 
to the control (0.58 +/- 0.03) (P=0.004). At the 72-hour time point, the intensity of 
the CCG-1423 treated MKL1 band for G9 cells was 1.70 +/- 0.18, which was 
significantly different to the control (0.82 +/- 0.15) (P=0.003) (Figure 27A). 
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The G44 cell line showed an increase in MKL1 build-up in the cytoplasm when 
treated with CCG-1423. The intensity of the MKL1 band at the 24-hour time point 
was 1.43 +/- 0.08, which was significantly different to the control (0.78 +/- 0.06) 
(P=0.002). At the 48-hour time point, the intensity of the CCG-1423 treated MKL1 
band was 1.31 +/- 0.15, which was significantly different to the control (0.80 +/- 
0.03) (P=0.009). At the 72-hour time point, the intensity of the CCG-1423 treated 
MKL1 band for G44 cells was 1.13 +/- 0.07, which was significantly different to 
the control (0.61 +/- 0.08) (P=0.008) (Figure 27B). 
 
The GL261 cell line showed an increase in MKL1 build-up in the cytoplasm when 
treated with CCG-1423. The intensity of the MKL1 band at the 24-hour time point 
was 1.02 +/- 0.10, which was significantly different to the control (0.70 +/- 0.04) 
(P=0.02). At the 48-hour time point, the intensity of the CCG-1423 treated MKL1 
band was 1.03 +/- 0.12, which was significantly different to the control (0.88 +/- 
0.07) (P=0.04). At the 72-hour time point, the intensity of the CCG-1423 treated 
MKL1 band for GL261 cells was 1.12 +/- 0.05, which was significantly different to 
the control (0.82 +/- 0.02) (P=0.004) (Figure 27C). 
 
The CNS1 cell line showed an increase in MKL1 build-up in the cytoplasm when 
treated with CCG-1423. The intensity of the MKL1 band at the 24-hour time point 
was 1.42 +/- 0.08, which was significantly different to the control (0.98 +/- 0.07) 
(P=0.01). At the 48-hour time point, the intensity of the CCG-1423 treated MKL1 
band was 1.21 +/- 0.08, which was significantly different to the control (0.75 +/- 
0.05) (P=0.003). At the 72-hour time point, the intensity of the CCG-1423 treated 
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MKL1 band for CNS1 cells was 0.94 +/- 0.04, which was significantly different to 
the control (0.70 +/- 0.06) (P=0.02) (Figure 27D). 
 
Western blots were also carried out on U251 and G9 cell lysates that had been 
treated with CCG-203971 in order to confirm inhibitor activity in comparison to 
CCG-1423 for in vivo experiments. The western blots showed that CCG-203971 
led to results comparable to CCG-1423 and was consequently taken forward for 
in vivo work (Figures 28-29). 
 
The U251 cell line showed an increase in MKL1 build-up in the cytoplasm when 
treated with CCG-203971. The intensity of the MKL1 band at the 24-hour time 
point was 1.45 +/- 0.04, which was significantly different to the control (0.73 +/- 
0.02) (P=0.0002). At the 48-hour time point, the intensity of the CCG-203971 
treated MKL1 band was 1.21 +/- 0.08, which was significantly different to the 
control (0.75 +/- 0.02) (P=0.002). At the 72-hour time point, the intensity of the 
CCG-203971 treated MKL1 band for U251 cells was 0.94 +/- 0.09, which was not 
significantly different to the control (0.93 +/- 0.04) (P=0.34) (Figure 29A). 
 
The G9 cell line showed an increase in MKL1 build-up in the cytoplasm when 
treated with CCG-203971. The intensity of the MKL1 band at the 24-hour time 
point was 1.44 +/- 0.13, which was significantly different to the control (0.87 +/- 
0.04) (P=0.001). At the 48-hour time point, the intensity of the CCG-203971 
treated MKL1 band was 1.42 +/- 0.07, which was significantly different to the 
control (0.73 +/- 0.08) (P=0.004). At the 72-hour time point, the intensity of the 
  
143 
CCG-203971 treated MKL1 band for G9 cells was 0.96 +/- 0.05, which was 
significantly different to the control (0.77 +/- 0.03) (P=0.007) (Figure 29B). 
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Figure 26. Western blot analysis of the effects of CCG-1423 on glioma cell lines. Patient derived 
cell lines G9 (26A) and G44 (26B), murine glioma cell line GL261 (26C) and rat glioma cell line 
CNS1 (26D) were treated ± 500nM CCG-1423. Following 24, 48 and 72-hour incubations, cell 
lysates were obtained. Expression of cytoplasmic MKL1 was determined by western blotting 
including a β-actin control to evaluate protein loading and transfer. 
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Figure 27. Western blot analysis of the effects of CCG-1423 on glioma cell lines. Patient 
derived cell lines G9 (27A) and G44 (27B), murine glioma cell line GL261 (27C) and rat 
glioma cell line CNS1 (27D) were treated ± 500nM CCG-1423. Following 24, 48 and 72-
hour incubations, cell lysates were obtained. Expression of cytoplasmic MKL1 was 
determined by western blotting including a β-actin control to evaluate protein loading and 
transfer. MKL1 band intensity was quantified and normalised to the β-actin control using 
Image J software. Graphs show mean ± SEM of 3 individual experiments. Asterisks show 
statistical significance where * = p≤0.05, ** = p≤0.01, *** = p≤0.001. 
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Figure 28. Western blot analysis of the effects of CCG-203971 on glioma cell lines. Glioma cell 
line U251 (28A) and patient derived cell line G9 (28B) were treated ± 500nM CCG-203971. 
Following 24, 48 and 72-hour incubations, cell lysates were obtained. Expression of 
cytoplasmic MKL1 was determined by western blotting including a β-actin control to evaluate 
protein loading and transfer. 
29A 29B 
Figure 29. Western blot analysis of the effects of CCG-1423 on glioma cell lines. Glioma 
cell line U251 (29A) and patient derived cell line G9 (29B) were treated ± 500nM CCG-
203971. Following 24, 48 and 72-hour incubations, cell lysates were obtained. Expression 
of cytoplasmic MKL1 was determined by western blotting including a β-actin control to 
evaluate protein loading and transfer. MKL1 band intensity was quantified and normalised 
to the β-actin control using Image J software. Graphs show mean ± SEM of 3 individual 
experiments. Asterisks show statistical significance where ** = p≤0.01, *** = p≤0.001. 
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4.3.2 CCN1 expression in patient tissues (TMA) 
A commercially available brain cancer TMA including 63 cases/cores and 1 
control core was stained for CCN1. Of the 63 cases, there were 31 astrocytomas 
grade 1 and 2, 7 astrocytomas grade 3, 14 GBMs, 6 oligodendrogliomas, 1 
ependymoma, 1 medulloblastoma, 3 cancer adjacent brain tissue cores and 1 
adrenal core as the control. Because of the small sample size of the 
ependymoma and medulloblastoma, these were not included in the data analysis 
(Figure 30). Cytoplasmic and membranous CCN1 staining was observed in the 
tumour cells with strong staining patterns observed in elongated cells and in cells 
in close proximity to blood vessels. Figure 31 shows examples of strong and weak 
CCN1 staining in astrocytoma cores as well as a positive control 
(pheochromocytoma) and cancer adjacent brain tissue. The clinical 
characteristics associated with the samples, including age, sex, and tumour 
grade are shown in Table 4. The samples were dichotomised into low and high 
CCN1 expression with low scoring samples having a score of 3 or less and high 
scoring samples having a score of 4 or more.  
 
The average score for the astrocytoma grade 1-2 cores was 2 +/- 0.30, which 
was not significantly different to the control (0.67 +/- 0.67). Astrocytoma grade 3 
cores had an average score of 3.43 +/- 0.72, which was significantly different to 
the control (0.67 +/- 0.67) (P=0.05). GBM cores had an average score of 4.93 +/- 
0.40, which was significantly different to the control (0.67 +/- 0.67) (P=0.0003). 
The average score for oligodendroglioma cores was 3 +/- 0.45, which was also 
significantly different to the control (0.67 +/- 0.67) (P=0.02).  
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Clinical 
Characteristics 
Low CCN1 
Expression 
(score ≤3, n=28) 
High CCN1 
Expression 
(score ≥4, n=24) 
P Value 
AGE 
Under 25 
26-60 
Over 60 
 
1 (3%) 
26 (94%) 
1 (3%) 
 
3 (13%) 
17 (70%) 
4 (17%) 
 
 
p=0.28 
SEX 
Male  
Female 
 
15 (54%) 
13 (46%) 
 
13 (54%) 
11 (46%) 
 
p=0.97 
TUMOUR GRADE 
1 
2 
3 
4 
 
1 (3%) 
24 (86%) 
3 (11%) 
0 (0%) 
 
0 (0%) 
8 (33%) 
4 (17%) 
12 (50%) 
 
 
p=4.79x10-7 
**** 
Figure 30. A graph showing a combined score of CCN1 staining strength and percentage of 
the core covered on a TMA containing astrocytomas grade 1-2, GBM, oligodendroglioma, 
cancer adjacent brain tissue as a control and an adrenal core as a positive control. Asterisks 
indicate statistical significance.   
Table 4. The clinical characteristics of the TMA astrocytoma samples. The results reveal 
associations of CCN1 expression levels with tumour grade. Eighty-six percent of the samples 
with low CCN1 expression are grade 2 astrocytomas, whilst 50% of the samples with high 
CCN1 expression are grade 4 astrocytomas (GBM). There were no associations of CCN1 
levels with age or sex.  
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Figure 31. CCN1 levels vary in tumour tissue samples from patients as determined by 
IHC. Examples of strong and weak staining in TMA cores at low and high 
magnification. Membranous and cytoplasmic labelling was observed. Top core shows 
a representative sample for positive stain (pheochromocytoma); the second core 
represents a sample from cancer adjacent brain tissue; the third core represents a 
sample from a grade 2 astrocytoma and the bottom core is an example of a grade 4 
astrocytoma (GBM) (Individual cores x10 magnification; magnified examples × 20). 
Arrows indicate CCN1 staining around vessels.   
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4.3.3 CCN1 expression in a cohort of GBM patients including recurrent 
tumours  
Sixteen GBM samples collected from 9 patients (Table 5) undergoing surgery 
were stained for CCN1 by immunohistochemistry. Scores for CCN1 staining were 
obtained as described for the TMA (Figure 32). Two of the patients had surgery 
for recurrent tumours, of which samples were also collected (Figure 33). Tumour 
edge samples, defined as 200µm from the tumour boundary, and tumour core 
samples, defined as the tumour region outside the edge margins (294), were 
collected from 4 of the 9 patients (Figure 34), 1 of which also had a sample of 
cancer adjacent tissue collected. 
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 Clinical Characteristics 
Patient 
no. Age Sex Treatment Survival  
30 
30R 
50 
52 Female 
Surgery 
Radiotherapy post recurrent surgery  
Chemotherapy post recurrent surgery 
Death 24 months 
post first operation 
40 66 Male Surgery  Radiotherapy post-surgery 
Death 18 months 
post first operation 
48 69 Male 
Surgery  
Radiotherapy post-surgery 
Chemotherapy post recurrent surgery 
Death 12 months 
post first operation 
49 56 Male Surgery Chemotherapy post-surgery 
Death 10 months 
post first operation 
52 56 Male 
Surgery 
Radiotherapy post-surgery 
Chemotherapy post-surgery  
Death 9 months 
post first operation 
58 66 Female Surgery Radiotherapy post-surgery 
Death 12 months 
post first operation 
63 
63R 
57 
57 Male 
Surgery 
Radiotherapy post primary surgery 
Chemotherapy post primary and 
recurrent surgery 
Death 18 months 
post first operation 
74 55 Female 
Surgery  
Radiotherapy post-surgery 
Chemotherapy post-surgery  
Death 12 months 
post first operation 
75 Unknown Male 
Surgery  
Radiotherapy post-surgery 
Chemotherapy post-surgery  
Death 30 months 
post first operation 
Table 5. Clinical variables recorded for GBM patient samples. Details of the 9 GBM patients 
including age (primary and recurrent, where applicable), sex, treatment and survival. 
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Figure 32. A graph showing the combined scores of CCN1 staining intensity and percentage 
of staining covering the sample collected from 9 GBM patients during surgery. Recurrent 
tumour samples were also collected for patients 30 and 63 (30R and 63R). Samples of the 
core and edge of the tumour were collected for patients 30, 40, 52 and 58. Patient 30 also 
had a sample of cancer adjacent tissue collected. 
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Figure 33. CCN1 levels vary between patient GBM primary and recurrent tumour 
samples as determined by IHC. Different intensities of CCN1 antibody labelling 
were observed between the primary and recurrent tumours of patients 30 and 63 
(recurrent tumours = 30R and 63R) as indicated by brown staining. Magnification 
x20. 
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Figure 34. CCN1 levels vary between patient GBM core and edge tumour samples as 
determined by IHC. Different intensities of CCN1 antibody labelling were observed 
between the core and edge tumour samples of patients 30R, 40, 52 and 58 as indicated 
by brown staining. Arrows indicate CCN1 staining around vessels. Magnification x20. 
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4.3.4 CCN1 levels in matched blood samples from GBM patients  
The serum from the matched patients blood samples was separated and 
collected for determination of CCN1 concentration by ELISA. The concentration 
of CCN1 was calculated from the absorbance values using the standard curve as 
well as the percentage increase as before (Figure 35).  
 
The average concentration of CCN1 in the serum of the primary tumour of patient 
no. 30 was 60.43pg/ml +/- 1.55pg/ml, which was significantly different to the 
control (45.26pg/ml +/- 2.15pg/ml) (P=0.0049). The recurrent tumour blood 
sample for patient no. 30 (30R) had an average CCN1 concentration of 
825.32pg/ml +/- 2.36pg/ml, which was very significantly different to the control 
(45.26pg/ml +/- 2.15pg/ml) (P=1.68x10-9) as well as the primary tumour blood 
sample for patient no. 30 (P=1.12x10-9). Patient no. 40 had an average CCN1 
concentration of 134.51pg/ml +/- 15.48pg/ml, which was significantly different to 
the control (45.26pg/ml +/- 2.15pg/ml) (P=0.0047). Patient no. 48 had an average 
CCN1 concentration of 2588.041pg/ml +/- 466.45pg/ml, which was significantly 
different to the control (45.26pg/ml +/- 2.15pg/ml) (P=0.0055). The average 
CCN1 concentration of patient no. 49 was 119.34pg/ml +/- 21.66pg/ml, which 
was also significantly different to the control (45.26pg/ml +/- 2.15pg/ml) 
(P=0.028). Patient no. 52 had a CCN1 concentration of 51.51pg/ml +/- 2.44pg/ml, 
which was not significantly different to the control (45.26pg/ml +/- 2.15pg/ml). The 
average concentration for patient no. 58 was 122.02pg/ml +/- 15.84pg/ml, which 
was significantly different to the control (45.26pg/ml +/- 2.15pg/ml) (P=0.0089). 
The primary tumour for patient no. 63 had a CCN1 concentration of 54.19pg/ml 
+/- 1.19pg/ml, which was significantly different to the control (45.26pg/ml +/- 
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2.15pg/ml) (P=0.027). The recurrent tumour blood sample for patient no. 63 (63R) 
had a CCN1 concentration of 933.32pg/ml +/- 73.82pg/ml, which was significantly 
different to the control (45.26pg/ml +/- 2.15pg/ml) (P=0.0003) as well as the 
primary tumour blood sample for patient no. 63 (P=0.0002). The CCN1 
concentration for patient no. 74 was 92.57pg/ml +/- 2.84pg/ml, which was 
significantly different to the control (45.26pg/ml +/- 2.15pg/ml) (P=0.0002). 
Finally, patient no. 75 had a CCN1 concentration of 1010.96pg/ml +/- 
106.57pg/ml, which was also significantly different to the control (45.26pg/ml +/- 
2.15pg/ml) (P=0.0008). 
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35A 
35B 
Figure 35. A graph to show CCN1 concentration in 9 patient blood serum samples 
(35A). Blood samples from patient no. 30 and 63 were also collected at their 
recurrent GBM tumour surgery (30R and 63R). The percentage increase of each 
patient compared to the control was also calculated (35B). Asterisks show statistical 
significance. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001 ****P≤ 0.0001. 
  
158 
4.3.5 The effects of CCG-1423 and CCG-203971 on angiogenesis in the 
aortic ring assay  
The aortic ring assay is a tool used to assess angiogenic or anti-angiogenic 
effects of inhibitors. Vessels grow away from the aortic ring allowing anti-
angiogenic effects to be evaluated by the number of vessels that grow in 
comparison to an untreated control (Figure 37). Both CCG-1423 and CCG-
203971 were used for this experiment in comparison at concentrations of 10µM, 
1µM and 0.1µM to confirm that they were having similar effects on angiogenesis 
(Figure 36). The average MI for the aortic rings treated with 10µM of CCG-1423 
was 3.00 +/- 0.06, which was significantly different to the control (9.72 +/- 0.75) 
(P=0.0009). For the rings treated with 1µM of CCG-1423, the average MI was 
3.58 +/- 0.32, which was significantly different to the control (9.72 +/- 0.75) 
(P=0.002). The average MI for rings treated with 0.1µM of CCG-1423 was 4.24 
+/- 0.42, which was also significantly different to the control (9.72 +/- 0.75) 
(P=0.003). For rings treated with 10µM of CCG-203971, the average MI was 2.53 
+/- 0.05, which was significantly different to the control (9.72 +/- 0.75) (P=0.0007). 
The average MI for rings treated with 1µM of CCG-203971 was 3.36 +/- 0.17, 
which was significantly different to the control. Finally, the average MI for rings 
treated with 0.1µM of CCG-203971 was 4.01 +/- 0.12, which was also significantly 
different to the control (9.72 +/- 0.75) (P=0.002). 
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Figure 36. A graph showing the MI of endothelial cells in the aortic ring assay. Aortic 
rings embedded in Matrigel were treated with 10µM, 1µM or 0.1µM of CCG-1423, CCG-
203971 or untreated and incubated for 7 days. The rings were imaged using a confocal 
microscope (Nikon Eclipse Ti) and the area of migration was measured using ImageJ 
and the MI calculated. Asterisks show statistical significance. **P≤ 0.01, ***P≤ 0.001. 
n=3. 
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CCG-1423 
CCG-203971 
Figure 37. Images of mouse aortas treated with 10µM, 1µM or 0.1µM of CCG-1423 or CCG-203971 or untreated (control). Once treated, rings were 
incubated for 7 days to allow vessel formation away from the ring. The rings were imaged using a confocal microscope (Nikon Eclipse Ti). The area of 
vessel formation was measured using ImageJ and the MI was calculated. Note the highest reduction in vessel formation at 10µM for both inhibitors. 
Scale bar = 400µm. 
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4.3.6 CCG-1423 and CCG-203971 detection and optimisation with MALDI 
and LESA 
The optimisation phase of MALDI using CCG-1423, determined that the preferred 
matrix to use for drug detection was DHB (160mg/ml) with recrystallization and 
the preferred isotopic pattern to detect was the sodium adduct [M+Na]+. The 
concentration of drug detected by MSI differs by a factor of 10.931 on glass 
versus on a tissue section. This value is calculated by using the following 
equation to first calculate the volume (V) of the tissue in µl.  
 
V = π x r2 x h, where r = radius of droplet and h = thickness of tissue section. 
 
The volume of the tissue is then used to calculate the concentration of the solution 
on tissue using the calculation:  
 
Concentration of tissue = Concentration of solution spiked x Volume spiked 
                                                              Volume of the tissue 
 
 
Detection of CCG-1423 by MALDI when spotted directly onto the glass slide was 
limited to a cut-off concentration of 55µM. The lowest concentration detected on 
tissue was 1.09mM. In order to improve the detection levels on tissue, 
modifications to the DHB matrix preparation was completed. The three 
modifications in attempt to improve detectability were DHB 40mg/ml in 90:10 
ACN:0.1% TFA and 1% DMSO, DHB 40mg/ml in 70:30 ACN:0.1% TFA and 1% 
DMSO and DHB 40mg/ml in 90:10 methanol:0.1% TFA and 1% DMSO. 
Unfortunately, these modifications were unsuccessful and the lowest 
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concentration detectable on tissue by MALDI was 1.09mM, which is considered 
a high concentration for MALDI detection as the detectable range for MALDI is 
sub-µM (295). LESA was then used in attempt to improve the detectability of 
CCG-1423 at a lower concentration. The detectability was improved with LESA 
providing a detection limit of 10.93µM on tissue (Table 6, Figure 38). Although a 
vast improvement, the optimum detection on tissue homogenate is 1µM and 
therefore it was unlikely CCG-1423 would be detected in the mouse brain 
sections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCG-1423 Concentration on 
glass slide (µM) 
CCG-1423 Concentration in 
Tissue (µM) Ion Intensity 
1000 10930 372887968 
100 1093 59215388 
10 109.3 7936420 
5 54.65 3515311 
1 10.93 1793659 
0.1 1.093 527391 
0 0 573856 
Table 6. The different concentrations of CCG-1423 on glass and in tissue. The 
concentration of drug detected by MSI differs by a factor of 10.931 on glass versus on a 
tissue section calculated by using the volume of tissue, volume of the drug and 
concentration of the drug. The ion intensity for each concentration of CCG-1423 is 
shown. The lower limit of quantification using LESA is the concentration of CCG-1423 
where the ion intensity is 5x the blank. For CCG-1423 the lowest limit of detection is 
10.93µM. 
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Figure 38. Graphs showing the ion intensity of different concentrations of CCG-1423 
detected by LESA mass spectrometry. The graphs include the equation of a straight 
line and linear regression analysis (R2) to assess the relationship between the variables. 
As R2 is close to 1, ion intensity and CCG-1423 concentration are strongly related. 
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During the optimisation phase of MALDI using CCG-203971, again, the best 
matrix to use for detection of the drug was DHB (160mg/ml) with recrystallization, 
however, the best isotopic pattern to detect this time was the potassium adduct 
[M+K]+. Detection of CCG-203971 by MALDI when spotted directly onto the glass 
slide was possible with a cut-off concentration of 1.09µM. The lowest 
concentration detected on tissue was 10.93µM, which is a vast improvement on 
CCG-1423 but still not as low as is required for MALDI detection. LESA was then 
used in attempt to improve the detectability of CCG-203971 at a lower 
concentration. Detectability was improved with LESA providing a detection limit 
of 1.09µM on tissue, which is the required drug concentration to reach at the 
optimisation phase using tissue homogenate (Table 7, Figure 39). CCG-203971 
was then taken forward to in vivo experiments for brain tissue collection and 
detection by LESA and MALDI.  
 
 
 
 
 
 
 
Solution Concentration (µM) Concentration in Tissue (µM) Ion Intensity 
1000 10930 676181376 
100 1093 190719952 
10 109.3 20417112 
5 54.65 9598493 
1 10.93 4303222 
0.1 1.093 2388824 
0 0 671175 
Table 7. The different concentrations of CCG-203971 on glass and in tissue. The 
concentration of drug detected by MSI differs by a factor of 10.931 on glass versus on a 
tissue section calculated by using the volume of tissue, volume of the drug and 
concentration of the drug. The ion intensity for each concentration of CCG-203971 is 
shown. The lower limit of quantification using LESA is the concentration of CCG-203971 
where the ion intensity is 5x the blank. For CCG-203971 the lowest limit of detection is 
1.09µM. 
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Figure 39. Graphs showing the ion intensity of different concentrations of CCG-
203971 detected by LESA mass spectrometry. The graphs include the equation 
of a straight line and linear regression analysis (R2) to assess the relationship 
between the variables. As R2 is close to 1, ion intensity and CCG-203971 
concentration are strongly related. 
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4.3.7 CCG-203971 drug detection in mouse brains and livers with MALDI 
Although the concentration of CCG-203971 was high for MALDI detection on the 
tissue homogenate sections, attempts were still made to use this method of 
detection for the brain samples. As predicted, the brain samples were all below 
the detection threshold of CCG-203971 using MALDI. The tumours were 
identified on the acquired MALDI images by using the long-chain fatty acid 
palmitoylcarnitine, a known tumour marker, and an unnamed tumour marker (m/z 
744.724). Previous work has shown that palmitoylcarnitine is upregulated in 
tumours, hence it can be accurately detected (296) (Figure 40).  
 
 
 
 
 
Palmitoylcarnitine 
Tumour Marker 
m/z 744.724 
40A 
40B 
Figure 40. Two tumour markers applied to the MALDI images of CCG-203971 treated 
mouse brains and untreated control mouse brains. Figure 40A is an unnamed tumour 
marker with a m/z of 744.724. Figure 40B shows the long-chain fatty acid 
palmitoylcarnitine which is involved in the metabolism of fatty acids and is upregulated 
in tumours. The colour spectrum shows the intensity of the tumour markers within the 
brain tissue samples.   
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CCG-203971 was also not detected in the matched liver samples, however, 
metabolic changes between the treated and control mouse livers were picked up 
showing that the drug was metabolised (Figure 41-42). Although the molecules 
cannot be identified, the image analysis and receiver operating characteristic 
(ROC) curves (from the Human Metabolome Database) show significant changes 
in chemical composition between the CCG-203971 treated mouse livers and the 
control mouse livers. These different chemical compositions were investigated in 
order to gain more information on whether the drug was present and having an 
effect despite being unable to detect CCG-203971 itself.   
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41A 
41B 41C 
Figure 41. Differences in the chemical composition of mouse livers treated with CCG-
203971 and untreated control livers with detected compound m/z 382.212. The colour 
spectrum shows the intensity of compound m/z 382.212 within the liver tissue samples 
(41A). This compound appears to be significantly downregulated in treated livers as shown 
in the ROC graph (41C). The area under the ROC curve (AUC) value is 0.852 (close to 1) 
meaning the differences in compound m/z 382.212 are very distinguishable between 
treated and untreated liver samples (41B). This method of analysis allows for less false 
positive results and the accurate identification of distinct changes between treated and 
untreated samples.     
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42C 42B 
42A 
Figure 42. Differences in the chemical composition of mouse livers treated with CCG-203971 
and untreated control livers with detected compound m/z 445.255. The colour spectrum 
shows the intensity of compound m/z 445.255 within the liver tissue samples (42A). This 
compound appears to be significantly upregulated in treated livers as shown in the ROC 
graph (42C). The area under the ROC curve (AUC) value is 0.850 (close to 1) meaning the 
differences in compound m/z 445.255 are very distinguishable between treated and 
untreated liver samples (42B). This method of analysis allows for less false positive results 
and the accurate identification of distinct changes between treated and untreated samples.     
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4.3.8 CCG-203971 detection in mouse brains and livers with LESA 
LESA mass spectrometry was also unable to detect CCG-203971 in the brain or 
livers of treated mice. The detected target mass of CCG-203971 was the 
potassium adduct ([M+K]+) at m/z 447.02. However, the mass spectra of the 
CCG-203971 calibration samples detected on glass slides did not match the 
spectra of the CCG-203971 treated brain or liver samples (Figure 43) meaning it 
was not possible to detect the drug in the brain or liver samples. As the mass 
spectrum peaks of the brain and liver samples were close to the calibration peaks, 
fragmentation (MS/MS) was performed in another attempt to detect CCG-203971 
but this was also unsuccessful. Figure 44 shows the spectra of all brain samples 
and Figure 45 for all liver samples. 
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Figure 43. Calibration mass spectra of CCG-203971 (m/z 447.02 [M+K]+) as a 
percentage of relative abundance. Mass spectra shown include the CCG-203971 
calibration samples spotted onto glass slides at concentrations of 0.1µM, 1µM, 10µM, 
100µM, 1000µM (red spectra) showing the m/z 447.02 of the drug. The green spectra 
show examples of the CCG-203971 treated mouse brain samples (including a tumour 
and non-tumour sample) that do not show the correct m/z of 447.02, meaning the drug 
has not been detected. The yellow spectra show examples of the CCG-203971 treated 
and untreated mouse liver samples that again do not show the correct m/z of 447.02, 
meaning the drug has not been detected. 
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44A 44B 
Figure 44. CCG-203971 treated and untreated brain sample mass spectra (m/z 447.02 [M+K]+) measured as ion intensity. Mass spectra shown include a 
calibration sample for reference (purple spectra) showing the target m/z of CCG-203971 at 447.02. The green spectra show the untreated mouse brain 
samples (in the tumour and outside of the tumour) (44A). The red spectra show examples of the CCG-203971 treated mouse brain samples (in the tumour 
and outside of the tumour) that again do not show the correct m/z of 447.02, meaning the drug has not been detected (44B). 
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Figure 45. CCG-203971 treated and untreated liver sample mass spectra (m/z 447.02 
[M+K]+) measured as ion intensity. Mass spectra shown include a calibration sample for 
reference (purple spectra) showing the target m/z of CCG-203971 at 447.02. The blue 
spectra show the CCG-203971 treated and untreated mouse liver samples that do not 
show the correct m/z of 447.02, meaning the drug has not been detected. 
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4.4 Discussion 
4.4.1 Cytoplasmic MKL1 is increased in a panel of glioma cell lines when 
treated with CCG-1423 and CCG-203971 
To determine clinical relevance of CCN1 the effects of CCG-1423 were firstly 
tested in a panel of glioma cell lines at Harvard Medical School, Brigham and 
Women’s Hospital, including patient derived cell lines G9 and G44, murine glioma 
cell line GL261 and the rat glioma cell line CNS1. All cell lines showed an increase 
in cytoplasmic MKL1 when treated with CCG-1423 and analysed by western 
blotting, confirming similar results using the cell line U251 carried out at the 
University of Leeds. Interestingly, GL261 produced the least build-up of 
cytoplasmic MKL1, which corresponds with this particular cell line being the least 
invasive out of all the tested cell lines. This observation may also be linked to 
MKL1 as a driver of  gene transcription of CCN1 (226), which in turn has been 
shown to be associated with tumour aggressiveness and invasiveness 
(239,242,284). From in vivo experiments with CCG-1423, it was realised that this 
inhibitor is highly cytotoxic and compound modifications have been attempted in 
order to reduce the cytotoxic effect for drug tolerability studies in xenograft 
models. Through a survey involving aromatic substitutions to CCG-1423, one 
analogue, CCG-203971, was identified having reduced cytotoxicity and improved 
potency to the inhibition of PC-3 cell migration. Therefore, CCG-203971 was 
taken forward in tolerability studies in normal mice using doses up to 
100mg/kg/day over 5 days injected intraperitoneally (225). Based on the 
published data on CCG-203971, western blots were carried out on U251 and G9 
cells treated with 500nM of CCG-203971 to firstly reproduce results obtained with 
CCG-1423. Similar effects on cytoplasmic MKL1 build up were observed for 
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CCG-203971 and this inhibitor was taken forward to in vivo models. This drug 
has not yet been reported in in vivo studies to investigate effects on the brain, 
therefore this experiment was one of the first using CCG-203971 in glioma 
research.    
 
4.4.2 CCN1 expression is increased in GBM patient samples  
CCN1 levels were elevated both in its secreted form and in tumour tissues from 
glioma patients. In the tissue, CCN1 was expressed in the cytoplasm of tumour 
cells, with highly stained cells appearing to be associated with blood vessels. 
Analysis of the TMA generated data revealed an association of CCN1 expression 
levels with high grade tumours in comparison to lower grade gliomas and cancer 
tissue adjacent to normal brain tissue. This data suggests that CCN1 expression 
is correlated with tumour invasiveness and aggressiveness, which confirms 
previous studies that performed a semi-quantitative IHC analysis of 100 gliomas 
and 12 normal brain samples correlating CCN1 with tumour grade. The IHC 
staining showed that in 88% of the WHO grade IV samples, CCN1 was 
overexpressed and that expression was positively correlated with the expression 
of c-Met, a receptor tyrosine kinase involved in proliferation, migration and 
invasion. When investigated in vivo using a U87 xenograft in mouse models, 
CCN1 siRNAs significantly inhibited proliferation by 57% compared to the control 
(243).  
 
Interestingly, levels of secreted CCN1 in the GBM tissue samples were mirrored 
in the matched patient blood in comparison to normal bloods. Figure 46 shows 
CCN1 staining of the patient GBM tissue samples with the lowest and highest 
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levels of CCN1 found in the matched blood samples. Patient no. 52 (core) 
presented with the lowest concentration of CCN1 in the matched blood sample 
(51.51pg/ml), whilst patient no. 48 presented with the highest concentration of 
CCN1 in the matched blood sample (2588.041pg/ml), which is apparent in the 
IHC staining of the GBM tissue samples.  
 
 
From the results of the IHC, it is evident that the edge samples contain a higher 
concentration of CCN1 when compared to the core samples of the same patient, 
which correlates with tumour edge cells being more invasive than tumour core 
cells. This observation complements studies that have shown tumour-associated 
macrophages to have a key role at the tumour edge where they enable invasive 
cell phenotypes and drive tumour cell invasion via a paracrine signalling loop. 
The recruitment of these cells to the tumour edge has been shown to be activated 
Figure 46. CCN1 IHC staining correlates with the CCN1 concentration determined for the 
matched blood samples. The GBM tissue sample from patient no. 52 (core) presented 
with the lowest concentration of CCN1 in the blood (51.51pg/ml) which correlates with 
the low intensity CCN1 staining in the tissue sample. The GBM tissue sample from 
patient no. 48 presented with the highest concentration of CCN1 in the blood 
(2588.041pg/ml), which correlates with the high intensity CCN1 staining in the tissue 
sample. Magnification x20. 
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by CCN1 in both breast cancer and glioma (297). Furthermore, a study into 
oncolytic virus therapy in GBM showed that activation of CCN1 inhibited the 
efficacy of the oncolytic virus through this recruitment of tumour-associated 
macrophages. Following antibody neutralisation of CCN1, the response to the 
oncolytic virus therapy improved in glioma, most considerably in GBMs that 
possessed a high macrophage count (298).  
 
In addition, the samples from the patients with the recurrent tumours, including 
blood samples, showed a significant increase in CCN1 levels both in the tumour 
tissues and in the blood sample in comparison to the primary tumour and blood 
sample. Compared to the control, the recurrent tumour sample for, for example, 
patient 30 (30R) achieved a percentage increase of 1723.5% compared to the 
control and a percentage increase of 1265.7% compared to the primary tumour 
blood sample. For patient 63, the percentage increase of the recurrent tumour 
(63R) compared to the control was 1962% and compared to the primary tumour 
blood sample, it was 1622.4%. The observed increases in CCN1 levels between 
primary and secondary tumour blood samples are considerable; therefore, after 
validation of the preliminary data using larger sample size and further 
experiments, CCN1 could potentially be an extremely useful blood biomarker for 
the monitoring of brain tumour patients following initial primary tumour surgery to 
predict disease recurrence. This means that a simple blood test for the monitoring 
of secreted CCN1 may be developed for the early detection of recurrent tumours 
leading to advanced treatment options and improved survival rates in GBM 
patients. There were also significant differences in CCN1 concentrations between 
the control and primary tumour blood samples. Improved sensitivity to enhance 
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the detection levels of an ELISA based screening system may lead to the 
development of a cost-effective and non-invasive diagnostic tool for advanced 
early detection of brain tumours considering that early diagnosis of brain tumours 
is still limited. The molecular subtyping of brain tumours themselves has 
advanced diagnosis and treatment options; however, a conclusive diagnosis is 
still largely based on the interpretation of the histopathology of tumour samples, 
which may be open to human error and bias. The growing identification and use 
of biomarkers and genomics will enhance brain tumour diagnosis by providing 
more detailed information when paired with the traditional histopathology method 
(299). 
 
4.4.3 CCG-1423 and CCG-203971 prevent blood vessel formation 
(angiogenesis) in the aortic ring assay  
Both inhibitors exerted the same effect in the aortic ring assay, leading to a 
significant reduction in vessel formation. As part of the data analysis for this type 
of assay, the number of vessels that have formed in the control and in the treated 
are counted (300). Intriguingly, both drugs fully suppressed vessel formation, as 
the aortic endothelial cells appeared to round up and migrate away from the aorta. 
For this reason, the area of migration was measured by calculating a MI rather 
than the number of vessels. With increased concentration of CCG-1423 or CCG-
203971 a lower MI was observed. This may be indicative of the critical role that 
CCN1 plays in angiogenesis and may also address its association with tumour 
invasiveness, however further investigation would be needed to confirm this. 
Previous studies have also concluded that CCG-1423 possesses an anti-
angiogenic effect by also producing a near complete inhibition of vessel formation 
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in the aortic ring assay as well as in in vivo angiogenesis experiments using 
zebrafish embryos (301). Angiogenesis is an essential process in tumour growth. 
With an enhanced vascular network, tumours can be supplied with oxygen and 
nutrients and dispose of their metabolic waste, all of which support tumour 
invasion and metastasis (302). Furthermore, during the development of the heart, 
endothelial cells differentiate into mesenchymal cells through endothelial-
mesenchymal transition in the endocardial cushion, a critical step in the formation 
of cardiac valves. This has also been implemented in the development of a 
number of cardiac diseases including myocardial infarction, atherosclerosis and 
cardiac fibrosis (303,304). Based on the findings from the previous chapter on 
MAT it is conceivable that as the aortic endothelial cells are undergoing 
endothelial-mesenchymal transition, CCG-1423 and CCG-203971 activity forces 
the transitioned endothelial cells to round up but allows them to continue to 
migrate, mirroring the effect observed in glioma cells. Further experiments are 
needed to investigate this theory. Live cell imaging of the aortic rings over 3 days 
would allow for visualisation of the MAT process and continued migration of the 
cells. In addition to this, repeating the 3D spheroid invasion assay with endothelial 
cells could be advantageous in observing the migratory switch as for the tumour 
cells. This paired with the iSIM microscopy would provide a detailed look at the 
effect of CCG-1423 and CCG-203971 on endothelial cells and angiogenesis. 
Previous studies have been successful in using spheroid assays for angiogenesis 
investigations, highlighting the assay’s high sensitivity and endothelial cell 
compatibility. The assay was successfully used for the identification of pro and 
anti-angiogenic drugs (305). 
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4.4.4 Mass spectrometry imaging of CCG-203971 in mouse brains 
Both the MALDI and LESA experiments performed to investigate localisation and 
effect of CCG-203971 on the brain tissue and the tumours in vivo were 
unsuccessful. Preliminary results indicate that the drug was present in the 
circulation of the treated animals but was unable to cross the blood brain barrier 
(BBB). Although it was also undetected in the liver samples, metabolic changes 
were observed in the livers. The inability to detect CCG-203971 in the liver may 
be due to the fact that animal sacrifice was performed too late after the final dose 
was given (2 hours) due to the fact that metabolic changes were identified 
between treated and untreated liver samples but not the drug itself. This time 
frame was, however, in keeping with the tolerability study from Bell et al. who 
reported plasma levels of the drug to exceed the previous PC-3 cell migration 
IC50 of 4.2µM for up to 3 hours after a single dose in vivo (225). Figure 47 shows 
the calibration peak with a m/z of 447.02 and a CCG-203971 treated tumour 
sample with a m/z of 447.03, suggesting the drug has been detected in 1 of the 
treated brain tumour samples. Upon inspection of the treated brain tumour 
sample slide and the droplet placement using LESA, the drug was detected in a 
ventricle of a treated brain sample suggesting that the drug was present in the 
cerebral spinal fluid (CSF) within the ventricle. Drug presence in the CSF within 
the brain compartments cannot be taken as an indicator of transport across the 
BBB. The choroid plexus, which is the regulator of drug transfer from the blood 
to the CSF, is made up of different epithelial/endothelial barriers to the brain 
capillary endothelium that comprises the BBB (306). As it was not detected within 
the brain tissue, this suggests that CCG-203971 cannot cross the BBB, however, 
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despite unsuccessful detection in the liver samples, this provides more evidence 
to the chemical composition differences that the drug was circulating in the 
animal’s systems.     
 
 
Further experiments should include growing bigger tumours for easier tumour 
identification and better representation of brain tumour side effects such as a 
leaky BBB. Increasing the CCG-203971 dosage would also be advantageous to 
the study in order to increase the possibility of drug detection, as the animals 
responded extremely well at 100mg/kg/day with no abnormal side effects 
compared to the control animals. Based on the striking phenotypes observed in 
the aortic ring assay and the predominant localisation of CCN1 with blood vessels 
in brain tumours it would also be interesting to look into monitoring angiogenesis 
using MALDI. Haem can be used as a marker to visualise the lumen of blood 
vessels in the brain. By utilising this and pairing it with protein imaging for CCN1, 
again using MALDI, a better representation of the relationship between CCN1, 
tumour invasiveness and angiogenesis may be obtained. Furthermore, the 
Figure 47. Calibration mass spectrum (m/z 447.02 [M+K]+) and CCG-203971 treated brain 
sample mass spectra (m/z 447.03 [M+K]+) measured as ion intensity. The purple spectrum 
shows the calibration curve with a m/z of 447.02, meaning the drug has been detected. 
The red spectrum shows a CCG-203971 treated mouse brain tumour sample with a m/z 
of 447.03, also suggesting the drug has been detected in this sample. 
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continued development of CCG-1423 and its analogues could prove more 
successful in in vivo studies for brain tumour research.  
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Chapter 5: Conclusion 
Gliomas are highly aggressive tumours that possess diffuse and invasive 
behaviours. The infiltrative nature of these cancers contributes towards poor 
patient prognosis and highlights the need for clinical intervention to target the 
mechanisms that control cell migration and invasion. Understanding the relevant 
biology offers a unique opportunity to improve treatment of the most invasive and 
highly migratory tumours, such as GBM, and to enhance our understanding of 
tumour cell migration and invasion.  
 
Current treatment of GBM comprises surgical resection of the tumour followed by 
radiotherapy and adjuvant chemotherapy; most commonly with temozolomide 
(307). Further treatment may include immunotherapy, angiogenesis inhibitors in 
combination with chemotherapy and gene/antibody therapy. In spite of these 
treatment options, success in curing GBM has not ensued due to its invasiveness 
and cell migrating abilities (308). With recurrence being reported 2-3cm from the 
original tumour site, in more than 90% of patients with glioma, there is a strong 
need for the development of successful anti-migratory drugs (309).  
 
There has been a number of potential anti-migratory drug candidates reported 
through drug-repurposing. One such study, uncovered the therapeutic potential 
of anti-psychotic drugs as effective agents in glioma management. One of the 
drugs tested was a second-generation anti-psychotic drug called olanzapine 
which was shown to suppress cell migration in the glioma cell line A172 as well 
as enhance temozolomide activity when used in conjunction. However, 
contradicting studies found that olanzapine upregulated the protein expression of 
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the neurotrophin growth factor, brain-derived neurotrophic factor (BDNF) by 22% 
and seemingly induced tumour-promoting effects (310). These opposing results 
highlight the importance of gaining a more in depth understanding of the 
mechanisms involved in glioma cell migration. By delving deeper into the 
molecular biology of these cancers, research can focus on targeting multiple 
processes within tumour cells in order to completely arrest glioma cell motility and 
invasion, resulting in more successful treatments.   
 
Another study looked into the anti-cancer potential of the anti-hyperglycaemic 
agent, metformin in the treatment of GBM. This drug is used in the treatment of 
type 2 diabetes and was investigated for its effects on the serine/threonine-
specific protein kinase Akt (protein kinase B) in the PI3K pathway; a key process 
involved in cell migration (311). Not only was metformin shown to decrease 
SF268 and U87 cell motility in 2D wound healing assays by 80% but it presented 
with a potential role in the inhibition of the PI3K pathway by inactivating Akt. This 
demonstrates the possible use of metformin as an anti-invasive and anti-
migratory agent in GBM management (312). Although successful in 2D in vitro 
assays, as previously stated within this thesis, this can lead to overestimation of 
drug efficacy and produce inaccurate data, ultimately causing failure when taken 
forward into in vivo models. Screening drugs on migrating cells in a 3D 
environment aids a more representative assessment of the activity of anti-
migratory drug candidates and could produce successful in vivo studies that can 
then be taken forward to clinical trial. 
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There have also been investigations into effects of anti-epidermal growth factor 
receptor (EGFR) and anti-vascular endothelial growth factor receptors (VEGFR) 
agents on cell migration in glioma. Lapatinib is a drug currently used in the 
treatment of HER2-positive breast cancer. It is an ATP-competitive tyrosine 
kinase inhibitor for both EGFR and HER2/neu. EGFR is overexpressed in 50% 
of GBM patients and has a considerable role in the oncogenic activity of GBM. 
The anti-VEGFR agent investigated, called Sunitinib, is used in the treatment of 
renal carcinoma and refractory gastrointestinal stromal tumours. This tyrosine 
kinase inhibitor targets VEGFR and platelet-derived growth factor receptors. As 
cell migration is driven by the association of integrins with growth factors, this 
study by Dimitropoulos et al focussed on the formation of complex integrin 
β1/EGFR and complex integrin β3/VEGFR. It was shown that lapatinib inhibited 
complex integrin β1/EGFR formation within 30 minutes of application in GBM cell 
lines U87 and M059K, inhibiting cell migration. Sunitinib also inhibited cell 
migration through its disruption of complex integrin β3/VEGFR formation, within 
2 hours of drug application (313). These drugs have been used in small phase 
I/II clinical trials, however, used alone they did not show promising anti-cancer 
activity in recurrent GBM patients (313, 314). As GBMs implement many 
pathways in progression and invasion, using these drugs in combination may 
prove to be more effective. This will enable multiple pathways to be inhibited at 
one time, thus increasing the efficacy of anti-migratory treatments.    
 
The investigations within this thesis demonstrate a need to focus research on 
anti-migratory agents for GBM. In particular, the use of 3D assays in drug 
screening for a more accurate representation of tumour environment and drug 
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efficacy, and combination treatments for multiple pathway targeting to stop cell 
migration, reduce tumour recurrence and increase treatment successes. The first 
aim of these studies was met by exploring the migratory characteristics of 
different glioma cell lines as well as their response to different drug treatments. 
Distinct differences in cell response to treatment in terms of phenotype, migration 
mode and invasiveness were observed and analysed. A wide range of migration 
assays and a panel of chemical inhibitors to target the actin polymerisation 
pathway were utilised to investigate cellular responses to drug treatment in U87 
and U251 glioma cells. The second aim of these studies was met by identifying 
one compound, CCG-1423, from the inhibitor screen that uniquely failed to halt 
glioma cell migration and invasion in 3D invasion assays in spite of predicted anti-
migratory activity. It was hypothesised that MAT was induced by CCG-1423 
activity driving the switch from one migratory modality to another. By using iSIM, 
and a novel ImageJ plugin, the third aim of these studies was met by developing 
this unique workflow and analysis technique to investigate MAT in glioma cells 
treated with CCG-1423, confirming a distinct switch in cell phenotype in treated 
cells compared to control cells. This switch has so far not been characterised in 
great detail in GBM biology and targeting cellular components driving MAT in 
GBM may be explored to completely inhibit cell migration.   
 
Results from MKL1 immunofluorescence and western blotting profiles confirmed 
the action of CCG-1423 blocking MKL1 nuclear import, and subsequently, CCN1 
transcription, with significantly increased levels of MKL1 in the cytoplasm in 
treated cells compared to untreated cells. ELISA assays also confirmed CCG-
1423 activity with reduced secreted CCN1 levels following treatment. IHC was 
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used to confirm CCN1 expression in patient samples, an association with high 
grade tumours and as such clinical relevance. The results from this screen 
revealed a correlation between tumour grade and CCN1 expression, suggesting 
CCN1 has a key role in GBM progression and invasion. In addition to this, 9 in-
house patient samples were also stained for CCN1 including 2 patients with 
primary and secondary tumour samples and 4 patients with tumour edge and 
core samples. There was a significant increase in CCN1 expression between the 
primary and the secondary samples as well as between the edge and core 
samples. This also suggests that CCN1 is involved in GBM progression and 
invasion due to the fact that tumour edge cells are known to be invading cells that 
eventually reseed a tumour. Importantly, CCN1 was detected in the matched 
patient blood samples. Although all blood samples showed an increase in CCN1 
concentration in comparison to bloods from healthy donors, the matched 
secondary blood samples after recurrence showed a significant increase in CCN1 
levels, correlating with the CCN1 expression in the associated tissue samples. 
CCN1 has therefore presented itself as a potential biomarker for monitoring GBM 
progression and possibly, with increased sensitivity, a diagnostic marker. This 
could lead to earlier diagnosis and increased survival rates for GBM patients.  
 
CCG-1423, and its less toxic analogue CCG-203971, were used in western blot 
experiments of patient derived cell lines G9 and G44, murine glioma cell line 
GL261 and rat glioma cell line CNS1 to assess the similarity in effect of both 
drugs in order to take CCG-203971 forward into in vivo studies for MSI. CCG-
203971 showed inhibitor activity similar to those observed with CCG-1423 and 
therefore was used in in vivo studies due to its reduced toxicity and enhanced in 
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vivo tolerability. Following successful in vivo experiments with patient derived G9 
cells, MSI experiments were undertaken using MALDI and LESA. Although 
unsuccessful in locating CCG-203971 in the brain samples, the preliminary 
results will guide future in vivo work with this drug.  
 
The main novel findings presented here are becoming increasingly relevant in 
GBM research. Recently, it has been shown that microRNA, miR-634 sensitises 
glioma cells to temozolomide treatment via CCN1. miR-634 expression was 
significantly decreased in glioma tissue compared to normal tissue and was 
associated with tumour grade with miR-634 expression being higher in grades I 
and II compared to III and IV. In addition, patients with lower miR-634 expression 
had lower survival rates compared to those with higher expression. Furthermore, 
it was found that downregulation of miR-634 was involved in drug resistance in 
glioma cells. As it is known that CCN1 is a target of miR-634, this study 
investigated and showed that miR-634 can sensitise temozolomide resistant 
glioma cells by targeting CCN1 (316). As we have shown, not only does CCN1 
have a key role in glioma invasion but also in other aspects of glioma progression 
including drug-resistance.  
 
In addition, CCN1 affects the efficacy of oncolytic virus therapy. Activation of 
CCN1 elicits a number of anti-viral responses in this topical treatment option for 
GBM patients including macrophage recruitment and the induction of interferon-
α secretion leading to reduced efficacy of oncolytic virus therapy (213,295). As 
CCN1 can be detected in patient blood, it could be used as a predictor of patient 
response in oncolytic virus therapy. Patient blood test results with high 
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concentrations of CCN1 could identify low responses to oncolytic virus therapy 
due to the associated anti-viral responses induced by CCN1. Consequently, this 
could lead to the development of combination treatments involving CCN1 
inhibition as well as oncolytic virus therapy, thus enhancing a patient’s positive 
response to the treatment. By delving deeper into the role of CCN1, in all aspects 
of GBM biology, a greater understanding can be gained in its mechanism and 
how to target this protein for improved patient outcome. All in all, CCN1 can be 
utilised to measure patient progress, patient response to treatment and 
potentially as a diagnostic marker. 
 
In conclusion, the studies contained within this thesis present the importance of 
moving cell migration research into a 3D setting in order to gain more accurate 
drug efficacy results in an environment that replicates that of a tumour. 
Furthermore, it provides interesting and compelling evidence that glioma cells 
can undergo MAT in response to pharmacological intervention intended to 
prevent migration, resulting in continued migration and invasion, highlighting the 
need for more specific anti-migratory combination treatments. In addition, these 
studies have uncovered an important role for CCN1 in disease progression 
supporting CCN1 as potential biomarker for GBM, which could improve survival 
rates of this devastating disease. 
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